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Summary Muktha Sundar Natrajan 
Retinoid X Receptor activation reverses age-related deficiencies in myelin 
debris phagocytosis and CNS remyelination 
Remyelination is a regenerative process that occurs through the formation of 
myelin sheaths by oligodendrocytes, which are recruited as oligodendrocyte progenitor 
cells (OPCs) after demyelination in diseases such as Multiple Sclerosis (MS). A key 
environmental factor regulating OPC differentiation is the fate of myelin debris 
generated during demyelination. Myelin debris contains inhibitors of OPC 
differentiation and thus its clearance by phagocytic macrophages is an important 
component of creating a lesion environment conducive to remyelination. The efficiency 
of debris clearance declines with age, contributing to the age-associated decline in 
remyelination. Therefore, understanding the mechanisms of the age-related decline in 
myelin debris phagocytosis is important for devising means to therapeutically reverse 
the decline in remyelination. The aim of this study was to determine the 
functional/molecular differences between young and old phagocytes involved in 
myelin debris clearance, thereby identifying therapeutically modifiable pathways 
associated with efficient myelin debris phagocytosis.  
In this study, we show that expression of genes involved in the retinoid X 
receptor (RXR) and peroxisome proliferator-activated receptor (PPAR) pathways are 
decreased with ageing in both myelin-phagocytosing human monocytes and mouse 
macrophages. Disruption of RXR and PPAR using synthetic antagonists in young 
macrophages mimics ageing by reducing myelin debris uptake. Macrophage-specific 
RXRα knockout mice revealed that loss of RXR function in young mice caused 
delayed myelin debris uptake and slowed remyelination. Alternatively, receptor 
agonists partially restored myelin debris phagocytosis in aged macrophages. The 
FDA-approved agonists bexarotene and pioglitazone, when used in concentrations 
achievable in human subjects, caused a reversion of the gene expression profiles in 
MS patient monocytes to a more youthful profile and enhanced myelin debris 
phagocytosis by patient cells. Activation of these pathways also enhances 
immunoregulatory markers on monocytes from MS patients, further suggesting the 
regeneration-promoting capacity of activating these pathways in phagocytes. These 
results reveal the RXR/PPAR pathway as a positive regulator of myelin debris 
clearance and a key player in the age-related decline in remyelination that may be 
targeted by available or newly-developed therapeutics. 
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Introduction 
The central nervous system (CNS) has long been considered an immune-
privileged organ due to the presence of the blood brain barrier (BBB) made up of the 
meninges (pia, arachnoid, and dura) and tight junctions formed by endothelial cells. 
The BBB provides protection to the complex network of cells in the CNS, including 
neurons, astrocytes, oligodendrocytes, and microglia. Immune cells may enter the 
CNS to perform immune surveillance alongside microglia and astrocytes in the 
healthy brain, but in the absence of injury or disease, these activated cells tend to 
undergo apoptosis or exit the CNS (Bauer et al., 1998). In demyelinating diseases 
such as Multiple Sclerosis (MS), immune cells are recruited to the CNS and are 
involved in both the pathogenesis of disease and in the resolution of demyelinating 
events (Lassmann et al., 2012; Naegele and Martin, 2014). 
This thesis focuses on the role of infiltrating monocytes and macrophages in 
the process of remyelination, the major regenerative process that occurs after 
demyelination. Our understanding of the beneficial role of innate immune cells in 
remyelination still remains incomplete, and discovering the most effective ways to 
harness these cells can lead to targeted therapies to promote regeneration. This 
introduction will provide a brief overview of the processes of demyelination and 
remyelination in the context of MS and the potential role of the innate immune 
response in overcoming barriers that prevent remyelination in the ageing population. 
1.1 Myelin 
Myelin is formed by oligodendrocytes (OLs) in the CNS to ensheath axons. 
OLs are the glial cell responsible for myelination, and by extending their plasma 
membranes, they are able to efficiently wrap axons in multiple myelin layers (Fig. 
1.1). In addition to myelination, OLs interact with surrounding cells in the CNS and 
are able to communicate with axons, astrocytes, and endothelial cells. To 
communicate with axons, they form channel-like tubes from their nucleus to the axon 
(Paz Soldan and Pirko, 2012). OLs have also been shown to express receptors for 
neurotransmitters, such as NMDA receptors for glutamate (Karadottir et al., 2005), 
which play a role in transferring exosomes from the OL to the axon (Fruhbeis et al., 
2013). They are connected to astrocytes via gap junctions, which are composed of 
two hemichannels (each of six connexin membrane proteins) to allow diffusion of 
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ions between OLs and astrocytes (Orthmann-Murphy et al., 2009). In addition, OLs 
form a complex interaction with endothelial cells at the blood brain barrier through 
the shuttling of glucose. Glucose is transferred to OLs and astrocytes via 
monocarboxylate transporter 1 (MCT1) and broken down into lactate molecules, 
which provide energy to myelin and axons (Lee et al., 2012). OLs have a high 
energy demand and use lactate and other sources of energy to expand their 
surface area by over 6,500-fold and can myelinate up to 60 axonal segments at a 
time (de Monasterio-Schrader et al., 2012; Freeman and Rowitch, 2013). 
Figure 1.1: Myelin allows rapid saltatory conduction. Oligodendrocytes extend 
their plasma membranes to create multiple myelin sheaths around each axon. 
Myelinated portions of axon are known as the “internode” while unmyelinated 
portions are the “Nodes of Ranvier”. Myelination provides support and insulation to 
promote rapid firing of action potentials and electronic propagation down myelin 
segments (red dashed line), resulting in efficient neurotransmitter release. 
Electron micrographs of the spinal cord show the compact myelin sheath formed 
around the axon. 
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The uniquely polarised myelin membrane is primarily composed of lipids, 
which make up approximately 70% of its dry weight, in order to increase the speed of 
impulses up to one hundred-fold. The main lipids in myelin are cholesterol, 
phospholipids, and galactosylceramide (Edgar et al., 2009; Morell and Ousley, 1994; 
Norton and Poduslo, 1973). The remaining protein portion of myelin interacts with 
this high lipid content to create a properly folded, compact myelin sheath around 
segments of each axon (Baron and Hoekstra, 2010; Simons et al., 2012). The areas 
wrapped by myelin, known as the internode due to their placement between 
unmyelinated axon segments (Nodes of Ranvier), allow for rapid saltatory 
conduction of action potentials down the axon (Fig. 1.1). Myelin provides insulation 
to axons in an electrically charged environment by reducing capacitance and 
increasing membrane resistance, resulting in efficient neurotransmitter release at the 
end of axons (Aggarwal et al., 2011; Keirstead and Blakemore, 1999; Paz Soldan 
and Pirko, 2012). 
In addition to allowing rapid saltatory conduction, the second major function of 
myelin is to preserve the long-term integrity of the axon (Griffiths et al., 1998). Myelin 
has evolved in high level nervous systems, allowing for better axonal support, higher 
muscle function, and more complex behaviour (Harris and Attwell, 2012; Nave, 
2010). The myelin sheath especially protects the axon in diseased environments by 
providing trophic support to axons (via MCT1) and expressing neurotrophic factors 
such as brain derived neurotrophic factor (BDNF) and insulin-like growth factor (IGF- 
1). Unmyelinated axons contain more mitochondria than myelinated axons, 
suggesting that the axon must provide more of its own energy to maintain function in 
the absence of OLs (Smith et al., 2013). In addition, mice engaged in long term 
learning exercises preferentially generate myelin in adulthood, suggesting white 
matter changes in the brain (through an increase in OL production) occur during the 
learning process (McKenzie et al., 2014). This collection of evidence suggests that 
OLs are key to axonal survival by providing nutrients and a proper framework to 
support axonal health.  
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1.2 Oligodendrocyte Progenitor Cells 
OLs in the adult CNS can be replenished by a population of adult stem cells 
known as oligodendrocyte progenitor cells (OPCs). These cells have the capacity to 
differentiate and generate myelin throughout adulthood (Young et al., 2013), 
explaining why myelination can continue late into life (Fields, 2008). OPCs are 
abundant in the adult CNS, making up 5-8% of total glial cells and are dispersed in 
both the white and gray matter (Dawson et al., 2003; Levine et al., 2001; Pringle et 
al., 1992). The majority of OPCs are derived from developmental OPCs, which 
originate from neural progenitor cells in the motoneuron domain (pMN) of the 
ventricular zone during development. Sonic hedgehog (SHH) signalling is released 
during nervous system development and transcribes Olig2, which initiates 
differentiation of neural progenitor cells to motor neurons and OPCs (Briscoe et al., 
2000; Zhou and Anderson, 2002). OPCs are able to extend and retract processes as 
they migrate throughout the CNS during development and in adulthood, resulting in 
consistent spacing of OPCs in the parenchyma (Kirby et al., 2006). As they migrate, 
OPCs proliferate until they reach their final destination and exit the cell cycle 
(Wegner, 2008). OPCs are also able to regulate angiogenesis through their 
interactions with endothelial cells (Yuen et al., 2014), differentiate into astrocytes, 
Schwann cells, and neurons (Rivers et al., 2008; Tatsumi et al., 2008; Zawadzka et 
al., 2010), and in the majority of cases, differentiate to oligodendrocytes (Richardson 
et al., 2011).   
Several markers of OPCs have been established to identify these cells in 
various stages of development (Fig 1.2). OPCs begin as neural progenitor cells in 
the pMN and express Polysialylated-neural cell adhesion molecule (PSA-NCAM), 
Nestin, and Vimentin during this time. As these progenitors grow, they start to 
express platelet-derived growth factor α (PDFRα) and mature into OPCs, which 
express NG2, Nestin, and A2B5. As they further differentiate into pre-
oligodendrocytes, they also begin to express O4. Once they become pre-myelinating 
oligodendrocytes, they express GalC (a prominent myelin lipid), adenomatus 
polyposis coli (APC, also known as CC1), and 2’,3’-cyclic nucleotide 3’ 
phosphodiesterase (CNPase). Finally, mature myelinating oligodendrocytes express 
multiple myelin proteins, especially myelin basic protein (MBP), proteoplipid protein 
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(PLP), myelin oligodendrocyte glycoprotein (MOG), and myelin-associated 
glycoprotein (MAG) (Schumacher et al., 2012).  
Figure 1.2: OPC differentiation markers. Specific markers in oligodendrocyte (OL) 
differentiation allow distinction of development along the OL lineage. OPCs begin as 
Neural Progenitors expressing PSA-NCAM, Nestin, and Vimentin. Once they 
become bipolar OPCs, they upregulate NG2, A2B5, and PDFRα. They then become 
pre-myelinating OLs and begin to branch out further and express OL-specific 
markers. Finally, they differentiate to myelinating OLs and ensheath axons while 
expressing myelin-specific proteins, such as MBP, PLP, MOG, and MAG.  
To regulate differentiation, OPCs intrinsically control expression of several of 
these transcription factors to maintain a quiescent state. The repression model of 
myelination suggests that OPC differentiation is inhibited by continuous expression 
of transcription factors that inhibit myelin gene expression and mediate extrinsic 
signals. These factors include inhibitor of DNA binding-2 and 4 (ID2, ID4) and 
transcription factor 4 (Tcf4), which inhibit Olig2 expression (Kondo and Raff, 2000; 
Wegner, 2008). In addition, Wnt signalling stabilises Tcf4 transcription and disrupts 
OPC maturation by activating the Axin complex and releasing β-catenin (Fancy et 
al., 2009). To allow for differentiation, the surrounding environment of OPCs must 
promote downregulation of inhibitory transcription factors which allows for 
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transcription of myelinating OL genes. The promotion of OPC proliferation and 
differentiation is key to promoting myelin regeneration (remyelination) after a myelin 
destructive pathology (demyelination).  
 
1.3 Demyelination & Remyelination 
In normal adult white matter, an OL myelinates axons by extending 
cytoskeletal processes to form myelin around several axons (Asou et al., 1994; 
Matthews and Duncan, 1971). In diseases such as Multiple Sclerosis, demyelination 
occurs and these OLs and their processes are degraded, but remyelination and 
functional recovery can take place when OPCs are recruited and differentiated in 
distinct stages (Franklin and Ffrench-Constant, 2008; Murtie et al., 2005; Woodruff et 
al., 2004). In the recruitment stage, OPCs migrate to the demyelinated area of the 
axon. Then, they respond to both extrinsic and intrinsic factors to differentiate into 
oligodendrocytes and remyelinate axons (Fig 1.3) (Fancy et al., 2009; van 
Wijngaarden and Franklin, 2013). 
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Figure 1.3: Macrophage and microglia involvement in the stages of 
demyelination to remyelination. A) Myelinating oligodendrocytes, microglia, 
astrocytes and OPCs populate healthy CNS white matter. B) After demyelination, 
myelin debris is formed around denuded axons and blood-derived monocytes are 
recruited to the lesion site. OPCs are recruited and activated as well in response to 
demyelination. However, if macrophages are not properly recruited and activated, 
myelin debris is not cleared and OPCs are unable to differentiate causing 
remyelination to fail. C) Myelin debris is phagocytosed by macrophages and 
microglia, clearing the way for OPC differentiation. Phagocytes also release various 
cytokines and growth factors that promote differentiation and remyelination of the 
CNS. D) After proper removal of myelin debris and activation of differentiation cues 
in OPCs, macrophages and microglia largely exit the lesion area and return to a 
resting state. Mature oligodendrocytes effectively remyelinate the exposed axons 
with a thinner myelin sheath and proper conductance is restored.  
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The loss of myelin from a healthy axon is known as demyelination and is a 
feature of several neurological conditions (Franklin and Ffrench-Constant, 2008; 
Franklin and Gallo, 2014). Due to demyelination, conduction of action potentials 
can be slowed and lack of trophic support from the OL leads to compromised 
axonal integrity and eventually, axonal degradation (Irvine and Blakemore, 2008; 
Nave, 2010; Smith and McLeod, 1979). When demyelination accumulates in the 
CNS, there is an associated decline in neurological function seen in many 
neurological disorders, including neuromyelitis optica, Transverse myelitis, Acute 
disseminated encephalomyelitis, Adult-onset leukodystrophies, and the most 
prevalent, Multiple sclerosis.  
Remyelination and functional recovery can take place following demyelination. 
Remyelination is an endogenous process where OPCs are recruited to a site of 
injury and differentiate into myelinating OLs; it is vital for restoring function and 
preventing long-term neurodegeneration (Irvine and Blakemore, 2008; Kornek et al., 
2000). Through the generation of new OLs, contact can be re-established between a 
myelinating OL and the demyelinated axon, resulting in concentric wrapping and 
compaction of a new myelin sheath. This sheath is thinner and shorter than before 
demyelination, but studies do not suggest any reduced function in a remyelinated 
sheath (Franklin and Ffrench-Constant, 2008). In order to distinguish remyelination, 
this thinner sheath is easily recognizable through the measurement of the “g-ratio.” 
The g-ratio is used to determine the relationship between axon diameter and myelin 
sheath thickness by calculating the circumference of the axon divided by the 
circumference of the myelin sheath. The remyelinated sheath (higher than normal g 
ratio) is able to provide effective trophic support and restore proper conductance 
across the axon (Franklin, 2002; Irvine and Blakemore, 2008; Kornek et al., 2000).  
1.4 Multiple Sclerosis 
Multiple Sclerosis (MS) is the most common inflammatory demyelinating 
disease of the CNS, affecting more than 2 million people worldwide (Compston and 
Coles, 2008; McFarland and Martin, 2007). MS is a complex disease with diverse 
symptoms and levels of progression, making it difficult to effectively treat. The 
demographics of MS patients have been extensively studied. Although the cause of 
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the disease remains uncertain, several factors have been associated with higher 
risks of MS. The average age of onset is 30 years old and ranges from 15-50 years 
in a predominantly female population (2-3:1, female:male ratio in relapsing-remitting 
disease) (Compston and Coles, 2008; Duquette et al., 1987). MS is more prevalent 
in Europe, North America, Australia, and New Zealand (Koch-Henriksen and 
Sorensen, 2010) and is associated with low vitamin D levels and cigarette smoking 
(Ascherio et al., 2014; Handel et al., 2010; Mikaeloff et al., 2007).  
Several triggers of MS have been discussed; although no one cause has yet 
been confirmed, it is likely that the disease results from a combination of these 
factors (Fig 1.4). Genetic causes of MS have been extensively studied and have 
revealed a modest role of genetic effects. Approximately 20-25% of monozygotic 
twins both develop MS, in comparison to 2-5% of dizygotic twins and in the general 
population (Compston and Coles, 2008; Ebers et al., 1986), suggesting an increased 
susceptibility due to genetic traits. A more recent, large-scale study by the 
International MS Genetics Consortium identified genes within the major 
histocompatibility complex (MHC) and other immune-related genes as 
overrepresented in the MS population (International Multiple Sclerosis Genetics et 
al., 2011). In addition, there are >110 susceptibility loci reported in published 
literature, with the majority of these common allelic variants in non-coding regions 
with studies suggesting that these variants are specifically enriched for sequences 
involved in regulation of immune-related genes (International Multiple Sclerosis 
Genetics et al., 2013). These causes relate to the primary theory of MS as an 
autoimmune disease mediated by dysregulation of myelin-specific T-lymphocytes 
(Martin et al., 1992; McFarland and Martin, 2007). In this theory, autoreactive T cells 
invade the brain and elicit a local immune response resulting in demyelination; many 
studies report higher numbers or higher reactivity of myelin-specific T cells in MS 
(Martin and McFarland, 1995; Steinman, 2001; Wuest et al., 2014). 
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Figure 1.4: Multiple sclerosis (MS) is caused by an overlap of environmental, 
genetic, and immune factors. MS is a complex inflammatory neurodegenerative 
disease and is likely triggered by a combination of factors. Environmental factors 
such as low vitamin D exposure, cigarette smoking, diet, and distance from the 
equator have all been correlated to the disease. In addition, twins are more likely to 
develop MS, and large genetic studies have shown that several immune-related 
genes are more common among MS patients compared to the general population. 
These genes likely lend to the inflammatory reaction responsible for initial 
demyelination in the disease course.  
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Another theory is that MS is caused by primary OL apoptosis resulting in an 
inflammatory response. Due to evidence of demyelination before inflammation 
(Barnett and Prineas, 2004; Henderson et al., 2009), induction of OL apoptosis may 
be the primary cause of demyelination in some cases (Caprariello et al., 2012). 
However, genetic studies have clearly demonstrated that genetic predisposition to 
MS involves genes in immune regulation, and immunomodulatory therapies provide 
strong support for immune-mediated pathophysiology. Due to its likely immune-
mediated nature, the disease is also related to viral infections that prime immune 
cells to target OLs. The most commonly associated virus with MS is the Epstein Barr 
Virus (EBV) (Serafini et al., 2013; Tzartos et al., 2012), which displays significantly 
elevated levels of viral copies in MS patients compared to the general population and 
is present in 99.5% of MS cases, making it a likely necessary component of MS 
(Pakpoor and Ramagopalan, 2013). Studies have shown that EBV-encoded nuclear 
antigen-1 (EBNA1)-specific T cells accumulate in MS cases and allow cross-
recognition of autoantigens (Lunemann et al., 2006). EBV is a γ-herpesvirus and 
acts by infecting and expanding B cells. The latent EBV infection remains within B 
cells and is present in ~90% of the adult population (Pender and Burrows, 2014), so 
alone it is not sufficient to identify MS as it is common in the overall population. 
These studies together with genetic and epidemiological evidence suggest that MS 
is an immune-mediated disease, but the triggers of this immune response and which 
antigens specifically are targeted in MS remains unknown.  
A definitive cause remains elusive, and the symptoms of MS also vary greatly 
among patients and disease course. In general, patients suffer from sensory and 
motor symptoms during an MS attack. These include visual loss, gait disturbance, 
balance problems, vertigo, bladder problems, fatigue, and tremors (Compston and 
Coles, 2008). Symptoms develop from demyelinated lesions at specific sites within 
the CNS, in both the gray and white matter (Geurts and Barkhof, 2008), and an MS 
diagnosis requires demonstration of these lesions and their dissemination in time as 
well as exclusion of alternative diseases that cause CNS lesions separated in space 
and time (Polman et al., 2011). This demyelination often leads to degradation of 
axons (Evangelou et al., 2001). In addition, inflammation is readily apparent in MS 
lesions, including activated macrophages with ingested myelin, perivascular T-cell 
infiltrates, and a few B-cells (Lassmann, 2007; Lassmann, 2011). This inflammation 
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can result from and/or cause disruption of the blood brain barrier (BBB), which is 
recognised by enhanced accumulation of gadolinium in active MS lesions (Kirk et al., 
2003). The disease course of MS is unpredictable, but can generally be defined in 
four main groups.  
Relapsing-remitting MS (RRMS) is the most common form of the disease and 
is characterised by short timeframes of disability followed by recovery periods with 
no decline. Most cases (~85%) are first diagnosed as RRMS, and patients generally 
do not experience any symptoms between their attacks (Bethoux et al., 2001). This 
is partially due to the efficiency of remyelination in these patients. At early stages of 
RRMS, areas of acute demyelination undergo robust regeneration due to a 
conducive environment for remyelination. On patient pathology, this remyelination is 
visualised by “shadow plaques,” areas with thinner myelin sheaths and higher than 
normal g ratios (Bramow et al., 2010; Lassmann, 2007; Patrikios et al., 2006). In 50-
65% of RRMS cases, the disease begins to progress between relapses and 
remyelination begins to decline; this type of MS is called secondary progressive MS 
(SPMS). In SPMS, patients accumulate disabilities over time, usually over the course 
of decades. There does not appear to be increased mortality in these patients but 
rather an increase in disability burden with no remission (Weinshenker et al., 1989).  
One less common forms of MS involves progression of disability from the 
onset of disease. A further 10% of patients are diagnosed directly with primary 
progressive MS (PPMS), where there are no periods of relapse or remission from 
disease onset and disabilities worsen with little recovery. PPMS patient MRIs tend to 
show a lower T2 and T1 focal lesion load compared to SPMS patients and also have 
a higher number of diffuse abnormalities in both the brain and spinal cord (Ingle et 
al., 2002; Lublin et al., 2014; van Walderveen et al., 1998). Also, PPMS tends to 
show abnormalities in the spinal cord rather than the brain (as in RRMS and SPMS) 
(Nijeholt et al., 1998). However, the course of the disease can be indistinguishable 
from SPMS and is based purely on clinical diagnosis.  
Several therapeutic agents are currently used to treat MS and especially 
assist in relapse reductions and reduce formation of new lesions. The most common 
and longest used treatments are Interferon β-1a/b. They have been shown to reduce 
frequency of relapses but have several side effects (Walther and Hohlfeld, 1999). 
30
The strongest second-line treatment is Natalizumab, a selective monoclonal antibody 
against α4 integrin receptor on leukocytes, preventing their entry into the CNS 
(Yednock et al., 1992). However, natalizumab can reactivate John Cunningham (JC) 
polyomavirus and cause progressive multifocal leukoencephalopathy (PML) (Brew et 
al., 2010; Clifford et al., 2010). Fingolimod, a new oral drug, modifies the 
sphingosine-1-phosphate receptor on lymphocytes to prevent them from leaving the 
lymph nodes and crossing the BBB (Mandala et al., 2002). Glatiramer acetate, made 
up of a subset of amino acids in MBP, is used to prevent relapses by limiting T cells 
attacking myelin (Comi et al., 2001). Alemtuzumab, a recently FDA-approved 
treatment for RRMS, is a monoclonal antibody against CD52 on mature 
lymphocytes, causing depletion of lymphocytes and reduction of relapses compared 
to interferon β (Cohen et al., 2012; Coles et al., 2012). The currently prescribed 
agents for MS are highlighted in Table 1.1. 
These agents do not successfully promote structural recovery and 
remyelination and have limited efficacy when applied in late stages of MS. All the 
current treatments have limited effects on damage resulting in accumulated disability 
and progression of disease. There is still a great amount of research to be done on 
treatments that provide strategies to overcome demyelination and axonal 
degeneration in MS, and in order to fully research the spectrum of treatments, ideal 
models of the disease must be utilised.  
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Drug Trade names Target Administration Side effects 
Interferon β-
1a/b  
Avonex, Rebif, 
Cinnovex, 
Extavia, 
Betaferon  
Reduces MHC 
II expression, 
Th1, and Th17 
production  
Subcutaneous, 
1-3 /week  
Skin site reactions, 
flu-like symptoms, 
thyroid dysfunction, 
liver abnormalities  
Natalizumab  Tysabri  Monoclonal 
antibody 
against α4 
integrin 
receptor on 
leukocytes  
Intravenous, 
1/month  
Headache, joint 
pain, skin site 
reactions, 
infections, PML  
Glatiramer 
acetate  
Copaxone  T cells 
recognise this 
subset of 
amino acids 
from MBP  
Subcutaneous, 
1-3 /week  
Skin site reactions, 
nausea, joint pain, 
headaches  
Fingolimod  Gilenya  Retains 
lymphocytes 
within lymph 
nodes  
Oral, 1/day  Back pain, cough, 
diarrhoea, 
headache  
Teriflunomide  Aubagio  Blocks enzyme 
dihydoorotate 
dehydrogenase 
and T cell 
proliferation  
Oral, 1/day  Diarrhoea, nausea, 
tingling in skin, hair 
loss  
Alemtuzumab  Lemtrada  Monoclonal 
antibody 
against CD52 
on mature 
lymphocytes  
Intravenous, 
1x3-5 day 
cycle/year  
Fever, chills, 
dizziness, muscle 
stiffness, increased 
risk of other 
autoimmune 
diseases  
Dimethyl 
fumarate  
Tecfidera  Activates 
nuclear factor-
like 2 (Nrf2), 
Nicotinic 
receptor 
agonist  
Oral, 2/day  Redness, itching, 
stomach pain, 
diarrhoea, nausea, 
vomiting, PML  
 
Table 1.1. Drugs available for MS treatment. This table lists several drugs 
currently approved for reducing relapses in MS patients with varying adverse effects 
and administration routes/frequency. Adapted from (Tullman, 2013) 
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1.4.3 Animal Models of MS 
As the aetiology of MS is incredibly complex, achieving representative in vivo 
models of the disease remains difficult. One of the oldest and most well-
characterised models is experimental autoimmune encephalomyelitis (EAE). In this 
model, clinical symptoms can be induced by several myelin epitopes as well as 
some non-myelin antigens, and myelin-reactive T-cells induce demyelinating lesions 
resembling those seen in MS. EAE is characterised by infiltration of blood-derived 
immune cells to the CNS and complex demyelination/remyelination process resulting 
in relapsing disability and clinical symptoms in mice (Gold et al., 2000). When 
studying questions of the adaptive immune response in MS, this model is ideal. It 
maintains a complex immune response that may mirror the components of 
autoimmune CNS disease. However, when studying remyelination of the CNS and 
progressive stages of MS, where several immunomodulatory therapies have shown 
little efficacy (Miller and Leary, 2007), the EAE model is not ideal.  
Remyelination biology is more easily manipulated in toxin models of 
demyelination, where demyelination can be induced and subsequent remyelination 
efficiency can be studied using markers for stages of oligodendrocyte (OL) 
differentiation (Fig .1.2). Oral cuprizone, a copper chelator causing dysfunction in 
mitochondrial complex IV, results in selective OL toxicity throughout the corpus 
callosum and hippocampus. This model is used for studies of response of resident 
CNS inflammatory cells, such as microglia and astrocytes, because little infiltration of 
recruited monocytes occurs (Krauthausen et al., 2014; McMahon et al., 2002). 
However, in studies of the infiltrating innate immune response to demyelination and 
remyelination biology, lysolecithin and ethidium bromide-induced demyelination 
cause prompt demyelination followed by distinct stages of remyelination. These 
models allow for isolated demyelination in the CNS and can identify important 
cellular mechanisms that change during manipulation of this system. In addition, in 
young healthy mice, a consistent timeframe of OL differentiation can be followed. 
After initial infiltration of innate immune cells, OPC migration and proliferation mainly 
occurs from 4-7 days post lesion (dpl). OPC maturation and differentiation begins 
around 10dpl and continues to increase around 14-15dpl. Then, remyelination mainly 
occurs until around 21dpl, when most of the lesion is remyelinated. By 28dpl, 
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remyelination is fully complete in this model (Blakemore and Franklin, 2008; Hinks 
and Franklin, 1999).  
Remyelination therapies are necessary to improve disability outcomes; 
therefore, accurate modelling of this process and therapeutic targets that remove 
barriers to OPC differentiation must be created to allow this process to occur. 
Currently, several barriers have been identified that delay remyelination, and 
removing these barriers is an ideal way to promote OPC differentiation.  
1.5 Ageing and Myelin Debris inhibit remyelination 
In MS lesions, OPCs fail to remyelinate due to defective recruitment of OPCs 
and impaired OPC differentiation. In some MS patients, antibodies to NG2 cause 
OPC depletion, leading to chronic lesions due to defective recruitment (Mason et al., 
2004; Niehaus et al., 2000). However, the major delay in remyelination failure results 
from reduced OPC differentiation (Franklin, 2002; Franklin and Ffrench-Constant, 
2008; Kuhlmann et al., 2008). Many studies have suggested several factors that are 
involved in reduced OPC differentiation, from intrinsic factors in OPCs to extrinsic 
factors in the demyelinated lesion (Fig 1.5). Within OPCs, some pathways have been 
identified that prevent maturation. Activation of the Wnt signalling pathway inhibits 
developmental myelination and remyelination (Fancy et al., 2009). In addition, 
shuttling of the transcription factor Olig1 to the nucleus of OPCs is imperative for 
effective differentiation (Arnett et al., 2004).   
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Figure 1.5: Intrinsic and extrinsic factors prevent OPC differentiation. Several 
factors have been identified that prevent OPC maturation to myelinating 
oligodendrocytes. Intrinsic factors include Wnt activation of the β-catenin and Tcf4 
pathway and prevention of shuttling of Olig1 to the nucleus of the OPC. In addition, 
several environmental factors have also been identified that directly inhibit OPC 
differentiation. Accumulation of myelin debris and extracellular matrix proteins, such 
as hyaluronan, fibronectin, and chondroitin sulfate proteoglycans (CSPGs), also 
inhibit remyelination.   
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1.5.2 Ageing 
As with many other cellular processes, a major inhibitor of remyelination is 
ageing. There is an obvious age-dependent pattern of reduced remyelination in 
animal models (Franklin and Kotter, 2008). The aged rodent CNS has an 
abundance of OPCs (Rivers et al., 2008; Sim et al., 2002), which are efficient at 
repopulating various regions of the CNS in the face of recurrent demyelination 
(Penderis et al., 2003). Remyelination is regulated by age-dependent epigenetic 
control in OPCs. Downregulation of HDACs in aged OPCs results in reduced 
differentiation and reduced remyelination in ageing animals (Shen et al., 2008). The 
protein klotho, which declines with age in the CNS, enhances OPC differentiation 
via activation of the Akt pathway in cuprizone-induced demyelination (Chen et al., 
2013). Aged OPCs are also less responsive after toxin-induced demyelination, 
showing reduced expression of late myelin markers such as MBP (Sim et al., 2000). 
As animals grew older, they experienced a decline in both recruitment and 
differentiation of OPCs 
(Sim et al., 2002). Demyelinated lesions are fully remyelinated in young rats by one 
month post lesion, while aged rates do not fully remyelinate until two months post 
lesion (Shields et al., 1999). In animal models, remyelination is delayed and the rate 
of remyelination is compromised in the aged CNS, but it can still proceed to 
completion with time.  
However, ageing has also proven to be a significant, persistent barrier to 
remyelination in progressive MS. In humans, both cognitive ability and white matter 
volume decline with age (Bartzokis et al., 2001; Bartzokis et al., 2010; Mabbott et al., 
2006). During the clinical course of MS, ageing results in accumulated disabilities 
(Scalfari et al., 2011). Age is a greater determinant of disability milestones in MS 
than number/presence of preceding MS attacks (Confavreux and Vukusic, 2006), 
suggesting that age-associated defects in tissue repair, including remyelination, may 
be the driving force behind accumulation of progressive disability. Older patients 
tend to have more physical limitations than younger, irrespective of disease duration 
(DiLorenzo et al., 2004). As patients age, OPCs become less effective at 
remyelination and the number of shadow plaques is reduced (Suzuki et al., 1969). 
OPCs remain abundant in these lesions (Chang et al., 2002; Kuhlmann et al., 2008; 
Wolswijk, 1998), further suggesting impairment in differentiation and not recruitment. 
OPC differentiation is also largely inhibited by extrinsic factors.  
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1.5.3 Myelin debris 
Many extrinsic factors can also inhibit OPC differentiation. Fibronectin was 
recently shown to aggregate in demyelinated lesions and impair remyelination in 
EAE mice (Stoffels et al., 2013). PSA-NCAM is produced by axons as a negative 
regulator of remyelination and was present in demyelinated MS lesions as compared 
to remyelinated shadow plaques (Charles et al., 2002). Hyaluronan, a 
glycosaminoglycan, accumulates in demyelinated MS lesions and mice with EAE, 
and OPC cultures do not mature in the presence of this protein (Back et al., 2005). 
Another glycosaminoglycan, chondroitin sulfate proteoglycan, also accumulates in 
MS lesions and prevents OPC differentiation in vitro and in vivo (Lau et al., 2012) 
(Fig. 1.5).  
One major external barrier to remyelination is the presence of myelin debris. 
Primary demyelination produces large amounts of debris as myelin sheaths degrade 
(Franklin, 2002). Upon demyelination of the CNS, degenerating oligodendrocytes 
form debris around denuded axons. This debris can create a dense matrix that may 
present a physical barrier to the demyelinated axon. Previous studies have shown 
that myelin debris does not affect the number of OPCs recruited to the lesion site; 
however, differentiation of OPCs into myelinating oligodendrocytes is impaired by the 
extracellular accumulation of debris (Franklin and Kotter, 2008; Kuhlmann et al., 
2008). Cultured OPCs plated onto CNS myelin substrates and myelin protein 
extracts in vitro were unable to effectively differentiate (Baer et al., 2009; Robinson 
and Miller, 1999). Increased intracellular calcium in the OPC in response to myelin 
also leads to decreased process motility and collapse of the oligodendrocyte 
structural formation on contact with myelin (Moorman and Hume, 1994). 
Observations in animal models of focal demyelination reveal an association between 
myelin debris removal and effective OPC differentiation and rapid remyelination 
(Fancy et al., 2010). Injection of excess myelin debris into demyelinated lesion sites 
further confirmed impairment of rapid CNS remyelination by degenerated myelin 
(Kotter et al., 2006).  
Myelin debris is a major cause of impaired OPC maturation through the 
expression and release of molecules that inhibit differentiation (Fig. 1.6). This 
impairment is mainly due to interactions between the protein extracts from myelin 
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and OPCs, not the lipids or salts present in the debris (Syed et al., 2008). More than 
100 proteins were identified in these myelin extracts, including MAG, MBP, PLP, and 
MOG; however, the current datasets only reveal a list of potential candidates that 
cause the inhibitory effects of myelin debris (Baer et al., 2009). Although the specific 
inhibitory proteins have not yet been identified, differentiation pathways that the 
debris targets and soluble factors released by debris have been studied. One of the 
proteins released by degraded myelin is Semaphorin3A (Sema3A), a molecular 
guidance cue. Semaphorins play a role in diverting OPC processes through negative 
guidance cues, and Sema3A is specifically upregulated in active demyelinating 
lesions of MS patients. Sema3A also prevents OPC differentiation in vitro in OPC 
cultures and in vivo in animal models of demyelination. Artificially increasing 
Sema3A in demyelinated lesions leads to more demyelination and further induces 
failure of remyelination (Syed et al., 2011). Several signalling processes activated by 
myelin debris proteins also result in a similar failure of remyelination. Protein kinase 
C (PKC) signalling is involved in translocation of myristoylated alanine-rich C-kinase 
substrate (MARCKS) from the OPC membrane to the cytosol, which is known to 
regulate differentiation. In differentiating OPCs, MARCKS is present in the cell 
membrane, and in OPC inhibition, it is localised to the cytosol (Baron et al., 1999). 
Myelin protein extracts activate PKC signalling, thereby promoting MARCKS 
translocation to the cytosol and impairing OPC differentiation.  
 Fyn-1 is an Src family tyrosine kinase, and activation of this molecule is one of 
the earliest events triggered in OPC differentiation. This receptor regulates process 
extension of OPCs to form myelin sheaths, and myelin debris inhibits 
phosphorylation and activation of this kinase. Impairment of Fyn-1 allows for 
activation of RhoA, an important negative regulator of oligodendrocyte differentiation. 
RhoA activates Rho-associated, coiled-coil containing protein kinase 2 (ROCKII) 
which leads to actin depolymerization and prevents OPC process extensions from 
expanding and forming new myelin sheaths (Baer et al., 2009). Effective removal of 
myelin debris to prevent activation of PKC, Sema3A, and RhoA/ROCKII signalling 
will improve OPC differentiation and enhance effective remyelination.  
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Figure 1.6: Myelin debris prevents OPC differentiation via Sema3A, RhoA, and 
PKC pathways. The inhibitory effects of degraded myelin on remyelination regulate 
several pathways in OPCs. Fyn-1 is a positive regulator of OPC differentiation and 
prevents RhoA phosphorylation by activating Rho-GTPases (O'Meara et al., 2011). 
When Fyn-1 is dysregulated in the presence of myelin debris, RhoA-GTP activates 
ROCK2, resulting in actin depolymerization and inhibited remyelination. PKC is also 
activated when Fyn-1 is dysregulated, and it prevents OPC differentiation by 
translocating the MARCKS protein from the plasma membrane, where it is active 
during OPC differentiation, to the cytosol, where it is inactive during OPC 
quiescence. PKC has also been shown to play a role in RhoA activation. Finally, the 
negative guidance cue Sema3A has been shown to impair OPC differentiation and 
remyelination, possibly through activating the RhoA pathway. Myelin debris activates 
and releases these negative regulators of OPC differentiation to prevent 
remyelination. Green text = Activates OPC differentiation.  Red text = Inhibits OPC 
differentiation.  
 
1.6 Beneficial Role of Monocyte-derived Macrophages and Microglia in 
Remyelination 
The healthy brain is largely depleted of adaptive immune cells, with T-cells 
predominating in the CSF. However, cells with innate immune functions are present 
in the CNS at all times, primarily astrocytes and microglia, but also a minority of 
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monocytes are settled in the meninges and perivascular spaces of parenchyma 
capillaries and arteries (Ransohoff and Engelhardt, 2012). As the brain is relatively 
immune-privileged, antigen presenting cells (APCs) have limited capacity to present 
antigens (Ransohoff and Cardona, 2010). However, adaptive immune cells can enter 
the CNS by trafficking across the BBB to the CNS allowing for some activation of 
innate immune cells in both the healthy brain and when the BBB has been 
compromised due to disease or injury  (Ransohoff and Engelhardt, 2012).  
Macrophages and microglia have many roles as APCs of the CNS, including 
monitoring the tissue environment for pathogens, maintaining homeostasis, and 
phagocytosing dead cells (Diemel et al., 1998; Giulian et al., 1989; Rawji and Yong, 
2013). Although macrophages and microglia are both myeloid cells, they are derived 
from different origins and maintain unique markers within the CNS. Microglia are 
derived from the yolk sac during early development and reside in the CNS through 
adulthood, whereas blood-derived monocytes are differentiated from bone marrow 
cells and are usually recruited to the CNS in response to an insult (Ginhoux et al., 
2010; Neumann et al., 2009; Ousman and Kubes, 2012).    
 
1.6.1 Microglia 
  Microglia are the resident macrophages of the CNS and constitute 
approximately 15% of CNS cells (Lawson et al., 1992). They mediate innate immune 
responses in this system and originate during early development. These cells 
express many toll-like receptors to recognise pathogens and protect the brain and 
spinal cord (van Noort and Bsibsi, 2009). Microglia can display other innate immunity 
via these receptors; they also help maintain homeostasis independent of this 
immune activity. In contrast to blood-derived macrophages, microglia express low 
levels of CD45 and do not express the C-C chemokine receptor 2 (CCR2), which is 
targeted in monocyte recruitment. Also, circulating monocytes are short-lived, while 
microglia can self-renew and are long-lived (Perry et al., 2010). Due to this, they are 
extremely malleable cells and can rapidly change their function and phenotype. 
 Based on their environment, microglia can display different morphologies and 
functions. In their resting state of the healthy CNS, microglia display a ramified 
morphology, with small soma and fine cellular processes (Streit et al., 1988; Vinet et 
al., 2012). These microglia elongate and retract their processes to monitor their 
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surrounding environment (Nimmerjahn et al., 2005). They have also been known to 
promote the survival and maturation of developing OPCs (Nicholas et al., 2001). 
They contribute to myelin turnover through macropinocytosis of exosomes from OLs 
(Fitzner et al., 2011). Due to infection, trauma, disease, etc., a profound change 
occurs in microglial phenotype. During this activation, microglia become less 
complex than the ramified state and take on a more amoeboid phenotype. They are 
able to become more active and move to lesion sites in this activated state (Haynes 
et al., 2006; Stence et al., 2001). They may proliferate in response to the diseased 
state as well. They can also phagocytose tissue debris, damaged cells, and 
pathogens in their activated state as well as upregulate TLRs, MCHII, and CD68 
(Beyer et al., 2000; Kettenmann et al., 2011; Olson and Miller, 2004).  
Although neuroinflammation has traditionally been considered a pathogenic 
driver of MS (Lassmann, 2007; Nataf, 2009), it has more recently been associated 
with myelination and remyelination as well (Foote and Blakemore, 2005; Setzu et al., 
2006). Using a cuprizone model, one study was able to distinguish the effects of 
microglia and monocytes in remyelination. They found that activation of microglia 
supported remyelination through the activation of MHCII with effective phagocytosis 
of myelin debris (Olah et al., 2012). A more recent study of microglia in the EAE 
model also suggested microglia are more involved with debris clearance early in the 
demyelination process and express several receptors associated with MS tissue 
sections, including CCR7 and CD40 (Yamasaki et al., 2014). Through the use of 
CX3CR1 labelling to identify microglia, the authors were also able to show that 
microglia act earlier in debris clearance. However, at later stages of EAE 
progression, during remyelination, both cell types are indistinguishable and both act 
in myelin debris phagocytosis and neuroinflammation.  
1.6.2 Monocyte-derived macrophages and remyelination 
Although microglia and monocyte-derived macrophages are difficult to 
distinguish once they are activated, studies have suggested that monocyte-derived 
cells play the pivotal role in myelin debris clearance and CNS remyelination (Kotter 
et al., 2005; Ruckh et al., 2012), but both cell types are able to phagocytose debris 
(Neumann et al., 2009; Olah et al., 2012; Yamasaki et al., 2014). Monocytes and 
macrophages can enhance remyelination through the release of protective cytokines 
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and growth factors in response to demyelination. Macrophages have been shown to 
release growth factors that specifically promote OPC differentiation thereby 
stimulating recovery (Table 1.2). In a study looking for growth factors upregulated 
during remyelination, insulin-like growth factor 1 (IGF-1) and transforming growth 
factor β (TGFβ) were both released by myelin-phagocytosing macrophages and had 
been shown to enhance OPC differentiation in culture. The release of IGF-1 by M2 
microglia in vitro exerts beneficial effects on neural progenitor cells and encourages 
oligodendrogenesis (Butovsky et al., 2006). Both growth factors become more 
abundant after monocyte-derived macrophage infiltration rather than astrocyte or 
microglia activation, indicating that they are primarily produced by blood-derived 
phagocytes. IGF-1 and TGFβ exhibit increased expression in a similar temporal 
pattern as new myelin sheaths are formed, so they seem to share a similar function 
in OPC maturation (Hinks and Franklin, 1999). These growth factors also show 
lowered peak expression in aged animals and are associated with delayed 
remyelination, indicating their expression is importation for effective recovery (Hinks 
and Franklin, 2000).  
 Leukemia inhibitory factor (LIF) is released by macrophages as a member of 
the interleukin (IL)-6 family and is known to be a neuropoietic cytokine that 
encourages OPC differentiation both in vitro and in vivo (Deverman and Patterson, 
2012). When LIF binds to receptor complexes on macrophages, it activates 
phosphatidylinositol-3-kinase (PI3K) pathways known to activate myelin debris 
phagocytosis and has been shown to stimulate phagocytosis in models of 
demyelination and remyelination. Release of LIF inhibits production of reactive 
oxygen species (ROS) and stimulates proliferation and differentiation of OPCs 
through the activation of the gp130 receptor (Hendriks et al., 2008). Another 
secretory peptide released by macrophages is endothelin 2 (ET-2). ET-2 is a 
cytokine and growth factor that regulates chemotaxis and activation of macrophages 
and affects their inflammatory capacity. In cerebellar slice cultures, ET-2 was 
released by macrophages in demyelinated environments and promoted 
remyelination. The receptor for ET-2, endothelin receptor B, responds to this release 
and is expressed on oligodendrocytes during remyelination. Blocking ET-2 activity by 
using an antagonist for this receptor inhibited OPC maturation, indicating that ET-2 
release is necessary for efficient remyelination (Yuen et al., 2013). The cysteine 
protease inhibitor cystatin F is activated during acute demyelination and stays active 
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in remyelinating areas. Cystatin F is expressed by macrophages and microglia, and 
myelin debris phagocytosis induces its release. This induction is specific to the 
phagocytosis of myelin debris and results in the overexpression of cystatin F 
specifically in remyelinating areas, indicating that its expression in phagocytes may 
play a unique role in OPC differentiation (Ma et al., 2011). 
 In addition to growth factors and cytokines, macrophages can also regulate 
other molecules that encourage OPC differentiation. Iron is required for the 
proliferation and maturation of cells due to its role in DNA synthesis and oxidative 
metabolism. Regulation of iron content is also specifically involved in 
oligodendrogenesis and is necessary for OPC differentiation and remyelination 
(Schulz et al., 2012). Ferritin, an effective iron storage component, is present in 
activated macrophages and allows them to colocalise with areas of cell genesis in a 
dose-dependent manner. Ferritin can sequester thousands or iron atoms and 
functions to oxidise the more toxic Fe2+ to the less reactive Fe3+. Since iron is a pro-
oxidant and oxidation causes cell cycle arrest, the release of iron from macrophages 
can help enhance OPC differentiation. M2 myelin-phagocytosing macrophages 
release iron after myelin debris phagocytosis and are the main source of iron for 
OPCs. Excess ferritin can also negatively regulate OPC differentiation, but when iron 
is released by macrophages at the appropriate timepoint after demyelination, it 
improves OPC maturation and helps replace lost oligodendrocytes (Mehta et al., 
2013; Schonberg et al., 2012). By enhancing OPC differentiation, all of these trophic 
factors can encourage recovery in demyelinating disorders and confirm the beneficial 
effects of macrophages in remyelination.  
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 Released factor  Mechanisms causing OPC differentiation  Reference  
IGF-1 (Insulin-like 
Growth Factor 1)  
Binds IGF1R to enhance both 2’-3’ cyclic 
nucleotide 3’-phosphohydrolase (CNP) and 
myelin basic protein (MBP) expression  
(Mozell and 
McMorris, 1991)  
TGFβ 
(Transforming GF 
β)  
Downregulates PDGF and FGF, both of 
which promote OPC proliferation and 
precursor cell state, thereby promoting 
maturation  
(McKinnon et al., 
1993a; McKinnon 
et al., 1993b)  
LIF (Leukaemia 
inhibitory factor)  
Limits ROS production; Activates gp130 on 
OPCs  
(Hendriks et al., 
2008)  
ET-2 (Endothelin 
2)  
Activates Endothelin Receptor A & B on 
OPCs, which mediate ERK and CREB 
phosphorylation and transcription of mature 
oligodendrocyte genes  
(Gadea et al., 
2009; Yuen et al., 
2013)  
Iron/Ferritin  Acts in oxidative metabolism to cause cell 
cycle arrest in OPCs and promote maturation  
(Todorich et al., 
2008)  
 
Table 1.2: Factors released by myelin-phagocytosing macrophages and 
microglia that promote OPC differentiation and remyelination. Both growth 
factors and other trophic molecules promote remyelination by activating receptors 
and downstream pathways involved in OPC differentiation. Several studies have 
shown that monocytes and macrophages are primary sources of these molecules.  
 
1.7 Ageing reduces phagocytosis of myelin debris 
CNS remyelination occurs more rapidly in young animals partly due to 
extrinsic factors such as the macrophage response, so it is important to consider the 
effects of age on these cells (Hinks and Franklin, 2000; Sim et al., 2002). Ageing has 
a profound impact on the immune system, and several studies have shown 
significant changes in the gene expression profiles of innate immune cells as they 
age (Lloberas and Celada, 2002; Stout and Suttles, 2005). Recruited monocytes and 
macrophages display impaired phagocytic function in respiratory disorders, and 
wound-healing macrophages show a considerable reduction in phagocytosis of cell 
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debris in response to age. The tissue remodelling and repair function of 
macrophages declines through decreased release of growth factors and impaired 
cytoskeletal rearrangement in these models (Ashcroft et al., 1997; Mancuso et al., 
2001; Swift et al., 2001). Human monocytes are also altered with age, and these 
age-related changes include impaired phagocytosis, shortened telomeres, and 
weakened anti-inflammatory functions (Hearps et al., 2012). Similar to other 
systems, the macrophage response to demyelination declines with age (Hinks and 
Franklin, 2000). Lesions in old animals contain more myelin debris, while lesions in 
young animals contain less debris and more remyelinated axons (Ruckh et al., 2012; 
Shields et al., 1999). There is a delay in both the recruitment and proliferation of 
monocyte-derived macrophages in aged animals; there was also an increase in 
expression of various pro-inflammatory cytokines, including tumour necrosis factor 
(TNF) α, IL1β, IL6, IL12, and IL23. These pro-inflammatory macrophages contribute 
to the decline in remyelination of aged animals (Shields et al., 1999; Zhao et al., 
2006). 
Monocytes and blood-derived macrophages appear to be the key regulators 
in the age-related decline in remyelination. By connecting the circulatory systems of 
young and aged animals, a model called heterochronic parabiosis, aged mice were 
exposed to the systemic milieu of young mice. Young mice were GFP+, so Ruckh, et 
al. were able to distinguish the young cells recruited to the demyelinated lesions in 
the aged partner. These cells proved to be blood-derived monocytes; impairing 
recruitment of young monocytes to demyelinated lesions prevented effective 
remyelination. Conversely, recruitment of young monocytes improved remyelination 
in this model. In addition, there was significantly more myelin debris in the lesions of 
old animals compared to that of young animals, indicating the efficiency of myelin 
debris clearance is impaired with age. However, when myelin debris clearance in old 
mice is accelerated with monocytes from young mice, there is a significant decrease 
in fractionated myelin and a considerable increase in remyelination (Ruckh et al., 
2012). This study proved that in CNS biology, signals from the systemic 
environment, such as those from young macrophages, are able to override age-
related deficits in myelin debris phagocytosis and CNS remyelination (Fig 1.7). 
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Figure 1.7: Efficient myelin debris clearance and the recruitment of young 
monocytes restore remyelination in aged animals. Aged mice experience 
impaired remyelination and reduced myelin debris phagocytosis compared to their 
young counterparts. One of the key differences between young and old 
demyelinated lesions is the efficiency of circulating monocytes to promote 
remyelination in young animals. A-C) Oil red O staining in lysolecithin-induced focal 
demyelination reveals myelin debris in the lesion. There is significantly less inhibitory 
myelin debris in the lesions of young animals (A) and old animals exposed to young 
monocytes (C) as compared to old animals (B). D-F) CC1, a mature oligodendrocyte 
marker, and Olig2, a pan-OPC and oligodendrocyte marker, were used to measure 
efficient differentiation of OPCs. Young animals (D) and old animals exposed to a 
young systemic milieu (F) expressed significantly more CC1+/Olig2+ mature 
oligodendrocytes as compared to old animals (E) (Ruckh et al., 2012).  
1.7.2 Macrophage Receptors involved in Myelin Debris Clearance 
Macrophages act as efficient phagocytes in response to demyelination by 
removing excess myelin debris. Other cell types, such as astrocytes and Schwann 
cells, may also be involved in debris clearance, but the major actors in the CNS are 
macrophages. Phagocytically active macrophages containing myelin degradation 
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products are present in both animal models of demyelination and in actively 
demyelinating MS lesions (Shi et al., 2011; Vogel et al., 2013). When macrophages 
are artificially depleted before inducing demyelination, a greater number of axons 
remain demyelinated and remyelination is impaired (Kotter et al., 2001). Persistent 
myelin debris after spinal cord injury is correlated with a decrease in infiltrating 
monocytes (Imai et al., 2008). Release of chemotactic factors, such as monocyte 
chemoattractant protein-1 (MCP-1) and gelsolin, is also impaired in the presence of 
degenerated myelin. Gelsolin is necessary for macrophage motility and actin 
polymerization, so it has a role in phagocytosis after monocyte recruitment. Gelsolin 
knockouts experience both impaired recruitment of monocytes and delayed 
remyelination of the peripheral nervous system due to a decreased macrophage 
response (Goncalves et al., 2010). Myelin debris phagocytosis by myeloid cells is a 
vital component of remyelination; therefore, macrophages provide an essential role 
in enhancing OPC differentiation and recovery.  
 The mechanisms of myelin phagocytosis are dependent upon expression of 
multiple receptors and soluble compounds in macrophages, most importantly 
complement receptor 3 (CR3), Galectin3 (MAC-2), C1q, nuclear receptors, and 
triggering receptor expressed on myeloid cells (TREM2) (Fig. 1.8). The presence of 
complement component 3 (C3) on degenerating myelin encourages phagocytosis via 
CR3 (Carroll, 2009). CR3 is expressed by myelin-phagocytosing, monocyte-derived 
macrophages and microglia in EAE models. As an integrin composed of two 
transmembrane subunits, CD11b and CD18, CR3 mediates many cell functions 
including adhesion, motility, and phagocytosis. After binding to ligands from myelin 
debris such as C3, CR3 transmits signals across the cell membrane to engage 
filamentous actin, resulting in actin rearrangement and phagocytic activity (Reichert 
et al., 2001). Expression of this receptor has proven to be essential in myelin debris 
removal via PI3K-dependent phagocytosis (Lutz and Correll, 2003). PI3K is also 
controlled by the MAC-2 pathway. Galectins are a family of β-galactosidases binding 
lectins, with MAC-2 perpetually expressed in macrophages and microglia that 
phagocytose myelin. When conditioned media from MAC-2 expressing microglia is 
added to OPC cultures, it promotes oligodendrocyte differentiation in culture 
(Pasquini et al., 2011). MAC-2 regulates scavenger receptor II and Fcγ receptors, 
which are both involved in myelin phagocytosis, and stabilises Ras GTPases, which 
phosphorylate PI3K. When PI3K pathways are enhanced, actin polymerization and 
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myelin debris phagocytosis are also enhanced (Rotshenker et al., 2008). Another 
component of the complement system, C1q, is importantly linked to phagocytosis 
mechanisms and is upregulated after myelin phagocytosis. Macrophages release 
C1q and then bind and opsonise apoptotic cells to signal phagocytosis (Bogie et al., 
2012; Nauta et al., 2003). 
 Modulating expression of TREM2 also enhances myelin debris clearance. 
TREM2 is a receptor belonging to the Ig superfamily and serves to induce 
cytoskeletal reorganization, augment phagocytosis, and reduce TNF-α and nitric 
oxide synthase production in monocytes, macrophages, and microglia. Blocking 
TREM2 results in exacerbation of demyelination in EAE mice by removing the 
protective functions of macrophages, such as the control of local inflammation and 
clearance of debris (Piccio et al., 2007). Enhancing TREM2 function in EAE limits 
tissue destruction and allows macrophages to maintain CNS homeostasis after 
demyelination. These TREM2 enhanced macrophages also maintain an anti-
inflammatory cytokine profile, further proving their regulatory and regenerative 
capacity (Neumann et al., 2009; Takahashi et al., 2007). These receptors and 
proteins specifically expressed in myeloid-derived cells respond to myelin debris 
signals and show the particular role of macrophages and microglia in the 
phagocytosis of degraded myelin.  
 Macrophages also upregulate many members of the nuclear receptor 
subfamily in response to phagocytosis. Liver X receptors (LXRs), peroxisome-
proliferator activated receptors (PPARs), and retinoid X receptors (RXRs) are 
members of the nuclear receptor family. LXRs are activated by oxysterols and 
lipoproteins such as those in myelin fragments, and their downstream genes have 
been linked to immunoregulatory functions in monocytes and macrophages. PPARs 
have been shown to ameliorate symptoms in mouse models of MS, and they also 
regulate anti-inflammatory gene function in macrophages. RXRs form a heterodimer 
with both of these receptors to enhance their functions. Upregulated gene 
expression of these receptors is seen in myelin-phagocytosing macrophages, 
resulting in suppressed inflammation and activated lipid metabolism (Bogie et al., 
2013; Bogie et al., 2012).  
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Figure 1.8: Macrophages express unique receptors and compounds that 
promote myelin debris phagocytosis. Monocytes, macrophages, and microglia 
are primarily responsible for the removal of inhibitory myelin debris to enhance 
remyelination. Through signals such as MCP-1 and Gelsolin, these myeloid-derived 
cells are recruited to the CNS and express membrane receptors, nuclear receptors, 
and complement components to enhance phagocytosis mechanisms. A) Activation 
of CR3 and MAC-2 leads to PI3K phosphorylation and phagocytosis. LXR, PPAR, 
and RXR are activated by lipid-derived ligands and act as transcription factors to 
enhance phagocytosis and immunoregulation. TREM2 pathways activate 
cytoskeletal rearrangement and response to apoptotic cells which results in effective 
myelin debris clearance. B) Oil Red O stained myelin debris in a demyelinated 
lesion; C) TREM2 staining of region (B) showing phagocytic TREM2+ macrophages; 
D) Actin rearrangement during myelin debris phagocytosis by macrophages; E) CR3
activation in (D); F) Galectin-3 activation in (D); G) Galectin-3 activation in myelin-
phagocytosing microglia (Adapted from: (Gitik et al., 2011; Hadas et al., 2010; Piccio 
et al., 2007)) 
1.7.3 Macrophage polarization 
The phagocytosis of cellular debris is considered to be mainly an anti-
inflammatory process. Two extreme types of macrophages, known as M1 and M2, 
have been identified and are classified into distinct categories based on their 
inflammatory properties such as induction factors, cytokine production, and 
phagocytosis type. However, macrophages show phenotypic plasticity and may fall 
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anywhere along this continuum. Cells are also not committed to the M1 and M2 
phenotype terminally; rather, these are transient differentiation states in 
macrophages (Laskin, 2009; Olah et al., 2012). The presence of these two extreme 
categories has not been shown to be easily distinguished in humans and is likely an 
in vitro paradigm. Specific pathologies may be more associated with one extreme or 
the other depending on stage of disease and timecourse, but mixed populations of 
macrophages with different phenotypes often coexist in these states. In addition, 
among the M1/M2 states, several subcategories exist along the spectrum, resulting 
in a complex mix of macrophage subtypes and functions (Chinetti-Gbaguidi et al., 
2015; Sica and Mantovani, 2012). Nonetheless, this categorization is useful in 
identifying targets in macrophages that may affect diseased states as it allows for 
identification of specific stimuli, signalling pathways, and transcription factors within 
these cells. 
The hallmarks of the two major polarization states are discussed here (Fig 
1.10). M1 macrophages are classically activated macrophages that express pro-
inflammatory cytokines and cell markers while M2 macrophages are alternatively 
activated macrophages that express anti-inflammatory and immunomodulatory 
markers. M1 polarization is induced by interferon-γ (IFNγ) and TNFα from Th1 cells 
and lipopolysaccharide (LPS) released by bacteria. Activation by these three 
molecules results in a high production of pro-inflammatory mediators and destruction 
of micro-organisms and tumour cells. M1 macrophages express CD80 and CD86 co-
stimulatory molecules as well as chemokine receptor 7 (CCR7), resulting in efficient 
antigen presentation. They also release TNFα, nitric oxide (NO), IL6, and IL1β in 
response to stimulation. When macrophages produce NO, they create cytotoxic 
ROSs and also stimulate the secretion of IL-12, another pro-inflammatory cytokine. 
These cytokines increase antigen-presenting activity and may assist in perpetuating 
the autoimmune response (Mikita et al., 2011; Shechter and Schwartz, 2013; 
Vereyken et al., 2011).  
The switch from M1 to M2 macrophages occurs between the OPC recruitment 
and differentiation stage in the lysolecithin model of remyelination and is central to 
recovery after demyelination (Miron et al., 2013). M2 macrophages are induced by 
IL-4, IL-10, IL-13, and lipid mediators from Th2 type inflammation, which are 
inhibitors of the Th1 response. Their primary functions are scavenging cellular debris 
and apoptotic cells, remodelling tissues, and expressing anti-inflammatory molecules 
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(Vereyken et al., 2011). In remyelination, myelin-containing foamy macrophages are 
characterised as M2 macrophages conferring immunoregulatory functions. These 
foam cells in MS lesions express anti-inflammatory molecules and lack pro-
inflammatory cytokines (Boven et al., 2006). Various surface markers such as 
CD209 (on microglia), CD23, CD163, CD206, and mannose receptors indicate M2 
macrophages, which are known to be better at phagocytosing opsonised particles. 
They also produce growth factors that assist in tissue remodelling and repair (Laskin, 
2009). 
M2 cytokines are known to reduce inflammation and have higher angiogenic 
potential. They express high levels of arginase-1 (Arg-1), an enzyme that competes 
with inducible nitric oxide synthase (iNOS). iNOS converts L-arginine to NO and 
exacerbates inflammation, while Arg-1 consumes L-arginine by converting it to 
ornithine and urea, both noninflammatory molecules. Higher levels of Arg-1 in M2 
macrophages are associated with phagocytosis of myelin debris in EAE and 
contribute to modulating neuroinflammation. The increase in iNOS levels at early and 
peak stages of the disease is followed by a decrease during recovery and high 
arginase-1 levels, suggesting that M2 macrophages are important for improvement 
(Ahn et al., 2012; Durafourt et al., 2012). Arg-1 positive macrophages also express 
the M2 cytokine activin A, which is a member of the TGFβ family known to be a 
neuroprotective cytokine expressed in the CNS. Addition of activin A to microglia 
cultures also reduced NO production and downregulated IL-6 and IL-18, showing its 
anti-inflammatory characteristics (Sugama et al., 2007; Wilms et al., 2010). Blocking 
activin A expression inhibits OPC differentiation in vitro and is associated with 
inhibited remyelination in vivo, while adding M2-conditioned media containing activin 
A enhanced OPC differentiation by binding to ACvr2, the activin receptor on OPCs 
(Miron et al., 2013).  
51
Figure 1.10: Expression profiles of M1 and M2 macrophages. CNS monocytes 
and microglia can change their expression profiles based on activation cues present 
in the local environment. The two major subsets are M1 (pro-inflammatory) or M2 
(anti-inflammatory) macrophages. M1 macrophages express CD80, CD86, CCR7, 
and TLRs and release TNFα, iNOS, NO, IL1β, IL6, IL12, and IL23. M2 macrophages 
maintain an immunoregulatory profile in response to IL4 stimulation, and they 
express CD23, CD163, CD206, and mannose receptors and release IL10, PDGF, 
VEGF, iron, Arg-1, and activin A. In response to myelin debris phagocytosis, 
macrophages have a more M2-like phenotype and can help support tissue repair, 
suppress the detrimental immune response, and promote CNS remyelination 
(Adapted from (Laskin, 2009)). 
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Since the balance of regulating inflammation is pivotal for efficient 
remyelination (Miron et al., 2013; Vogel et al., 2013; Zhao et al., 2006), the 
modulation of two monocyte-specific soluble and surface markers, CD14 and 
CD163, can be used to identify M1 and M2 type monocytes. CD14 is an LPS 
binding protein and is associated with activating inflammation. It is a co-receptor for 
LPS along with toll-like receptor 4 (TLR4), and it is expressed on the surface of 
monocytes with no intracellular domains due to being anchored to the surface of 
cells by glycosylphophatidylinositol-anchored protein. When LPS binds to the 
CD14-TLR4 complex, it induces inflammatory pathways and the release of several 
inflammatory cytokines, including IL-6, CXCL8, and TNFα. Dysregulating CD14 in 
monocyte cultures results in suppression of IL-10, TNFα, and CXCL8 release (Levy 
et al., 2009). In addition, CD14 has an important role in LPS-mediated injury 
( T r i a n t a f i l o u  a n d  T r i a n t a f i l o u ,  2 0 0 2 ) .  
CD163 has been identified as a primarily immunoregulatory marker. As a 
member of the class B scavenger receptor cysteine-rich superfamily, it is responsible 
for endocytosing haemoglobin complexes. CD163 acts as an anti-inflammatory 
scavenger receptor recognizing free haemoglobin-associated damage and results in 
secretion of anti-inflammatory cytokines such as IL-10. In addition, CD163 surface 
expression is increased in response to M2 activation by IL-10 and M-CSF. CD163 is 
shed from monocytes after proteolytic cleavage due to stimulation by pro-
inflammatory LPS or TLR activation. Soluble CD163 (sCD163) is thought to be 
involved in inflammation resolution as shedding of CD163 occurs in response to 
inflammatory activation by LPS and results in the release of TNFα (Møller, 2011; 
Tippett et al., 2011). In MS, proteolytic shedding of CD163 in the plasma of patients 
results in increased sCD163 levels due to increased matrix metalloproteinase 
activity in plasma (Davis and Zarev, 2005; Fabriek et al., 2007).  
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1.8 Summary 
 OPCs respond to both intrinsic and extrinsic factors to differentiate into 
oligodendrocytes and remyelinate axons (Franklin and Ffrench-Constant, 2008; 
Groves et al., 1993). When remyelination fails in clinical disorders, OPC recruitment 
is often not greatly affected; it is generally due to a failure in the maturation and 
differentiation of OPCs (Dyall et al., 2010; Fancy et al., 2010; Kuhlmann et al., 2008).   
There are multiple extrinsic factors involved in the failure of OPC differentiation, 
including the accumulation of inhibitory myelin debris, age-related decline, and the 
lack of growth factor signalling in the demyelinated area (Hinks and Franklin, 2000; 
Kotter et al., 2006; Robinson and Miller, 1999). Myelin debris clearance and growth 
factor signalling can be the result of an innate immune response performed by 
monocyte-derived macrophages and resident microglia. Innate immune cells, such 
as macrophages, play a prominent role in the remyelination process, and discovering 
a rapid remyelination course is imperative to preventing axonal loss, protecting 
vulnerable axons, and organizing the neural environment for optimal signal 
conduction (Franklin and Ffrench-Constant, 2008). The function of innate immune 
cells in neuroimmunological disorders is currently a complex topic, and determining 
the best method to harness the beneficial role of phagocytes in remyelination is an 
important step in identifying the therapeutic capability of these cells.  
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1.9 Scope of this thesis 
Due to the axon-protective properties of myelin, promoting remyelination is a 
therapeutic goal in demyelinating diseases, specifically for MS, the most prominent 
demyelinating disorder. The beneficial effects of monocytes and monocyte-derived 
macrophages in myelin debris clearance and CNS remyelination can be beneficial in 
remyelination therapies for MS through the peripheral blood system. Ageing has also 
proven to be a significant barrier in macrophage activity and impairs remyelination.  
The overall aim of this project was to address the impact of ageing on myelin 
debris clearance and CNS remyelination. Using both human and murine model 
systems, this project allowed for modulation of receptor activation and expression in 
the genetically controlled mouse system and sought to translate these results to the 
more heterogeneous human population. Using these tools, four key questions were 
investigated: 
1. What are the intrinsic differences between young and old macrophages that
allow young macrophages to clear myelin debris more efficiently?
2. Is myelin debris phagocytosis deficient in ageing human monocytes and those
from MS patients?
3. Can aged macrophages be made to behave like young macrophages?
4. What are the therapeutically-modifiable targets in monocytes and
macrophages that can create a more youthful state and enhance myelin
debris clearance?
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2. Materials and Methods
Animal Models 
2.1 Animals 
Female C57Bl/6 mice from Charles River Laboratories were used for in vitro cell 
isolations. All mice used for in vitro studies were euthanised by the United Kingdom 
Home Office Schedule 1 methods using a CO2 chamber. All experiments were 
performed under the UK Home Office project licenses issued under the Animals 
(Scientific Procedures) Act. 
2.2 Mouse Bone Marrow Monocyte-Derived Macrophage Cultures (BMMs) 
Bone marrow cells were collected from the tibiae and femurs of C57Bl/6 mice by 
scraping and flushing with a 23-25g needle and 5 ml syringe and using complete 
RPMI (cRPMI) medium consisting of RPMI 1640 (Invitrogen) supplemented with 
15% heat-inactivated foetal bovine serum (FBS, Biosera), 20% L929 fibroblast-
conditioned media (to provide macrophage colony stimulating factor, M-CSF), 100 
u/ml penicillin, 100 μg/ml streptomycin, 2 mM L-glutamine, 0.05 mM β-
mercaptoethanol, and 0.1 mg/ml Na-pyruvate.  
For collection of L929 conditioned media, approximately 200,000 L929 fibroblast 
cells were seeded in 75 cm2 flasks in 20 ml of: RPMI 1640 supplemented with 10% 
heat-inactivated FBS. Cells were incubated at 37 °C in a humidified 5% CO2
atmosphere incubator (used for all further studies) and grown to confluency. Media 
were discarded, and cells were scraped into 5 ml of pre-warmed media per T-75 
flask. Cells from 3 flasks were pooled in a 15 ml conical tube and centrifuged at 250 
g for 5min. Supernatants were aspirated and cells were resuspended in 20 ml pre-
warmed media. The cell suspension was equally distributed to 10 T-175 flasks 
containing 100 ml L929 media. After ~1 week, the conditioned media of the confluent 
fibroblasts were harvested and filtered using a 1000 ml, 0.22μm pore Millipore 
Stericup Filter and aliquoted at 25 ml in 50 ml conical tubes and stored at -20 °C for 
up to 1 year. 
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Cell numbers from the bone marrow cells were counted using a haemocytometer, 
and the cells were seeded in tissue culture plates in fresh cRPMI at 1x107 cells per 
100 mm tissue-culture treated dishes (Corning) in 10 ml cRPMI. Cells were 
incubated at 37 °C in a humidified 5% CO2 chamber for 3 days, and the non-
adherent population was aspirated on Day 3. Media was replaced with 10 ml fresh 
cRPMI. On Day 7, numerous adherent cells were evident and remaining non-
adherent cells were aspirated and removed. BMMs were gently washed with 5 ml 
warm phosphate buffered saline (PBS) 1X (per dish), and then scraped and 
collected in 3 ml cRPMI. Each 100 mm dish yielded approximately 7-10x106 
macrophages. Macrophages were pooled into a 15 ml conical tube (BD), and cells 
were centrifuged for 10min at 200 g. Supernatant was aspirated, and cells were 
resuspended in 3-5 ml cRPMI to count macrophages on the haemocytometer. Cells 
were plated in cRPMI at a density of 1x105 cells/well in a 24-well plate (for 
immunocytochemistry analysis) or 7-10x106 cells/dish in a new 100 mm dish (for 
Western blots and flow cytometry). After plating overnight, media were changed to 
Macrophage Serum-free Media 1X (Gibco 12065-074) with 1 ml/well in a 24-well 
plate and 10 ml/dish in 100 mm dishes. Macrophage isolation procedure is 
highlighted in Figure 2.1. All agonist, antagonist, and myelin treatments below were 
performed in serum-free media. The adherent cells were identified with a 
macrophage surface antigen, CD11b or Iba1 (Primary antibodies in Table 2.1), to 
confirm that they were bone marrow monocyte-derived macrophages (BMMs). 
Figure 2.1 Collection of bone marrow from hind limbs. Bone marrow was 
isolated from femurs and tibiae of C57Bl/6 mice and cultured in media conditioned 
with M-CSF from L929 media to promote macrophage growth and differentiation 
from pre-monocytic cells. Cells can then be used to study macrophage activity, 
including phagocytosis, nuclear receptor expression and modulation, and ageing.  
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 2.3 Myelin Isolation 
Whole brains were collected post-mortem from C57Bl/6 mice from age 1-32 mo. 
Myelin was isolated using a discontinuous sucrose gradient (Norton and Poduslo, 
1973) as shown in Figure 2.2. Sucrose was dissolved in sterile-filtered 2.5 mM 
Tris/HCl, pH 7.0, to form 0.32 M and 0.85 M solutions. The brains were 
homogenised in ice-cold 0.32 M sucrose (10 ml/brain) using a 40-ml Dounce 
homogeniser. The homogenate was layered over 10 ml 0.85 M sucrose in 37.5 ml 
thick-walled Beckman ultracentrifuge tubes and ultracentrifuged at 75,000 g for 30 
min (Beckman-Coulter). The interface was collected and pelleted in 0.32 M sucrose 
(75,000 g, 30 min). The pellet was resuspended in 40 ml distilled H2O and washed 
(75,000 g, 20 min) and then osmotically shocked with 40 ml ice-cold distilled H2O 
(40,000 g, 20 min). After centrifugation, the pellet was washed once more in 40 ml 
ice-cold H2O (40,000 g, 15 min), and the weight of purified myelin was determined. 
The protein concentration was determined using a bicinchoninic acid (BCA) Assay 
Kit (Thermoscientific). BCA works by colourimetric detection of the cuprous cation 
(Cu+1) chelating with two molecules of BCA, producing a purple-coloured reaction 
product with absorbance at 562nm. This absorbance is linear with protein 
concentration from 20-2000 µg/ml. BCA assay revealed that age did not affect 
protein content in myelin fragments (Fig 2.3). Myelin fractions were resuspended in 
PBS 1X at 20 mg/ml and stored in 500 μl aliquots at -70 °C. For all experiments, 
myelin was added to BMMs at 50 μg/ml. For phagocytosis assays, 50 μg/ml 
fractionated myelin was added to 24-well plates or 100 mm dishes for 8h after 
agonist/antagonist treatment and before collection.  
Figure 2.2 Purified myelin fractions. Overview of myelin isolation from whole brain 
tissue. 
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Figure 2.3 Age does not have an effect on protein concentration in isolated 
myelin. The BCA assay was used to measure protein concentration in myelin 
fragments. Myelin fragments from the brains of mice aged 2mo, 8mo, and 12mo 
were compared. One-way ANOVA, post-hoc t-test, n=3/age group. 
2.4 Peritoneal Macrophages and Microglia Cultures 
Experiments performed by Eimear Linehan at the University of Belfast. 
Peritoneal macrophages were harvested by peritoneal lavage with 10ml of cold PBS 
1X. Peritoneal macrophages were plated in Dulbecco’s Modified Eagle Medium 
(DMEM, Invitrogen) supplemented with FBS (10%), l-glutamine (2mM) and penicillin/
streptomycin (100U/ml). For Microglia, a cell suspension from CNS tissue of C57Bl/6 
mice was prepared using a Neural Tissue Dissociation Kit (Miltenyi). Myelin debris 
was removed using Myelin Removal Beads II (Miltenyi). Microglia were then isolated 
using anti-CD11b MicroBeads (Miltenyi). Peritoneal macrophages and microglia 
were seeded on chamber slides (7x104/well) for immunocytochemistry or in 96-well 
plates for flow cytometry.  Fluorescently-labelled myelin debris (10 μg/ml protein) 
was added for 2h. Cells for flow cytometry were incubated with anti-CD16 and anti-
CD32 to block Fc receptors, stained with anti-CD11b and anti-CD45 
(eBioscience) and fixed with Medium A (Invitrogen) prior to acquisition on 
BDFACSCantoII. Chamber slides were fixed with 4% paraformaldehyde (PFA) then 
washed and blocked with 10% normal goat serum (NGS, Sigma). Cells were stained 
with CD11b-APC (eBioscience), washed and stained with DAPI. Finally, slides were 
washed, mounted and visualised with a Leica DM5500 microscope using a Leica 
DFC340 FX camera. Objectives: 40X HCX PL APO 0.85 Corr, 100X HCX PL 1.40- 
0.7 Oil and quantified using ImageJ software.
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2.5 Immunocytochemistry of BMMs 
BMMs were fixed in 4% PFA for 10 min and washed twice with PBS 1X. Before 
staining, the coverslips were blocked in 5% NGS with 0.1% Triton-X-100 (Sigma) for 
1h at room temperature (RT). Then the coverslips were incubated with primary 
antibodies (Table 2.1) diluted in blocking solution for 1h at RT. After washing 
3x10min with PBS 1X, secondary antibodies diluted in blocking solution were applied 
for 1h RT (Table 2.2). After the incubation, coverslips were washed 3x10min and cell 
nuclei were stained 5min RT with Hoechst (Sigma), 10mg/ml diluted 1:5000 in PBS 
1X. Coverslips were washed 2x10min with PBS and mounted with Fluoromount G 
(Southern Biotech) onto polysine slides and dried overnight. Quantification was 
performed by obtaining pictures of five randomly chosen areas of the 13mm 
coverslip with a 20X objective using Zeiss Axiovision Observer A1 fluorescence 
microscope. Using ImageJ software and the cell counter plug-in, the number of cells 
positive for Iba1 (macrophage marker), Retinoid X Receptor (RXR) α, RXRγ and/or 
MBP (myelin basic protein) (Table 2.1) were determined and used to visualise 
intracellular, phagocytosed myelin. 
2.6 Western Blots 
BMMs treated and not treated with myelin from ages 1-24mo were lysed with 10% 
sucrose with Halt protease and phosphatase inhibitor cocktail 1:100 
(ThermoScientific) and homogenised by pipetting. The protein concentration was 
determined using a BCA Assay Kit (ThermoScientific). Samples were incubated with 
BCA reagents for 30 min at 37 °C and protein concentration measured using a 
nanodrop spectrometer. 
The lysate was mixed with NuPAGE sample LDS loading buffer with 1X NuPAGE 
Reducing Agent (10X). The samples were boiled at 95 °C for 10min. 5-15μg of 
sample in a volume of 40μl was loaded in NuPAGE Novex 4-12% Bis-Tris gels. Gels 
were run at 100V for 2h 30min in MOPS SDS running buffer 1X. In the inner 
chamber, 250μL of NuPage antioxidant (Invitrogen) was added per 100 mL of MOPS 
SDS running buffer 1X. Precision Plus standard protein ladder (Bio-Rad) was used 
to determine protein molecular weight. Once the proteins were properly separated, 
gels were transferred onto nitrocellulose membrane (GE Healthcare Amersham 
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Hybond ECL membrane). Transfer was run in a Bio-Rad tank for 100min at 90V at 
4°C on ice using Tris/Glycine/SDS transfer buffer 1X (Bio-Rad).  
Nitrocellulose membranes were blocked with 5% milk in PBS 0.1% Tween-20 
(Sigma) for 1h at RT. Primary antibodies diluted in 5% milk in PBS-T were used to 
detect RXRα, RXRβ, RXRγ, and Peroxisome Proliferator Activated Receptor γ 
(PPARγ) (Table 2.1) in an overnight incubation at 4°C. Three 10min washes with 
PBS-T removed excess primary antibody. HRP-conjugated goat anti-mouse and 
rabbit secondary antibodies in 5% milk in PBST were added for 2h at RT to detect 
the primary antibodies (Table 2.2). Three 10min washes with PBS-T removed 
excess secondary antibody. Proteins were detected with the highly sensitive 
enhanced chemiluminescent reagent (ECL, Amersham) peroxidase substrate, and 
the horse radish peroxidase (HRP) reaction was detected using exposure films 
(ThermoScientific) which were exposed for 2min, 5min, 15min, or 30min. The film 
was developed by immersion in Kodak GBX developer for 1min and fixing the film in 
Kodak GBX fixer for autoradiography for 1min (Sigma). Developed films were 
quantified using ImageJ software. The films were scanned as an 8bit image and 
each band was surrounded and selected and its integrated density measured. Each 
of the bands was normalised using the correspondent β-actin band measured in the 
same way.  
2.7 Treatment with agonists and antagonists 
RXR and its binding partner PPARγ agonists and antagonists were used to modulate 
these pathways in BMM cultures. The agonists and antagonists were added for 24h 
before beginning the myelin phagocytosis assay for a further 8h. The following 
concentrations of agonists and antagonists were used: RXR agonist 9 cis Retinoic 
Acid (9cRA) at 1μM, RXR antagonist HX531 at 10 μM, and PPARγ antagonist N-(4′-
aminopyridyl)-2-chloro-5-nitrobenzamide (T007) at 10 μM (Yamauchi et al., 2001). 
2.8 Fluorescence Activated Cell Sorting (FACS) for BMMs 
BMMs were replated to 100 mm dishes (Corning) and allowed to adhere overnight. 
Media was changed and 10 µM of the antagonists HX531, T007, or DMSO controls 
were added for 24h to 2mo young controls. Subsequently, DiO-labelled myelin (50 
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µg/ml) was added to phagocytosing groups for 8h. Cells were then washed, 
detached, and centrifuged at 300 g for 5 min. Pellets were resuspended in FACS 
buffer (PBS 1X, 1% FBS) and CD11b-APC (eBioscience, 1:300) was added for 
30min at 4ºC. Cells were then washed and resuspended in FACS buffer prior to 
acquisition on a BD FACSCalibur. Phagocytosis index was determined by the 
percentage of macrophages CD11b-APC+/DiO Myelin-FITC+ using SigmaPlot 
software.  
Myelin was labelled with the lipophilic dye DiOC18(3) (DiO, Sigma) by taking 0.0020 g 
DiO and resuspending in 1ml DMSO. 375 μl of DiO/DMSO solution was added to 10 
ml PBS 1X. Then, 40 mg of isolated myelin was added to DiO-PBS solution. Myelin 
was incubated in diluted DiO solution for 30 min at 37°C. Then, the solution was 
centrifuged at 300 g for 10 min in a 15 ml conical tube. Labelled myelin was 
resuspended in 2 ml PBS 1X and stored at –80°C. 
2.9 Co-Immunoprecipitation 
BMMs were replated and kept in serum-free media for 24h in 100 mm dishes and 
then phagocytosing groups were treated with myelin for 8h. Cells were washed with 
PBS 1X and then lysed with 50 μL IP lysis/wash buffer from the kit (0.025M Tris, 
0.15M NaCl, 0.001M EDTA, 1% NP40, 5% glycerol) together with Halt protease and 
phosphatase inhibitor cocktail 1:100 (ThermoScientific). Protein amount was 
measured with BCA protein assay (ThermoScientific). Immunoprecipitation was 
performed following the protocol of Pierce crosslink immunoprecipitation kit 
(ThermoScientific). 10μg of the antibody against PPARγ (Table 2.1) were bound to 
the Protein A/G agarose beads at RT on rotation for 1h. Then antibodies were 
crosslinked to the agarose beads with 2.5mM DSS crosslinker for 1h to avoid the 
elution of antibodies with the proteins. After crosslinking, between 200 and 600μg of 
the cell lysates were added and incubated at 4°C overnight. Antigen elution was 
performed in 30μL elution buffer and the samples were prepared for SDS-page gels 
and used for western blot (explained above). In order to analyse the binding of RXRα 
to the same pulled down protein, western blot membranes were stripped with 
stripping buffer (50mM Tris-HCL pH 6.8, 2% SDS, 50mM DTT or 100mM β-
mercaptoethanol diluted in water) for 30 min at 75°C. Then the membranes were 
washed 2x10min with double distilled water and another 3x with PBST. Membranes 
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were blocked for 1h at RT with 5% milk in PBST and incubation with PPARγ was 
repeated. After western blots, each band was selected and integrated density was 
measured in ImageJ. Each band was normalised by dividing their integrated density 
by the integrated density of the co-immunoprecipitation protein, PPARγ.  
2.10 Knockout Mice 
Knockout mice bred and genotyped by Vanessa Nunez at the CNIC Madrid. 
Mice with floxed RXRα alleles were crossed with lysozyme-M (LysM) Cre 
recombinase transgene (Cre) mice to generate offspring with macrophage-specific 
loss of RXRα (Núñez et al., 2010). Mice were bred on a mixed C57Bl/6 and 129/Sv 
background. The offspring containing the lox-P-targeted RXRα gene and the Cre 
transgene (LysM-Cre+/ RXRαfl/+) were then crossed with RXRαfl/fl mice to generate 
mice with an active Cre transgene and the RXRα floxed allele (LysM-Cre+/RXRαfl/
fl). LysM-Cre-negative RXRα floxed mice were considered wildtype (WT) and RXRα 
floxed-LysMCre+ mice were considered knockout (KO) animals. Mice aged 4mo 
were used for experiments. Mice were bred and genotyped at the CNIC, Madrid, 
Spain. Mice were genotyped by PCR using the primers P1, P2, and P3 as 
described (Ricote et al., 2006). KO and WT distinction is visualised in Fig. 2.4. 
Figure 2.4 Generation of Lysozyme-M Cre-RXRα floxed WT and KO mice. 
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2.11 Lysolecithin-induced Demyelination 
Demyelinating lesions were induced in the ventral funiculus of the thoracic spinal 
cord with 1 μl 1% lysolecithin (lysophosphatidylcholine, vol/vol). Lysolecithin was 
prepared by dissolving powder (Sigma) in sterile PBS 1X and storing it at -20°C. 
Solution was defrosted and sonicated for 15min and vortexed to eliminate any 
micelles or particles. Mice were induced under general anaesthesia with 2.75% 
isofluorane (Abbott) in oxygen. Buprenorphine (Vetergesic, Alstoe) was administered 
subcutaneously at 0.02 mg/kg and used for preoperative analgesia. Hair was clipped 
from the dorsal cervical and thoracic regions and skin was prepared with diluted 
chlorhexidine (Hibiscrub). A skin incision (5 mm) was made over the caudal thoracic 
vertebrae. The subcutaneous fascia and paravertebral muscle were dissected 
between the T12 and T13 vertebrae. The dorsal spinal cord was visualised, and the 
dura was pierced. Using a 10 µl Hamilton syringe with a pulled glass microelectrode 
pipette, lysolecithin was injected in the ventral funiculus for 2min for solution to 
disperse. Muscle and skin were closed using nylon stitches (Ethilon). Mice were 
placed in a warm incubator for recovery.  
Mice were intracardially perfused with 4% glutaraldehyde (for electron microscopy) 
or 4% PFA at 5 days post lesion (dpl), 14dpl, and 21dpl. These timepoints represent 
significant events in the demyelination/remyelination process: 5dpl = OPC 
recruitment and proliferation, 14dpl = OPC differentiation, 21dpl = complete 
remyelination. Before perfusion, mice were heavily anesthetised with 3% isofluorane 
in oxygen and sacrificed with intraperitoneal injection of pentobarbitone (Pentoject). 
Once fully anesthetised, the thoracic cavity was opened and left ventricle was 
pierced with a 23g butterfly catheter hooked to a pre-filled pump. The left atrium was 
pierced and perfusion was continued for 3 min. Spinal cords were dissected from the 
vertebral canal and transferred to 20% sucrose (Fischer). PFA-fixed spinal cords 
were post-fixed overnight and cryoprotected in sucrose before optimal cutting 
temperature (OCT) embedding (Tissue-Tech) and storage at −80 °C. OCT-
embedded tissue was cut in 12µm segments using a Leica Cryostat Microtome, 
collected on poly-l-lysine coated glass slides, and stored at −80 °C prior to staining.  
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2.12 Oil Red O Staining (ORO) 
Tissue sections were dried in 100% propylene glycol (Sigma) for 1min then stained 
at 60°C in 0.5% Oil Red O solution (ORO, Sigma) dissolved in propylene glycol for 
6min. Then, slides were switched to 85% propylene glycol for 2min followed by 
rinsing with distilled water for 1min in coplin jars. Nuclei were stained with 
haematoxylin (Sigma) for 1min and washed with tap water. Slides were mounted 
with jelly mounting media and visualised in brightfield at Nikon Eclipse E600 
microscope and DS-Vi1 camera using 20X (Plan Fluor 20X / NA 0.3) and 40X (Plan 
Fluor 40X / NA 0.75) objectives. Area of ORO and Haematoxylin staining were 
quantified using ImageJ Software, with lesion area denoted by haematoxylin+ 
staining and ORO staining quantified by ORO+ area/total lesion area.   
2.13 Immunohistochemistry 
Cryostat cut sections were dried for 1h at RT and washed with PBS 2x10min. Slides 
were blocked in 7% NGS (Sigma) with 0.1% Triton in PBS for 1h at RT. Primary 
antibodies diluted in blocking solution were applied for 12h at 4°C (Table 2.1). Slides 
were washed 3x10min with PBS 1X and secondary antibodies in blocking solution 
were applied (Table 2.2) for 2h at RT. Slides were washed again and stained with 
Hoechst nuclear stain (1:5000). Slides were washed 2x10min PBS1X and mounted 
with coverslips using Fluoromount G. For nuclear antigens (Olig2), tissue sections 
were incubated for 10min at 75 °C with pre-boiled 1X citrate buffer pH 6 antigen 
retrieval solution (Dako) diluted in double distilled water and continued as above. 
For mouse antibodies (CC1), slides were washed in tris-buffered saline (TBS, 
Fischer) with 0.05% tween-20 (TBST) after initial blocking. Before adding primary 
antibodies, slides were incubated with mouse on mouse (MOM, VectorLabs) for 1h 
at RT. Slides were further washed in TBS-T for the remaining protocol as above. 
Slides were mounted and visualised with 40X objective (EC PLAN 40X / 0.50 Ph1 
numerical aperture) using a Zeiss Axiovision Observer A1 AX10 fluorescence 
microscope with AxioCam HRC HAL100 camera. Cells were counted using ImageJ 
software.   
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2.14 In Situ Hybridisation 
Proteolipid protein (PLP) probe was prepared and diluted in hybridisation buffer and 
denatured for 10min at 75°C then 150 μL of the probe was added to spinal cord 
sections. Slides were coverslipped and incubated in a chamber with 50% formamide 
and SSC in diethylpyrocarbonate-treated dH2O and hybridised overnight at 65°C. 
Slides were then incubated in wash buffer (1X SSC, 50% formamide, 0.1% Tween-
20) at 65°C for 15min. Slides were washed in wash buffer at 65°C and washed twice
for 10min in MABT (100mM maleic acid, 150mM NaCl, 0.1%Tween-20, pH 7.5) at 
RT. Slides were then incubated in blocking solution (2% blocking reagent and 10% 
heat-inactivated sheep serum in MABT) for 1h at RT. Anti-digoxygenin-alkaline 
phosphatase fragments (Roche Molecular Biochemicals) were diluted to 1:1500 in 
blocking solution and added to slides, and slides were incubated overnight at 4°C. 
Slides were then washed 3x10min in MABT and twice in staining buffer (100mM 
Tris-HCl, 100mM NaCl, 5mM MgCl2, pH 9) followed by incubation in 5-bromo-4-
chloro-3-indolyl-phosphate/nitro blue tetrazolium (BCIP/NBT) stock solution (Roche) 
at 37°C for 1-2h. Slides were rinsed in double distilled water containing Hoechst 
followed by 2x1min soaks in 100% ethanol and 2x1min soaks in xylene. Slides were 
coverslipped with Aquamount and visualised in brightfield with a Nikon Eclipse E600 
microscope and DS-Vi1 camera using 20X (Plan Fluor 20X / NA 0.3) and 40X (Plan 
Fluor 40X / NA 0.75) objectives. PLP+ cells and Hoechst+ area were quantified using 
ImageJ Software. 
2.15 Electron Microscopy 
Glutaraldehyde-perfused spinal cords were post-fixed in 2% osmium tetroxide 
(Oxkem Ltd) in phosphate buffer at 4°C overnight followed by dehydration in 70% 
ethanol for 15min, 95% for 15min, and 100% for 3x10min. Tissue was then put in 
propylene oxide twice for 15min and left in 50% propylene oxide, 50% resin mix 
(TAAB embedding resin mix) for 3h and transferred to 100% resin mix overnight. 
Embedding capsules were incubated at 60 °C for 12-24h until resin was solid. 
Embedded samples were cut in 90 nm sections on an ultramicrotome (Reichert 
Ultracut E) with a diamond knife (Diatome) and visualised using a Transmission 
Electron Microscope (Hitachi H600). Electron microscope films (Kodak) were 
developed and scanned at high resolution and analysed with ImageJ software. The 
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g-ratio was used to determine extent of remyelination on all axons. G-ratio = (axon 
diameter) / (diameter of the axon including outer myelin). 
2.16 Statistics for Animal Studies 
Data are presented by mean ± S.E.M in all graphs. All the statistical analysis was 
done using Excel 2010 and Graphpad Prism 6. When comparing more than two 
groups with only one independent variable, one-way ANOVA was used followed by 
Tukey’s multiple comparisons test as a post-hoc test, as in the cases of comparing 
protein expression by western blot. In this case, the single explanatory variable (age) 
had multiple levels (from 2mo-24mo). When two or more variables were involved, a 
two-way ANOVA was used to check interaction amongst the variables and if 
interaction was positive, further analysis was done by Sidak’s multiple comparisons 
test considering these variables separately, as in comparing agonist treatment and 
protein expression by immunohistochemistry. Two-tailed unpaired Student t-tests 
were used to compare antagonist treatment. Results were considered significant if 
p<0.05. Technical replicates were performed at least two or more times for each 
experiment, with n≥4 biological replicates (animals) per experiment. Specific n 
numbers and significance values are indicated in the results section.  
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Human Models 
2.17 Subjects 
Studies were performed according to US National Institutes of Health guidelines and 
all subjects signed informed consent. Study subjects were healthy volunteers in 2 
age groups, Young donors (≤35 years old) and Old donors (≥55 years old) or 
multiple sclerosis (MS) patients in the same age groups. MS patients were 
previously diagnosed as relapsing remitting (RRMS), secondary progressive 
(SPMS), or primary progressive (PPMS) patients based on the 2010 revisions of the 
McDonald diagnostic criteria. 
2.18 Human Monocyte Isolation 
Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood using 
lymphocyte separation medium (LSM, Lonza). Whole blood (30 ml) and 10ml PBS1X 
were mixed and layered over 10 ml LSM in a 50 ml conical tube (BD). Tubes were 
spun at 1200 rpm for 30min at RT. Diluted serum was aspirated, and the remaining 
PBMC layer (above LSM and red blood cells) was carefully removed with a 1 ml 
pipette. Collected cells were washed with 30ml cold PBS 1X and centrifuged at 300 
g for 10 min at 4°C. Cells were resuspended in 10ml cold MACS buffer (2 mM EDTA, 
0.5% Bovine Serum Albumin, BSA in PBS 1X) and spun again. Buffer was aspirated, 
and the cell pellet was lightly dislodged. Cells were resuspended in 200 μl MACS 
buffer and 50 μL CD14+ magnetic microbeads (Miltenyi) and incubated at 4°C for 
15min. Cells were washed with 10 ml MACS buffer and centrifuged at 300 g for 
10min. Supernatant was aspirated and cells were resuspended in 500 μl MACS 
buffer. CD14+ monocytes were isolated by positive selection by running 
magnetically-labelled cells through an LS column attached to MACS magnetic 
separator (Miltenyi). Columns were washed 3x3 ml with MACS buffer. Columns were 
removed from the magnet and 5ml MACS buffer was loaded into each column. 
Columns were then immediately plunged so positively selected cells could be 
collected. Cells were counted by a Neubauer haemocytometer (Hausser Scientific). 
Monocytes were plated in 6-well plates at 1x106/well (for RNA/supernatants) or in 
suspension in 96-well plates at 1x105/well (for flow cytometry) in X-vivo without 
phenol red (Lonza). Monocyte isolation is highlighted in Fig. 2.4. 
70
Figure 2.5 Monocyte isolation from PBMCs. Monocytes were isolated from 
PBMCs by CD14+ selection using CD14 magnetic microbeads (Miltenyi).  
2.19 Human Myelin Isolation and Labelling 
Brain tissue was obtained post-mortem from a PPMS patient. The same protocol 
used for myelin isolation in mice was followed to isolate human myelin (Section 2.3). 
Myelin was stored in 100 μl aliquots at -80 °C. For FACS, myelin was labelled with 
pHrodo green STP ester (Life Technologies). pHrodo dyes are pH-sensitive, suitable 
for studying low pH environments of the phagosome. The dye increases fluorescein+ 
(FITC+) fluorescence upon engulfment by monocytes and macrophages. pHrodo dye 
was reconstituted to 1 mg/ml in DMSO, and 1μL of dye was added to 100 μl of 
myelin. Myelin was protected from light and incubated at RT on a shaker for 30 min. 
Myelin suspension was then washed with 1 ml PBS1X and spun at 250 g at 4°C for 
10min in a microcentrifuge. PBS was aspirated, and pHrodo-labelled myelin was 
resuspended in 100 μl PBS1X and stored at -20 °C for further experiments.  
2.20 Fluorescence Activated Cell Sorting (FACS) of Human Monocytes 
Monocytes in 96-well plates were incubated with 1 µM Bexarotene or Pioglitazone 
(treated groups, Sigma) or the equivalent DMSO (controls) in 100 μl/well of X-vivo 
without phenol red for 30min at 37 °C. Cells were then stained with CD14-APC 
(eBioscience) and CD163-PE (R&D Systems) for 10min at 37 °C. Cells were washed 
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in cold FACS buffer (1 g/L Sodium Azide, 1% FBS, 1X PBS) by adding an equal 
volume of FACS buffer (100 μl/well) and centrifuging at 250 g, 5min, 4 °C. Cells were 
then resuspended in 100 μl warm X-vivo. 10 µg/ml pHrodo-labelled myelin was 
added to phagocytosing groups for 20min at 37 °C. An equal volume of cold FACS 
buffer was then added, and cells were immediately acquired on a BD LSR II and 
analysed with BD FACSDiva 6.1 software. Gating was based on non-phagocytosing 
controls, and myelin-phagocytosing FITC+ cells were normalised to controls. 
Amount of myelin phagocytosis in each treated group was calculated by by the 
phagocytosis index = (Myelin+ fluorescence in treated groups) / (Myelin+ 
fluorescence in non-phagocytosing controls)       
2.21 Microarrays 
Monocytes were separated in 6-well plates at 1x106/well. There were 4 donor 
groups: Young HVs (≤35 years old), Old HVs (≥55 years old), Young MS Patients, 
and Old MS Patients. There were 6 wells per donor (1 well/treatment): Control cells 
(no treatment), Phagocytosing cells (treated with myelin (10µg/ml)), Bexarotene-
treated cells (Sigma, 1µM), Bexarotene-treated Phagocytosing cells, Pioglitazone-
treated cells, Pioglitazone-treated phagocytosing cells. All treatments were 2h. 
Supernatants were incubated for 24h, collected, centrifuged at 250 g at 4°C for 
10min in a microcentrifuge, and stored at −80 °C (for cytokine detection, see Section 
2.25). Cells were then collected in Trizol (Invitrogen) and stored at −80 °C until RNA 
isolations. RNA was isolated using the miRNeasy kit (Qiagen) according to 
manufacturer’s instructions with n=4 per treatment/group.  RNA concentration was 
measured using a Nanodrop ND-2000, and RNA integrity was assessed using 
Bioanalyzer 2100 (Agilent). RNA was sent to the NIH Microarray Core Facility, and 
microarrays were performed on GeneChip Human Gene 1.0 ST Arrays (Affymetrix). 
Ingenuity Pathway Analysis software was used to create diagrams for comparing 
biological pathways. Microarray experiments performed by core facilities are below.  
2.21.1 Sample Preparation for Microarray Hybridisation 
Performed by Abdel Elkahloun at NIH Microarray Core Facility. 
RNA quality control, quantitation, cRNA (complementary RNA) 
synthesis and labelling were performed on a sample-by-sample basis 
according to manufacturer’s guidelines for use 
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with the Affymetrix Human 1.0 ST GeneChip (Affymetrix).  DNase 
treatment was included as part of isolation to remove possible 
contaminating DNA.  Bioanalyzer nanochip (Agilent) and NanoDrop were 
used to validate and quantitate the RNA prior to cRNA synthesis and 
labelling.  For cRNA synthesis and labelling, 5 μg of total RNA was used 
per sample in conjunction with the Affymetrix 3’ one-cycle Target labelling 
Kit (Affymetrix).  
2.21.2 Microarray Hybridisation 
Labelled cRNA were hybridised to Affymetrix Human 1.0 ST GeneChips 
(Affymetrix) in a blinded, interleaved fashion.  The Affymetrix scanner 3000 
was used in conjunction with Affymetrix GeneChip Operation Software to 
generate more than 750,000 oligonucleotide probe measurements for 
each hybridised cRNA. 
2.21.3 Microarray Data Analysis 
Performed by Kory Johnson as the NIH Bioinformatician. Probe 
measurement summarisation and normalisation was accomplished using 
the Affymetrix Expression Console with the "RMA Sketch" option selected 
(Affymetrix).  Subsequent analysis of the data generated by the Console 
was done in “R”.  Data quality was first inspected and assured via sample-
level Tukey box plot, covariance-based PCA scatter plot, and correlation-
based Heat Map using the “box.plot()”, “princomp()”, “cor()”, and “image()” 
functions respectively.  After, gene fragments not having at least one 
expression value greater than system noise were deemed "noise-biased" 
and discarded.  System noise was defined as the expression value across 
experiment groups at which the observed C.V. (Coefficient of Variation) 
grossly deviates from linearity.  For gene fragments not discarded, 
expression values were floored to equal system noise if less than system 
noise then subject to the one-factor ANOVA test under BH (Benjamini and 
Hochberg) FDR (False Discovery Rate) MCC (Multiple Comparison 
Correction) condition using Experiment Group as the factor.  For gene 
fragments having a corrected p-value < 0.05 only, the Tukey HSD 
(Honestly Significant Difference) test was applied and the fold-
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change between all possible group means calculated.  Gene fragments 
having both a Tukey HSD p-value < 0.05 and a fold-change ≥ 1.5 for a 
pair-wise group comparison were flagged as having expression 
significantly different for that comparison.  Subsequent annotation for each 
gene fragment flagged and corresponding enriched pathways and 
functions was obtained using IPA (http://www.ingenuity.com). 
2.22 PCR Arrays and Semi-quantitative Real-Time PCR 
Isolated RNA was converted to cDNA using the QuantiTect Reverse Transcription 
Kit (Qiagen) according to the manufacturer’s instructions. cDNA was stored at −20°C 
prior to experiments. cDNA was pooled from 4 samples in each group and added to 
SYBR Green qPCR SuperMix (Bio-Rad). Each sample was aliquoted on the Human 
Retinoic Acid Signalling PCR Array (SABiosciences), with primer pairs for 84 genes 
in the RXR signalling pathway. Plates were run on a CFX96 Touch Real-Time PCR 
Detection System (Bio-Rad) for 10min at 95 °C, then 40 cycles of 15s 95°C, 60s 
60°C. Data normalisation was performed using Excel 2010 to correct Ct values to 
average Ct values for several constantly expressed housekeeping genes on the 
array. To analyse PCR-data, relative quantification was used to compare samples to 
untreated, Young (≤35 years old) controls, resulting in ∆Ct values used to calculate 
relative fold changes. The effect of bexarotene treatment (|FC| > 1.5) was plotted. 
2.23 Electrochemiluminescence (ECL) 
Electrochemiluminescent assays were developed and optimised to quantify the 
concentrations of selected biomarkers in cell culture supernatants using the Meso 
Scale Discovery (MSD) detection system. The MSD detection system provides a 
combination of high sensitivity with low background and a 5-log-order of magnitude 
dynamic range. The concentrations of soluble CD14 (sCD14) and sCD163 were 
developed in the NDU laboratory. All samples were run in duplicate. Each assay 
contained additional reference samples (minimum of 2) on each plate to check the 
intra- and inter- assay reliability.  
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The standard protocol for the developed assays was as follows; standard binding 
plates (MSD) were coated with 30 µl of working solution of capture antibody and 
stored at 4 °C overnight. The next morning, the coating solution was aspirated, and 
plates were blocked with 150 µl of 1% BSA in PBS 1X for 2h at RT on a shaker at 
200 rpm. After washing plates 3 times with PBS-T, 25 µl of each supernatant sample 
was added to each well, and the plates were incubated for 2h at RT on a shaker at 
200 rpm. Plates were washed again 3x with PBS-T. 25 µl of working solution of 
detection antibody was added to each well, and the plates were incubated as above. 
The plates were then washed and incubated 1h with 25 µl of 0.25 µg/ml Sulfo-tag 
labelled Streptavidin solution (MSD). Finally, plates were washed 3 times with PBS-T 
and 150 µl of 2 fold-concentrated Read Buffer was added for the SI2400 image 
analyser (MSD). The standard curve was generated from a serial dilution of standard 
proteins in 1% BSA in PBS. The details are depicted in Table 2.3. 
2.24 Human M1/M2 Macrophage Cultures 
Monocytes were isolated as in Section 2.8 and plated at 1x106/well in 12-well plates 
(Corning). Two groups were studied: Young HVs (≤35 years old) and Old MS 
patients (≥55 years old, progressive). For each donor group, 8 treatment groups 
were studied:  
1) M1-polarised Cells
2) M1-polarised myelin-phagocytosing cells
3) M1-polarised Pioglitazone-treated cells
4) M1-polarised Pio-treated phagocytosing cells
5) M2-polarised Cells
6) M2-polarised myelin-phagocytosing cells
7) M2-polarised Pioglitazone-treated cells
8) M2-polarised Pio-treated phagocytosing cells
All cells were plated in 1 ml media/well. Media and protocol were adapted from (Mia 
et al., 2014). Basic media was composed of RPMI 1640, 10% FBS, 100 u/ml 
Pen/Strep, and 20 μM β-mercaptoethanol. For M1-polarised cells, 50 ng/ml 
granulocyte macrophage colony stimulating factor (GM-CSF) was added to media. 
For M2-polarised cells, 50 ng/ml M-CSF was added to media. On Day 3, media was 
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changed on both M1 and M2 cells, and 1 μM pioglitazone was added to the 
treatment groups. On Day 6, cells were further polarised to M1 and M2 phenotypes. 
M1 cells were plated in basic media plus: 20 ng/ml IFNγ, 20 ng/ml TNFα, and 50 
ng/ml LPS (Peprotech). M2 cells were plated in basic media plus: 20 ng/ml IL-4 and 
20 ng/ml IL-10 (Peprotech).  
After 24 hours of polarisation, cells were collected and analysed by FACS. Using a 
cell lifter, cells were gently scraped and centrifuged in a microcentrifuge at 2000 rpm 
for 10 min in 2 ml tubes. Cells were resuspended in X-vivo without phenol red and 
1x105 cells/treatment group were stained with M1 and M2 markers (highlighted in 
Table 2.1) for 15 min at 37°C in a 96-well plate. For M1 markers, CD80 and CCR7 
were used. For M2 markers, CD206 and CD163 were used. For all macrophages, 
CD11b was used. After staining, 10 μg/ml pHrodo labelled myelin was added to 
phagocytosing groups for 20 min at 37°C. Cells were washed with FACS buffer and 
fixed using BD FACS Cytofix buffer (100 μl/well) for 20 min at 4°C. Plates were 
centrifuged at 250 g at 4°C for 5min. Then, cells were resuspended in FACS 1X 
Perm/Wash Buffer (BD) and centrifuged as before. Cells were finally resuspended in 
150 μl FACS buffer/well and run on a BD LSR II flow cytometer using BD FACSDiva 
6.1 Software. Mean fluorescence intensity for all markers was determined by dividing 
the MFI of each treated group to the MFI of the control, resting macrophages.  
2.25 Statistics for Human Studies 
SAS and power analysis performed by Tianxia Wu, NIH statistician. Data are 
presented by mean ± S.E.M in all graphs. All the statistical analysis was done using 
SAS 9.2 and Graphpad Prism software. Initial power analysis was performed on a 
small cohort of young HVs, old HVs, young MS patients, and old MS patients. 
Power analysis was conducted using an internal pilot study including 18 young HVs 
and 17 old HVs with outcome measures from pre-treatment, and 48 MS patients 
with outcome from both pre- and post-treatment. Based on  a significance level of 
0.05, a sample size of 18 subjects was required to have 80% power for detecting 
the difference between pre and post-treatment using a paired t-test; a sample size 
of 34 subjects per group was required to have 80% power for detecting the 
difference between the young HV and old HV group using a two-sample t-test. 
nQuery program was used for the power analysis.  Two-way repeated measures 
ANOVA was performed to evaluate the effect of group (between-subject factor, MS, 
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young-HV, old-HV) and treatment (within-subject factor, pre- and post- treatments), 
and the interaction between group and treatment. When the interaction was 
significant, pairwise comparisons among the combinations (group x treatment) were 
conducted with Tukey’s correction procedure.  Natural-logarithm was applied to the 
outcome, Myelin debris phagocytosis, since the distribution had a long right tail. SAS 
9.2 and Graphpad Prism software were used for the statistical analysis and p<0.05 
was used as the significance level. In the case of measuring ECL cytokines and 
surface markers, if interaction was positive, further analysis was done using Sidak’s 
multiple comparisons test. Results were considered significant if p<0.05. Each 
biological replicate also represented a technical replicate as patients/donors were 
collected at independent times.  
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2.26 Antibodies 
Antigen Species Manufacturer Cat. No. Dilution 
RXRγ Rabbit Abcam Ab15518 1:100 
RXRβ Rabbit Santa Cruz SC-774 1:100 
PPARγ Rabbit Santa Cruz SC-1008 1:100 
PPARγ Mouse Santa Cruz SC-271392 1:100 
RXRα Rabbit Santa Cruz SC-553 1:100 
β-actin Mouse Sigma A5441 1:5000 
MBP Rat Serotec MAC409S 1:500 
Olig2 Rabbit Millipore AB9610 1:1000 
CC1 Mouse Calbiochem OP80 1:200 
Iba1 Rabbit Wako 019-19741 1:500 
CD11b Rat Serotec MCA711 1:250 
CD11b-APC Mouse eBioscience 9017-0118 1:300 
CD45-PE Rat eBioscience 12-0451 1:500 
Hoechst N/A Biotium 40043 1:5000 
CD14-APC Mouse eBioscience 17-0149 1:500 
CD163-PE Mouse R&D Systems FAB1607P 1:250 
CD206-APC Mouse R&D Systems FAB25342A 1:250 
CD80-PerCP Mouse eBioscience 46-0809-41 1:500 
CCR7-PeCy7 Rat eBioscience  25-1979-41 1:500 
CD11b-AF450 Mouse R&D Systems FAB16991V 1:250 
Table 2.1 Primary Antibodies. 
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Species Manufacturer Cat. No. Dilution 
HRP Goat anti-mouse Dako P0447 1:1000 
HRP Goat anti-rabbit Dako P0448 1:1000 
Goat 488 anti-rabbit Invitrogen A11034 1:1000 
Goat 488 anti-mouse Invitrogen A11029 1:1000 
Goat 568 anti-rabbit Invitrogen A11036 1:1000 
Goat 568 anti-mouse Invitrogen A11031 1:1000 
Goat 568 anti-rat Invitrogen A11077 1:1000 
Table 2.2 Secondary Antibodies. 
Molecule Manufacturer (Antibodies) Dilution 
factor 
Detection 
limit 
CV 
sCD14 R&D systems  (MAB3833, BAF383) 10 4 ng/mL ≤20% 
sCD163 R&D systems (MAB16071, BAM16072) 10 2 ng/mL ≤20% 
Table 2.3 ECL reagents and detection limits for sCD14 and sCD163. 
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3. Results
Age-related changes in monocytes and macrophages reduce myelin debris 
phagocytosis in vitro 
The aim of the present study was to elucidate the causes of impaired myelin 
debris clearance previously seen in ageing rodent models of remyelination (Ruckh et 
al., 2012; Shields et al., 1999). These studies prompted us to use in vitro 
macrophage cultures to study myelin debris phagocytosis in aged macrophage 
subtypes. Determining the effects of age on phagocytes in vitro would then allow us 
to further study the mechanisms of the age-related decline in myelin debris 
clearance in cultures.  
3.1 Bone marrow monocyte-derived macrophages phagocytose myelin debris 
Bone marrow monocytes were isolated from the tibia and femurs of female 
C57Bl/6 mice and differentiated to bone marrow monocyte-derived macrophage 
(BMM) cultures. These cultures were then exposed to myelin debris, isolated from 
the brains of C57Bl/6 mice, for 8 hours. Light micrographs of BMMs reveal bipolar, 
amoeboid, and branched morphologies among activated BMMs at 20X (Fig 3.1A) 
and 40X (Fig 3.1B) magnification. This phenotypic heterogeneity is represented in 
previous studies of these cultures as well (Trouplin et al., 2013; Wang et al., 2013; 
Wang and Harris, 2011). Electron microscopy of myelin-phagocytosing BMMs shows 
a myelin-laden BMM (Fig 3.1C-D). The multilamellar myelin fragments are located 
throughout the intracellular compartment of the BMM after 8h of incubation, 
confirming ingestion of myelin particles.  
Immunocytochemistry was used to label BMMs and myelin debris to confirm 
myelin debris phagocytosis in vitro (Fig 3.1E-H). The activated macrophage marker, 
Iba1 (Fig 3.1G), was used to label myelin-phagocytosing macrophages, and myelin 
basic protein (MBP) was used to label myelin debris (Fig 3.1H). Degraded myelin 
was determined by punctate debris staining, and MBP+ debris within Iba-1+ 
macrophages was deemed intracellular, phagocytosed myelin debris.   
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Figure 3.1 Bone marrow monocyte-derived macrophages (BMMs) consume 
myelin debris in vitro.  A-B) Light micrographs of BMMs in vitro at 20X (A) and 40X 
(B). BMMs were incubated with myelin isolated from the brains of 2mo mice and 
phagocytosis was analysed. C-D) Electron microscopy was used to show a 
micrograph of a heavily laden, myelin-phagocytosing macrophage and allows 
visualisation of intracellular myelin debris (D).  E-H) An overlay showing myelin 
debris (red=Myelin Basic Protein, MBP) contained inside BMMs (green=Iba1). DAPI 
(F), Iba1 (G), and MBP (H) labelling of myelin-phagocytosing BMMs.  
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3.2 Ageing impairs myelin debris phagocytosis in tissue-derived macrophages 
Previous studies have revealed an age-associated decline in myelin debris 
clearance following experimental induction of primary demyelination (Ruckh et al., 
2012; Shields et al., 1999; Sim et al., 2002). In addition, research also indicates a 
decrease in phagocytosis by various types of macrophages with age (Aprahamian et 
al., 2008; Hearps et al., 2012; Plowden et al., 2004). Both CNS-resident microglia 
and infiltrating macrophages are present in MS lesions and both are involved in 
myelin debris clearance (Franklin and Ffrench-Constant, 2008).  
To test whether a change in myelin debris phagocytosis occurs because of an 
age-associated decline in the intrinsic function of phagocytic cells, the effects of 
ageing on myelin debris phagocytosis using peritoneal macrophages, CNS-derived 
microglia, and BMMs from mice were determined. These subtypes  produced a 
comparison of the phagocytic ability of macrophages derived from different tissues. 
The phagoctostosis index (a % of myelin-phagocytosing cells) was calculated either 
by counting the number of macrophages containing myelin and dividing by the total 
number of macrophages (immunocytochemistry) or by the cells staining positive for 
both macrophage and myelin fluorescence markers (flow cytometry).  
After incubating cells with myelin fragments, immunostaining suggested that 
peritoneal macrophages from young mice (2 months old, 2mo = young) (Fig 3.2A) 
were more efficient at engulfing myelin debris compared to their aged (15-20mo = 
old) counterparts (Fig 3.2B). Flow cytometry analysis confirmed this impairment in 
phagocytosis by aged peritoneal macrophages (Fig. 3.2C, H). BMMs also showed an 
age-dependent decrease in myelin phagocytosis by immunocytochemistry (Fig 3.2D-
E), with more than 50% of young cells phagocytosing myelin while less than 25% of 
aged BMMs (24mo) cleared debris (Fig 3.2H).  
Since microglia-derived macrophages are also likely to be involved in myelin 
debris clearance (Yamasaki et al., 2014), adult microglia cultures were used and 
showed a similar affect of ageing in mice (Fig 3.2F-G). Adult microglia isolated from 
the brains of young and aged (2mo and 15-20mo) mice also experienced a 
significant decrease in myelin debris phagocytosis with age (Fig 3.2G-H). In general, 
the number of phagocytosing microglia was significantly less than other macrophage 
types, with only 19% of young microglial cells phagocytosing myelin debris 
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compared to 50-70% phagocytosis in other young tissue-derived macrophages (Fig 
3.2H). This result may further indicate that monocyte-derived macrophages are more 
important in phagocytosing myelin debris than resident microglial cells in response to 
myelin debris accumulation in the CNS. These in vitro data indicate that ageing 
impairs myelin debris phagocytosis in tissue macrophages and that these cells can 
be used to study the effects of ageing on myelin debris phagocytosis. 
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Figure 3.2 Ageing impairs myelin debris phagocytosis. Macrophage cultures 
were incubated with fluorescent myelin and phagocytosis was analysed. A-C) Aged 
peritoneal macrophages showed impairment in myelin phagocytosis by both 
immunocytochemistry (CD11b-green; Myelin-red, A-B) and flow cytometry (C). D-E) 
Bone marrow monocyte-derived macrophages (BMMs) showed a decrease in 
myelin debris phagocytosis with age. F-G) Myelin debris uptake is reduced in 
microglia cultures from aged mice compared to young (G). H) All 3 macrophage 
subtypes showed significantly reduced myelin debris phagocytosis with age. There 
were significantly fewer myelin-phagocytosing microglia compared to peritoneal or 
BMMs regardless of age. Young=2mo mice, Old=15-24mo mice. Scale bars = 
50μm. Two-way ANOVA, posthoc Sidak’s multiple comparisons test *=p<0.05, 
**=p<0.01, ***p<0.001, n=4/age group. *Microglia experiments performed by 
Eimear Linehan
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3.3 Ageing does not affect BMMs grown in serum-containing media 
Although ageing reduced myelin debris phagocytosis in these macrophage 
cultures, the phagocytic ability of BMMs was not significantly affected when 
phagocytosis assays were performed in media containing serum (Fig 3.3A-D). 
Immunocytochemistry (Fig 3.3A-B) of young and old BMMs did not show a difference 
in the percentage of MBP+ myelin-phagocytosing macrophages. In addition, flow 
cytometry confirmed that there was no difference in myelin phagocytosis with age 
(Fig 3.3C-D). Aged BMMs had enhanced myelin phagocytosis when grown in serum-
containing compared to serum-free media. Factors in the fetal bovine serum (FBS) 
enhanced phagocytosis in our aged BMM cultures, suggesting environmental factors 
in the media improved phagocytosis in aged BMMs. Therefore, all further 
experiments were conducted using serum-free, well-defined media, as suggested by 
previous studies (Eske et al., 2009; Flesch et al., 1986). In all other experiements 
using BMMs, cells were placed in serum-free conditions 24 hours before incubation 
with fragmented myelin debris, resulting in a signifcant decrease in phagocytosis in 
aged BMMs (Fig 3.2H).  
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Figure 3.3 Ageing does not affect phagocytosis by BMMs in serum-containing 
media. BMMs cultured in serum-containing media were incubated with fluorescent 
myelin and phagocytosis was analysed. A-D) Aged BMMs showed no impairment in 
myelin phagocytosis by both immunocytochemistry (A-B) and flow cytometry (C). D) 
There was no significant difference when comparing myelin phagocytosis by young 
and old BMMs in serum-containing media. Young=2mo mice, Old=15-24mo mice. 
Scale bar = 25μm. Mann-Whitney test, n=4/age group.  
3.4 Myelin debris phagocytosis and RXR pathways are downregulated in aged 
myelin-phagocytosing monocytes 
As impaired myelin debris uptake was seen in animal models of phagocytosis 
(Fig. 3.2), this study sought to determine whether analogous defects in myelin 
phagocytosis observed in ageing animals are also present in ageing humans. Using 
blood-derived monocytes isolated from healthy volunteers (HVs), large numbers of 
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cells were obtained for both transcriptional and functional studies. Myelin 
phagocytosis index was calculated as follows for FACS experiments with human 
monocytes: (Myelin+ fluorescence in phagocytosing treated groups) / (Myelin+ 
fluorescence in non-phagocytosing controls). Pilot myelin-phagocytosis data was 
provided to the biostatistician for calculating sample size for functional comparison 
of monocytes derived from young (≤35 years old) and old (≥55 years old) HVs. 
Myelin debris phagocytosis was determined by comparing FITC+ fluorescence in 
phagocytosing cells to control cells. Myelin debris was labelled with pHrodo-green 
dye (Invitrogen), which activates FITC+ fluorescence in the low pH environment of 
the phagosome. Upon acquiring pre-determined sample sizes (n=34 for each 
group), there was a modest, but highly significant decrease observed in the 
efficiency of myelin phagocytosis in monocytes derived from old HVs (Fig. 3.4A-D). 
Monocytes from young HVs were highly effective at phagocytosing myelin debris in 
culture (Fig. 3.4A, 2.44±0.06), while cells from old HVs were not (Fig. 3.4B, 2.05
±0.04). The change in myelin debris phagocytosis was also highly correlated with 
age (Fig. 3.4D, R2=0.31). 
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Figure 3.4 Myelin debris phagocytosis is reduced in aged myelin-
phagocytosing human monocytes. A) CD14+ monocytes from HVs (≤35 years 
old) effectively phagocytose myelin debris (Phagocytosis index = 2.44±0.06). FITC+
gate was determined by non-phagocytosing control cells (gray background plots).  B-
C) Monocytes from aged volunteers (≥55 years old) show significantly impaired 
myelin debris uptake (2.05±0.04). D) Age is significantly negatively correlated to 
myelin debris phagocytosis (slope=0.011, R-square=0.31).  Adjusted p-values for 
pairwise comparisons in a Two-way repeated measures ANOVA with Tukey's 
procedure based on log-transformed outcomes, p=0.0014, n=36/group.  
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To identify possible mechanisms involved in the age-associated changes in 
phagocytic cells responsible for myelin debris clearance, we undertook gene 
expression profiling. We argued that human experiments might provide more 
general data, due to broad genetic heterogeneity among human subjects. This 
would also provide data that could be of direct relevance to patients and whose 
mechanisms could be explored subsequently using laboratory animal models. 
Microarrays were performed on myelin-phagocytosing monocytes from young and 
old HVs (Fig. 3.5). To define the mechanistic pathways enriched in monocytes upon 
phagocytosis, Ingenuity Pathway Analysis (IPA) found that the RXR pathway was 
differentially regulated upon myelin phagocytosis in young compared to old 
monocytes. RXRs are nuclear receptors that act both homodimerically and 
heterodimerically as ligand-activated transcription factors. In young cells, RXR 
heterodimer pathways were largely upregulated, with 19 positive regulators 
upregulated and 7 downregulated, while these pathways were largely downregulated 
in old cells. As RXR has several binding partners, activation and inhibition of several 
pathways were shown to be affected. Multiple RXR binding partners and 
downstream target genes were plotted with IPA, and the genes identified in the 
microarray of young cells showed mostly upregulation of positive regulators of RXR 
(Fig. 3.6A), while the profile of old cells showed mostly downregulation of genes in 
this pathway (Fig. 3.6B). Genes in green are upregulated upon phagocytosis in 
monocytes, and those in red are downregulated upon phagocytosis. 
To confirm the results from the microarray in an independent cohort, 
quantitative real-time PCR was performed with a Retinoic Acid Signalling PCR Array 
(SABiosciences). This array measures 84 genes in the RXR pathway, providing 
insight into RXR regulation. After monocytes were exposed to myelin debris, cells 
were collected and relative gene expression was determined from isolated cDNA. 
Groups of pooled young or old myelin-phagocytosing cells were compared to young 
controls. The PCR arrays confirmed the results seen in the microarray, with RXR 
genes more highly upregulated upon myelin phagocytosis in young monocytes (Fig. 
3.6C). This array also confirmed the changes seen in RXR protein expression in 
myelin-phagocytosing mouse macrophages, with an increase in RXRα and β 
expression in young monocytes and a decrease in aged cells. In addition the RXR 
binding partners RAR and PPAR are both similarly upregulated in young cells 
compared to old. These results further suggest a decrease in RXR in ageing cells. 
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Figure 3.5 Myelin phagocytosis causes upregulation of a unique set of genes 
in young monocytes compared to old. Myelin was added to young (≤35 years old) 
and old (≥55 years old) human monocytes, and myelin-phagocytosing groups were 
compared to resting cells A) Heat maps of resting controls compared to 
phagocytosing cells show differential gene expression upon phagocytosis in young 
and old monocytes. B) Venn diagram of microarray data with significantly different 
gene sets upon phagocytosis in young and old groups, with 537 genes of interest in 
young and 565 in old.  
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Figure 3.6 RXR pathways are downregulated in aged myelin-phagocytosing 
monocytes. A-B) Ingenuity Pathway Analysis (IPA) of microarray results showed 
that RXR-related genes with significant fold changes (p<0.05, |FC| > 1.5) were more 
highly upregulated in young-phagocytosing (A) compared to old-phagocytosing (B) 
groups (Green=upregulated, Red=downregulated). n=3/group. C) qPCR was 
performed using a Retinoic Acid Signalling RT2 Profiler PCR Array (SABiosciences). 
Expression changes were calculated by comparing young or old phagocytosing cells 
to resting controls. Genes in the RXR pathway with |FC| > 1.5 are shown here (White 
bars=Young cells vs Resting, Black bars=Old cells vs Resting). n=6/group. 
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3.5 Conclusions 
In a heterochronic parabiosis model of remyelination, the circulatory systems 
of young and aged animals were connected, and the major young cell population 
recruited to the old animal’s lesion site was identified as blood-derived monocytes, 
resulting in improved remyelination in aged animals (Ruckh et al., 2012). However, 
the underlying mechanisms of the age-related decline in myelin debris phagocytosis 
have not been fully elucidated. The in vitro data in this chapter indicate that ageing 
impairs myelin debris phagocytosis in blood-derived macrophages and microglia and 
this age-related decline may be related to a reduction in RXR pathways. The findings 
shown here indicate that the age-related decline in remyelination efficiency could be 
in part due to a deficiency in RXR activity in aged monocytes and macrophages, 
resulting in reduced phagocytosis by monocyte-derived macrophages. This pathway 
was further studied in subsequent chapters to determine if the defects in RXR 
signalling may be utilised to reverse this age-associated decline.  
These data also confirm that there is a defect in the phagocytic ability of 
myelin debris phagocytosing macrophages with age, suggesting that increased 
myelin debris load in aged subjects is not only due to a decreased number of 
recruited phagocytes or an increase in the amount of myelin debris in aged 
animals. Microglia are also impaired in vitro, but monocyte-derived macrophages 
appear to phagocytose more myelin debris in both young and aged groups. 
Previous studies have indicated that microglia play a pivotal role in myelin debris 
phagocytosis; however, these studies used models where infiltrating monocytes 
did not play a role (Olah et al., 2012) or were only measured during the early 
stages of demyelination (Yamasaki et al., 2014), also suggesting that later stages 
of remyelination may be modulated by a blood-derived monocyte response.  
This finding suggests that factors affecting macrophage plasticity in the 
ageing environment in vivo affect phagocytic ability. Since these cells have a great 
deal of heterogeneity and can adapt to different biological cues, modulating their 
environment and expression profiles can help recover age-related deficits, making 
them an ideal target for endogenous repair.  
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4. Results 
Retinoid X Receptor activation reverses the age-related deficiency in myelin 
debris phagocytosis and enhances remyelination 
We next asked whether the age-associated defects in RXR pathways in 
myelin-phagocytosing cells have in vivo consequences for remyelination by testing 
the hypothesis that RXR signalling is involved in the delayed myelin clearance that 
limits efficient remyelination with ageing. To do this, we reverted to animal models 
where this hypothesis could be tested experimentally.  
RXRs belong to a family of receptors known as nuclear receptors (NRs). NRs 
contain both a DNA-binding domain and a ligand-binding domain, allowing them to 
act as transcription factors to directly activate gene expression by binding to low-
affinity ligands (Nagy and Schwabe, 2004). These hormone receptors have a wide-
reaching capacity as they are expressed in several cell types and regulate a complex 
array of genes. NRs are classified into six different families depending on their 
evolutionary divergence. Many of the receptors in Class III-VI are defined as “orphan 
receptors,” meaning they currently have no known ligands. The Class I receptors, 
the most well characterised, and their currently defined natural ligands are described 
in Table 4.1. The Class II receptors include RXR, chicken ovalbumin upstream 
promoter transcription factor (COUP-TF), hepatocyte nuclear factor 4 (HNF-4), 
Tailles-related receptor (TLX), Photoreceptor specific nuclear receptor (PNR) and 
testis receptor (TR). Of these, RXR binds to several Class I receptors and regulates 
genes expression of their downstream targets. Class III receptors are steroid 
receptors and include glucocorticoid receptor (GR), androgen receptor (AR), 
progesterone receptor (PR), oestrogen receptor (ER), and oestrogen related 
receptor (ERR). Class IV includes NGF induced clone B (NGFI-B), Nurr1, and Nor1; 
Class V is steroidogenic factor 1 (SF-1); and Class VI is germ cell nuclear factor 
(GCNF) (Aranda and Pascual, 2001). 
Due to their complex function, these receptors have several components that 
allow for gene transcription and receptor function. They consist of six domains: an 
amino terminal region (consisting of two domains), DNA-binding domain (DBD), 
hinge region, ligand binding domain (LBD), and the C-terminal domain (Fig 4.1). The 
amino terminal region generally contains an autonomous transcriptional activation 
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function (AF-1) to activate the receptor in the absence of ligands. The DBD consists 
of two helix-forming Zn2+ fingers containing four cysteines, zinc ions, and carboxy 
terminal extension all acting together to recognise DNA-response elements. The 
hinge region acts to rotate the DBD. The most significant region for receptor 
activation is the LBD. This domain allows for ligand binding, homo/hetrodimerisation 
of NRs, and activation of downstream transcription. The LBD varies greatly in size 
between NRs, depending on the size of ligands and their receptor affinity (Aranda 
and Pascual, 2001). 
 
Nuclear Receptor  Isoforms  Ligands Identified  FDA-Approved 
Drugs  
Binding to RXR  
Retinoic Acid Receptor 
(RAR) 
α,β,γ  All-trans Retinoic 
Acid  
T-retinoin  Nonpermissive 
Heterodimer  
Vitamin D Receptor 
(VDR)  
N/A  Vitamin D3  Cholecalciferol  Nonpermissive 
Heterodimer 
Thyroid Hormone 
Receptor (TR)  
α,β  Thyroid hormone  Levothyroxine Nonpermissive 
Heterodimer 
Pregnane X Receptor 
(PXR)  
N/A  Pregnolone,  
Glucocorticoid  
N/A  Nonpermissive 
Heterodimer 
Constitutive androstane 
receptor (CAR)  
α,β  Androstenol  N/A  Nonpermissive 
Heterodimer 
Peroxisome proliferator- 
activated receptor 
(PPAR)  
α,γ,δ  Unsaturated fatty 
acids,  
Eicosanoids  
Pioglitazone, 
Rosiglitazone,  
Finofibrate  
Permissive 
Heterodimer  
Liver X Receptor (LXR)  α,β  Oxysterol  N/A Permissive 
Heterodimer 
Farnesoid X Receptor 
(FXR)  
N/A  Chenodeoxycholic 
acid,  
Fexaramine  
N/A  Permissive 
Heterodimer 
Retinoic acid orphan 
receptor (ROR)  
α,β,γ  Unknown  N/A  Unknown  
Retinoid X Receptor 
(RXR) – Class II  
α,β,γ  9-cis Retinoic Acid,  
Docosahexanoic acid  
Bexarotene  Homodimer, 
Homotetramer  
Table 4.1: Class I Nuclear Receptors and their association with Retinoid X 
Receptors. Class I NRs bind to RXR to form permissive and nonpermissive 
heterodimers. This table highlights the currently classified Class I NRs along with 
their known ligands, approved drugs, isotypes, and binding to RXR. Adapted from 
(Aranda and Pascual, 2001).  
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Once the LBD is activated, the DBD binds to hormone response elements for 
each NR (Szanto et al., 2004; Zilliacus et al., 1994). In general, RXR heterodimers 
consist of the RXR element upstream and the binding partner downstream 
(Kurokawa et al., 1993). When the LBD is activated, many NRs perform auto-
regulatory functions by synthesising or degrading their own ligands (Baker, 2011; 
Dave, 2012; Evans and Mangelsdorf, 2014; Sarang et al., 2014). In the absence of a 
ligand, NRs repress activation of downstream genes by binding to the hormone 
response elements and co-repressors. Several co-repressors have been identified, 
including silencing mediator for retinoic and thyroid hormone receptors (SMRT), 
nuclear co-repressor (NCoR) or small ubiquitous nuclear co-repressor (SUNCoR) 
and histone deacetylases (HDACs) (Chen and Privalsky, 1995; Chen and Evans, 
1995; Horlein et al., 1995). These co-repressors prevent transcription of downstream 
genes and allow NRs to perform transcriptional repression of their target sequences 
(Chen and Evans, 1995; Moras and Gronemeyer, 1998; You et al., 2013). When a 
ligand binds to the LBD, co-activators are recruited to this site and co-repressors are 
released. These co-activators include steroid receptor coactivator 1 (SRC-1), nuclear 
coactivator 2 (NCoA2), steroid receptor coactivator 2 (SRC-2), p300, and cyclic 
adenosine monophosphate-response element binding protein (CBP). Through 
histone acetyl transferase (HAT), HDAC co-repression is released and acetylation 
leads to an activated state (Lonard and O'Malley, 2012). These mechanisms are 
highlighted in Fig 4.1.  
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 Figure 4.1: Nuclear receptors act as ligand-binding transcription factors. A) 
NRs are composed of both a DNA-binding (DBD) and a Ligand-binding domains 
(LBD). Once the NRs dimerise through the LBD dimerisation motif, they use the DBD 
to bind to their respective hormone response elements (HREs). B) Co-repressors, 
such as NCoR, SUNCoR, and SMRT, bind to RXR and its NR binding partners to 
prevent activation of the HRE by deacetylating histones and stopping transcription. 
C) Once ligands for RXR and its NR binding partner activate their respective 
receptors, co-activator complexes consisting of SRC1-3, NCoA2, CBP, and p300 are 
recruited and allow for histone acetylation and transcription of downstream target 
genes. (Adapted from Aranda and Pascual, 2001). 
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Retinoid X Receptors 
Retinoid X receptors (RXRs) act as a binding partner for several Class I NRs, 
resulting in the expression of a large variety of genes. Due to extensive 
heterodimerisation, RXR pathways have a far-reaching effect in different cell types. 
They are known to be activated by endogenous ligands (Table 4.1) and can function 
as permissive and non-permissive heterodimers with other NRs. Permissive 
heterodimers allow for activation of the target sequence by ligands for either RXR or 
one of its NR binding partners. Permissive binding parts include, PPAR, LXR, and 
FXR. Ligands for both receptors may also act together synergistically to increase 
downstream expression (Chawla et al., 2001; Ogawa et al., 2005; Roszer et al., 
2013). Non-permissive heterodimers form when the RXR ligand is not sufficient to 
activate the complex, and the binding partner’s ligand must be present for 
transcription of downstream genes. In these cases, RXR activation is inhibited even 
in the presence of its ligand. Examples of non-permissive binding partners are VDR, 
RAR, and TR (Shulman et al., 2004). RXR can also form homodimers with other 
RXRs. These homodimers are activated by RXR ligands and result in RXR-specific 
gene transcription (Yasmin et al., 2010; Yasmin et al., 2004).   
Three main isoforms of RXR exist throughout the body. They regulate many 
processes from cellular proliferation to lipid metabolism. Each isoform has 
expression in various regions. RXRα is most commonly expressed in the liver, 
kidney, spleen, and epidermis. It also has the highest expression in monocytes and 
monocyte-derived macrophages (Roszer et al., 2013). RXRβ is largely expressed in 
the CNS as well as throughout the body. RXRγ shows the highest expression in the 
muscle and CNS (Brown et al., 2000; Kastner et al., 1996; Krezel et al., 1996). All 
three isoforms of RXR can provide compensatory functions for each other when the 
others are downregulated. They can be expressed in both the cytoplasm and 
nucleus of cells. Upon activation of NRs, RXRs are shuttled and localise to the 
nucleus. Through this nuclear localisation, RXRs are able to homo- and 
heterodimerise to activate downstream genes (Baumann et al., 2001; Katagiri et al., 
2000; Prufer et al., 2000).  
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In this chapter, the role of RXRs in ageing myelin-phagocytosing 
macrophages was studied to determine if this extensive pathway plays an age-
related role in myelin debris phagocytosis and can be targeted to reverse the age-
related decline in myelin debris clearance and CNS remyelination.  
4.1 RXRα expression declines with age in myelin-phagocytosing BMMs 
As many genes in the RXR pathway were downregulated with age (Fig. 3.5), 
we first assessed the levels of protein expression of this receptor family in monocyte-
derived macrophages, since they appear to play a key role in myelin debris 
phagocytosis (Kotter et al., 2001; Kotter et al., 2005; Ruckh et al., 2012). BMMs were 
used to study expression and modulation of nuclear receptor pathways during myelin 
debris phagocytosis. RXRα expression in myelin-phagocytosing macrophages was 
confirmed using immunocytochemical staining of Iba1+ BMMs (Fig. 4.2A) with RXRα 
found to be localised to the nucleus (Fig. 4.2B). BMMs from ageing mice (from 2mo 
to 24mo) were incubated with myelin debris, and phagocytosing cells were lysed and 
collected for protein analysis. Using western blots, the protein expression of RXRα in 
myelin-phagocytosing BMMs was determined and compared to β-actin controls at 
2mo, 8mo, 12mo, 16mo, and 24mo (Fig. 4.2A-C). The RXRα band has a weight of 
55kd with another non-specific band indicated on the gel (Fig. 4.2C); this distribution 
of bands has also been seen in previous studies (Kuhla et al., 2011; Menéndez-
Gutiérrez et al., 2015). By isolating BMMs from mice of different ages, the change in 
RXRα expression was correlated with ageing. In young, 2mo macrophages, RXRα 
expression was highest. BMMs isolated from adult mice had a slow decline in RXRα 
protein expression, which reached statistical significance (*p<0.05) when comparing 
RXRα expression in the youngest (2mo) to the oldest age group (24mo) (Fig. 3.4D), 
indicating that this receptor is significantly affected by ageing in myelin-
phagocytosing macrophages.  
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Figure 4.2 Myelin-phagocytosing BMMs undergo an age-related decline in 
RXRα expression. A-B) Immunocytochemistry of Iba1+ cells revealed (B) nuclear 
localisation of active RXRα in myelin-phagocytosing macrophages. Scale bar = 
50μm. C) Levels of RXRα expression in macrophages derived from 2-24mo mice 
were determined by western blot and analysed by ImageJ. Dividing line indicates 
different gels. RXRα band is indicated at 55K, with nonspecific bands (NSB) at lower 
values indicated on the gel. D) There was a significant reduction in RXRα 
expression in macrophages between 2mo and 24mo mice, measured by optical 
density (OD) of RXRα relative to actin controls. One-way ANOVA and post-hoc 
Tukey’s multiple comparisons test, *p<0.05, n=3/age group.  
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Although the other two isoforms of RXR show little expression in 
macrophages (Roszer et al., 2013), expression levels of both RXRβ and RXRγ were 
examined in BMM cultures as all three isoforms of RXR are expressed in the CNS 
(Dyall et al., 2010) and can show compensatory functions due to the loss of one 
isoform (Li et al., 2000). Immunocytochemistry staining of RXRβ did not have any 
reactivity in culture, while RXRγ cultures did show some nuclear localisation (Fig 
4.3A). However, this result was not reproducible, suggesting nonspecific binding of 
this antibody in vitro. Western blots against both isoforms analysed with ImageJ also 
revealed inconsistent band expression, with only an n=2 in each age group (Fig 
4.3B-C). These bands were only visible after 30min of incubation time with the 
Supersignal detection reagent, used for proteins with low immunoreactivity. These 
results further suggest that the main isoform expressed in myelin-phagocytosing 
BMMs is RXRα. 
Figure 4.3 RXRβ and RXRγ expression are not consistent in ageing BMMs. A) 
Immunocytochemistry showed nuclear localisation of RXRγ in myelin-phagocytosing 
macrophages, but expression was not highly reproducible (n=2). Scale bar = 50μm. 
B-C) Levels of RXRβ and RXRγ expression in macrophages derived from 2-24mo 
mice were determined by western blot and analysed by ImageJ. n=2/age group. 
Blots were not reproducible  
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4.2 The RXR agonist 9-cis retinoic acid enhances myelin phagocytosis in aged 
macrophages 
There are several synthetic ligands for RXR, and one of the most common is 
the 9-cis form of retinoic acid (9cRA). 9cRA is known to be a high affinity ligand for 
RXR and may be produced endogenously during retinoid metabolism (Heyman et 
al., 1992). Here, 1μM 9cRA was added to myelin-phagocytosing BMMs for 24h to 
activate RXR in vitro before adding myelin debris to macrophage cultures. 
Macrophages were labelled with the myeloid marker Iba1 and ingested myelin was 
labelled with MBP. Young (2mo) controls were able to effectively clear myelin, and 
the addition of 9cRA did not augment phagocytosis (Fig 4.4A-B). However, old 
(32mo) macrophages showed significantly reduced myelin debris clearance (Fig. 
4.4C, 10%±SEM) compared to young. When RXR was activated by 9cRA, 
significantly more old BMMs were able to phagocytose debris (Fig. 4.4D-E, 
34%±SEM). Myelin debris phagocytosed per macrophage was also calculated by 
determining the area of MBP+ staining per BMM. There was also a decrease in the 
amount of myelin debris phagocytosed per aged macrophage (Fig 4.4F). There was 
still a significant difference in myelin debris phagocytosis between 2mo and 
32mo+9cRA treated cells, indicating that RXR activation cannot restore phagocytic 
ability completely, but the addition of 9cRA has the potential to enhance debris 
clearance in aged animals. 
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Figure 4.4 RXR agonist 9cRA stimulates myelin debris phagocytosis in aged 
macrophages.  A-B) Macrophages from 2mo mice are able to effectively consume 
myelin debris, both before (A, 48.9%±2.6%) and after treatment with 9cRA (B, 
54.9%±1.5%). C) However, 32mo senescent macrophages were not able to 
efficiently phagocytose debris. D-E) Adding 1μM 9cRA significantly increased myelin 
debris consumption in aged macrophages. >50% of young macrophages were able 
to effectively clear myelin, while only 10.9% (±1%) of old macrophages were able to; 
however, 9cRA significantly increased myelin clearance to 33.6% (±1.7%) in aged 
cells. F) The amount of myelin debris phagocytosed per macrophage was also 
measured, showing a similar effect as (E). Scale bar = 50μm. Two-way ANOVA and 
posthoc Sidak’s multiple comparisons test, ***p<0.001, *p<0.05 n=6/age group. 
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4.3 Loss of RXR function in young macrophages impairs myelin debris 
clearance  
Since there was no significant difference when 9cRA was added to 2mo 
BMMs, we hypothesised that ligand-independent, constitutive RXR activation 
(Laursen et al., 2012; Nagpal et al., 1993) may be one of the key differences 
between young and old cells. The synthetic antagonist for RXR, HX531, was used to 
block RXR and determine if RXR activation was necessary for efficient myelin debris 
phagocytosis in young BMMs. After antagonist treatment and incubation with myelin 
debris, cells were stained with CD11b. Myelin+/CD11b+ cells were quantified by 
immunocytochemistry and flow cytometry. Young cells efficiently phagocytosed the 
DiO-labelled myelin (Fig. 4.5A-B, 36.6-42%), while macrophages treated with 10μM 
HX531 showed reduced myelin debris uptake and significantly fewer double positive 
cells (Fig. 4.5C-E, 19.8-23.8%). When RXR activation is inhibited by HX531, myelin 
debris phagocytosis is significantly impaired in young BMMs, suggesting that RXR is 
necessary for efficient myelin debris phagocytosis in young macrophages. 
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Figure 4.5 RXR antagonist slows myelin debris uptake in young macrophages. 
A-D) DiO-labelled myelin was used to measure myelin debris clearance by 
immunocytochemistry  and flow cytometry in young macrophages (A,B) and young 
macrophages treated with a synthetic RXR antagonist, HX531 (C,D). E) Blocking 
RXR with 10μM HX531 reduced myelin debris uptake in young BMMs from 42.8% 
(±2.5%) in young controls to 19.06% (±1.5%). Scale bar = 50μm. Student’s t-test, 
***p<0.001, n=4/treatment.  
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4.4 Loss of RXR function slows myelin debris uptake in vivo 
This study utilised lysolecithin-induced demyelination due to its focal capacity, 
synchronous timeframe, mainly OL loss and OL remyelination, and infiltration of 
innate immune cells (highlighted in section 1.4.3). A Cre-lox model system was used 
to specifically target genes in myeloid-derived cells during toxin-induced 
demyelination. The Lysozyme M (LysM) Cre driver is expressed in all myeloid 
lineage cells. However, since microglia are derived from the yolk sac during early 
development, the LysM Cre has shown little recombination in these cells (Goldmann 
et al., 2013). Therefore, the major targets in LysM Cre recombination are the 
monocyte-derived cells. RXRα floxed mice were crossed with LysM Cre mice to 
produce both LysM-RXRα knockouts, mice with active Cre recombinase and the 
efficient deletion of RXRα from myeloid-derived cells, and LysM-RXRα wildtype 
mice, mice lacking active Cre recombinase with active expression of RXRα in 
myeloid-derived cells. The RXRα isoform was specifically chosen due to its high 
expression in macrophage cell types (Fig. 4.2-4.3, (Roszer et al., 2013)); it was 
expected to have the greatest effect. The following experiments tested the efficiency 
of remyelination with the absence of RXR in myeloid-derived cells.  
Lysolecithin-induced focal demyelination was performed on 4mo WT 
(LysMCre– RXRαfl/fl) and KO (LysMCre+ RXRαfl/fl) mice, and demyelinated lesions 
were stained with oil red O (ORO) to quantify myelin debris accumulation. ORO 
labels neutral lipids and effectively measures myelin debris in the demyelinated 
lesion. There was little ORO staining at 5dpl in the WT at early stages of 
demyelination, while there was significantly more diffuse ORO staining in the KO at 
this timepoint when OPC recruitment into the lesion is maximal (Arnett et al., 2004) 
(Fig 4.6A-B, G), indicating reduced myelin debris clearance in the KO at 5dpl. Myelin 
debris clearance was more advanced at 14dpl (Fig 4.6C-D) and 21dpl (Fig 4.6E-F) in 
both WT and KO, the staining being more punctate and consistent with intracellular 
staining of phagocytosed myelin (Kotter et al., 2005). The greater level of myelin 
debris accumulation at early timepoints in the RXRα KO (Fig 4.6G) suggests 
impaired myelin debris phagocytosis at early stages of OPC differentiation in these 
mice.  
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 Figure 4.6 Loss of RXRα function in young macrophages slows myelin debris 
uptake in vivo. Lysolecithin-induced focal demyelination is denoted by black 
outlines. A-G) Oil red O was used to label neutral lipids in demyelinated lesions of 
RXRα myeloid-specific knockouts at 5dpl (A-B), 14dpl (C-D), and 21dpl (E-F). G) 
Myelin debris uptake was significantly slowed in KOs at 5dpl, with extracellular 
myelin debris indicated by black arrows in (B). At 14dpl and 21dpl, there is an 
increase in intracellular lipids, consistent with previous studies (Kotter, Zhao et al. 
2005). Staining is more punctate and less diffuse at these timepoints. Scale bar = 
100µm. Two-way ANOVA and post-hoc Sidak's multiple comparisons test, *p<0.05, 
**p<0.01, n=4/timepoint  
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Iba1, a marker of activated macrophages and microglia, was used to label 
phagocytosing cells (Fig 4.7A-B). Iba1 was visualised with diffuse staining 
throughout the lesion, providing effective demarcation of the lesion but was difficult 
to quantify as almost all DAPI-labelled cells appeared Iba1+. The staining provided 
evidence of macrophage activation throughout the lesion. The effects of this early 
accumulation of myelin debris were next studied with markers of OPC differentiation. 
Figure 4.7 Macrophages invade the demyelinated lesion. Lysolecithin-
induced demyelinated lesion is denoted by DAPI-labelling, and Iba1 was used to 
label blood-derived macrophages and microglia. A-B) In both WT and KO 
lesions, a prominent macrophage response is evident. Scale bar = 100µm. 
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4.5 Macrophage-specific RXR knockouts experience slowed OPC maturation 
Since myelin debris contains inhibitors of OPC differentiation (Baer et al., 
2009; Kotter et al., 2006; Syed et al., 2011), a delay in myelin debris clearance can 
impact OPC differentiation. To assess remyelination in the absence of myeloid-
specific RXRα, several oligodendrocyte lineage and myelination markers were used: 
Olig2 is a marker for all stages of the OL lineage, from OPC to mature OL; CC1 is a 
marker for mature OLs and labels the cell body;  and proteolipid protein (PLP) is a 
marker of myelinating OLs (Emery, 2010; Lu et al., 2002). The density of CC1+ and 
Olig2+ cells was determined using immunohistochemistry. Antibodies against CC1 
stained mature OLs at 14dpl (Fig 4.8A-B) and 21dpl (Fig 4.8C-D). At 5dpl, few CC1+ 
cells were present in the demyelinated lesion. By 14dpl, these CC1+ cells were more 
prevalent in both WT and KO lesions. However, there were significantly fewer CC1+ 
OLs in KO lesions at this timepoint. By 21dpl, there was no difference between CC1+ 
cells in the WT and KO lesions (Fig 4.8E). To confirm that this difference was not 
due to impaired recruitment of OPCs to the lesion, the total number of OL lineage 
cells was accounted for by dividing by the number of Olig2+ cells in each lesion. 
There were still significantly fewer CC1+/Olig2+ cells (Fig 4.8F) in the KO at 14dpl, 
suggesting delayed OPC differentiation in the myeloid-specific KO. In addition, 
Olig2+ cells in the same lesions (Fig 4.9A-D) showed a higher population of CC1-
/Olig2+ cells (OPCs and early OLs) in the KO lesions at 14dpl, further suggesting 
that there are a greater number of OPCs present in the KO that have not 
differentiated. The OPC numbers were reduced and comparable to WT by 21dpl (Fig 
4.9E), suggesting effective differentiation of OPCs by 21dpl in the KOs.  
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Figure 4.8 OPC maturation is impeded in RXR KOs. Lysolecithin-induced 
demyelinated lesion is denoted by DAPI-labelling. A-B) CC1 staining for mature 
OLs in the LysM-RXRα WT (A) and KO (B) mice. C-D) By 21dpl, CC1 marks many 
mature OLs in both the WT (C) and KO (D) lesions. E) At 14dpl, there are 
significantly more CC1+ cells in the lesions of WT mice compared to KOs. From 
5dpl to 14dpl, there is a dramatic increase in CC1+ cells in both groups. From 
14dpl to 21dpl, there is a significant increase in CC1+ cells in the KO. F) Olig2 is a 
pan-OL marker, so CC1+/Olig2+ cells indicate accurately marked mature OLs. At 
14dpl, there is a significant difference in CC1+/Olig2+ cells between WT and KO. 
There is also an increase in CC1+ cells from14dpl to 21dpl in the KO, indicating 
slowed differentiation. Scale bars = 100µm. Two-way ANOVA and post-hoc 
Sidak's multiple comparisons test, **p<0.01. 
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Figure 4.9 OPCs are more prevalent in LysM-RXRα KO lesions at 14dpl. 
Lysolecithin-induced demyelinated lesion is denoted by DAPI-labelling in previous 
figure (shown here in white lines). A-B) At 14dpl, there is a significant difference in 
CC1-/Olig2+ (OPCs) between WT and KO. C-E) There is also a decrease in 
CC1-/Olig2+ cells from 14dpl to 21dpl in the KO, indicating fewer undifferentiated 
OPCs by 21dpl. Scale bar = 100µm. Two-way ANOVA and post-hoc Sidak's 
multiple comparisons test; *p<0.05. 
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4.6 Delayed remyelination occurs in LysM-RXRα knockouts 
In situ hybridisation of the myelinating marker PLP was performed at 14 and 
21dpl. Unlike immunohistochemistry, ISH can be used to measure cell numbers of 
later myelinating markers such as PLP since this technique visualises mRNA 
expression localised to the nucleus (Fig 4.10A-D). The delay in OPC differentiation 
was confirmed in this experiment with less PLP+ myelinating OLs in the KO at 14dpl, 
indicating reduced differentiation. This impairment was again recovered by 21dpl, 
when there was no significant difference in PLP+ cells (Fig 4.10E).  
Figure 4.10 Macrophage-specific RXRα knockouts display delayed 
remyelination markers. A-E) In situ hybridisation of the myelinating marker 
proteolipid protein (PLP) in WT and KO lesions at 14dpl (A-B) and 21dpl (C-D). F) 
PLP+ myelinating OLs were decreased in KOs at 14dpl but not at 21dpl, suggesting 
a delay in PLP expression. Scale bar = 100µm. Two-way ANOVA and post-hoc 
Sidak's multiple comparisons test; n=4/group, **p<0.01. 
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Resin-embedded spinal cord tissues were stained and processed for electron 
microscopy (EM) analysis. EM was used to quantify the thickness of myelin sheaths 
within the demyelinated lesions (Fig 4.11A-B). EM images allowed visualisation of 
axonal cross-sections and myelin sheaths along with active mitochondria within 
axons. The relative amount of remyelination was measured using the g-ratio by 
comparing the thickness of the unmyelinated axon to the myelinated axon. The 
diameter of each axon was measured and divided by the total diameter including its 
myelin sheath. A higher g-ratio indicates a thinner myelin sheath (Fig 4.11C). A 
normally myelinated axon has a g-ratio of approximately 0.6-0.7, while a 
remyelinated axon has a g-ratio of >0.8 due to its thinner myelin sheath (Aharonowiz 
et al., 2008; Guy et al., 1989). Fully demyelinated axons with almost no myelin 
sheath have a g-ratio closer to 1. The delay in OL differentiation in KOs was 
associated with significantly thinner myelin sheaths (a larger g ratio) compared to 
WT at 14dpl, during the remyelination process (Fig 4.11D). WT mice at 14dpl had a 
mean g-ratio of 0.875, suggesting more remyelinated axons than KOs, with an 
average of 0.901. These findings indicate that RXRα plays an essential role in 
macrophage function during myelin debris clearance and CNS remyelination. 
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Figure 4.11 Macrophage-specific RXRα knockouts have decreased 
remyelination. A-B) Electron micrographs of demyelinated lesion tissue from both 
(A) WT and (B) KO mice at 14dpl. C) The g-ratio, used as a measure of myelin 
thickness and remyelination, was calculated by dividing diameter of each axon by 
the total diameter of the myelinated axon in representative lesions. D) Micrographs 
confirmed that KOs have a higher g-ratio (Mean=0.901, S.E.M =0.024) than WT 
(Mean=0.875, S.E.M.=0.026) and less remyelination at 14dpl. *Remyelinated axons. 
Scale bar = 2µm. Student’s t-test; ****p<0.0001, n=4/group 
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4.7 Conclusions 
In this chapter, the role of RXR in remyelination and macrophage function was 
studied using in vitro BMM cultures and a targeted knockout of RXR. RXR activation 
enhanced myelin debris clearance in aged macrophages and impairing RXR function 
in vitro reduced phagocytosis in young macrophages. To determine if RXR is a 
necessary component of efficient myelin debris clearance in young animals, RXR 
was knocked out specifically in myeloid-derived cells and resulted in significantly 
reduced OPC differentiation in knockout lesions, indicating that RXR has an 
important role in macrophage biology during remyelination. In the KOs, myelin debris 
clearance was reduced at 5dpl, in the early stages after demyelination and during 
OPC recruitment. By 14dpl and 21dpl, there was no difference in the myelin debris 
load between WT and KO mice. In addition, ORO staining at these timepoints was 
punctate and localised to cells within the lesion, likely macrophages and microglia. 
The accumulation of myelin debris at the early timepoint led to a delay in the OPC 
differentiation process.  
Loss of RXR in young macrophages further resulted in slowed remyelination 
in lysolecithin-induced focal demyelination, indicating that this receptor is necessary 
for efficient remyelination. Although mice do fully recover in this model and it is 
difficult to see persistent demyelination, this model can be used to determine 
changes in OPC differentiation and identify potential barriers to remyelination. In this 
case, the KO showed decreased OPC differentiation and remyelination at 14dpl, 
while these processes occurred efficiently in the WT. By 21dpl, there was no 
difference between KO and WT mice, and remyelination completed successfully. 
This recovery in delayed remyelination may be due to the KO of only the most 
significant form of RXR in monocytes, RXRα. The other isoforms, β and γ, may help 
compensate for the loss of RXRα by 21dpl. These observations indicate that RXRα 
is necessary for active myeloid cell activity in the demyelinated lesion, and without 
this receptor, young mice experience delayed recovery after demyelination. This 
study identified RXR in myeloid-derived cells as a target for enhancing myelin debris 
clearance and promoting endogenous remyelination in the murine system, which led 
to the question of how activation of this receptor may affect myelin debris clearance 
in the human population.  
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5. Results
Bexarotene reverses the decline of RXR pathways and myelin debris 
phagocytosis in MS patient monocytes
RXR activity was shown to be necessary in both in vitro and in vivo models 
of myelin debris phagocytosis and remyelination in chapters 3-4. Murine models 
provide a genetically-controlled, easily manipulated system to study this class of 
receptors. Due to the homogeneity between animal subjects, a smaller n number 
and fewer studies are required to test the function and expression of RXR in this 
system. As such, the studies shown here allowed for manipulation of RXR activity 
through ligand-modulated activation/inhibition and a knockout system of 
remyelination. It was possible to see the effects of targeting RXR in this controlled 
system due to the ease of experimental manipulation in models of 
demyelination/remyelination. However, the absolute predictive value of animal 
models in treatment strategies for disease remains difficult (van der Worp et al., 
2010). 
Although animal models provide an incredibly powerful predictive tool to 
study potential drug targets in human disease, confirmation of these targets should 
be performed in human studies as well. The heterogeneity and complex 
environment of human systems provides a barrier to well-controlled studies, but a 
large n number and effective control of certain variables in subjects (such as 
disease status, age, sex, race, etc.) can effectively overcome this barrier. This then 
allows for use of the human system to elucidate the efficacy of targets identified in 
animal models. Both healthy subjects and subjects with a disease of interest, in this 
case MS, can be manipulated in human models and studied. The last two results 
chapters in this thesis utilised samples from human MS patients and healthy 
volunteers (HVs) to study the role of RXR and its binding partner, PPARγ, in myelin 
debris clearance. 
Monocytes were isolated from the PBMCs of HVs and MS patients from two 
age groups. Subjects were considered “young” if they were ≤35 years old and “old” 
if they were ≥55 years old. This distinction was made due to the chronic and 
progressive nature of MS as well as the impairment of many biological processes 
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with age. The average age for MS diagnosis is 30 years old, so ≤35 years old 
constituted the young group of patients and HVs (Kremenchutzky et al., 2006). In 
addition, to provide a significant age difference and a greater likelihood to discover 
changes between age groups, an age difference of ≥20 years was chosen. Human 
in vitro models provide a more genetically diverse system compared to mice, so 
testing therapeutics and determining their effects on monocytes from humans 
allows for a more direct comparison of the effects of patient status and ageing in 
the human system. 
There is currently only one FDA-approved drug that directly targets RXR: 
Bexarotene. Bexarotene (brand-labelled Targretin) is currently used as an 
antineoplastic agent to treat cutaneous T cell lymphoma. As a vitamin A derivative 
and retinoid, this drug has been shown to control cellular differentiation and 
proliferation in vitro and inhibits growth of tumour cell lines from haematopoietic and 
squamous cells. It is currently prescribed in an oral dose of 300 mg/m2/day and has 
a terminal half-life of about seven hours. The prescribed dosage results in a 
maximum plasma concentration of 911 μg/L. The molecular weight of bexarotene is 
348.48 g/mol, so the concentration of the drug achieved in the serum of patients 
and the in vivo achievable maximum concentration is approximately 2.55 μM. In 
the following studies, a conservative concentration of 1 μM bexarotene was used 
on monocytes. Due to the complex nature of RXR interactions, bexarotene does 
have several associated side effects. Common adverse effects include increased 
triglycerides and cholesterol in the blood, sensitivity to sunlight, and underactive 
thyroid resulting in weight gain and low energy (Henney, 2000; Lowe and Plosker, 
2000; Richardson et al., 2007). 
Bexarotene was used to study the transcriptional and functional effects of 
modulating RXR in human monocytes with Affymetrix microarrays, confirmatory 
qPCR, fluorescence activated cell sorting (FACS), and electrochemiluminescence 
assays (ECL). Microarrays allow the determination of gene expression and 
comparative analysis between groups of a large set of commonly expressed human 
genes. This platform makes it possible to determine the specific genetic changes 
resulting from MS diseases status, myelin debris phagocytosis, and bexarotene 
treatments in in vitro monocytes. Arrays can compare the roles of known genes in 
various states of cell conditioning. In addition, several tools for analysing large 
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microarray datasets allow identification of functional analysis of genetic changes 
captured by this system. Ingenuity Pathway Analysis (IPA) contains a large 
database of frequently updated scientific findings that identify pathways, functions, 
and interactions of genes discovered by each array. These pathways include those 
involved in disease processes, basic biological processes of cells, and signalling 
pathways modulating cellular function. 
Using FACS and ECL, myelin debris uptake and receptor modulation in large 
cohorts of samples can be tested. Since the balance of regulating inflammation is 
pivotal for efficient remyelination (Miron et al., 2013; Vogel et al., 2013; Zhao et al., 
2006), the modulation of two monocyte-specific soluble and surface markers, CD14 
and CD163, was studied in this system. The dual functions of these two monocyte-
specific receptors in M1/M2 polarisation (see section 1.7.3) as well as their ability 
to be released in soluble forms made them ideal targets to study the inflammatory 
effects of modulating myelin debris phagocytosis with bexarotene in MS patients 
and HVs. 
5.1 Monocytes from MS patients show altered gene expression which is 
modulated by bexarotene treatment 
Microarrays were again used to determine if monocytes from MS patients 
could be distinguished from monocytes from healthy controls. Although there was a 
great deal of homogeneity among monocytes from both groups, monocytes from 
MS patients were still clearly distinguishable from those from HVs. RNA was 
isolated from MS patient monocytes and HVs (n=4/group) both before and after 
myelin debris phagocytosis. Disease status was a greater determinant of genetic 
make-up than myelin debris phagocytosis, with phagocytosing groups more similar 
to their resting controls within each group. The heat map comparing gene 
expression (green=higher value, red=lower value) showed clustering of MS 
patients and HV monocytes separately (Fig. 5.1A). This heat map also shows that 
many genes are commonly regulated amongst all monocytes, regardless of 
phagocytosis or disease state. However, significant differences can be seen 
between MS patients and HVs. This difference was confirmed in a principal 
component analysis of the microarray 
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data (Fig. 5.1B), showing clear clustering of MS monocytes separately from HV 
monocytes. In addition, monocytes from each subject were more likely to cluster 
with the myelin-phagocytosing monocytes from that subject than with other 
phagocytosing monocytes. IPA was used to determine which canonical pathways                        
were differentially regulated in MS monocytes compared to HVs. The analysis 
showed that the most highly expressed pathways were involved in inflammatory 
functions of monocytes, including IL-17 signalling, which has previously been 
largely associated with MS (Matusevicius et al., 1999; McFarland and Martin, 
2007), expression of pattern recognition receptors, and IL-8 signalling (Fig. 5.1C). 
The specific genes involved in each of these pathways that are differentially 
regulated in myelin-phagocytosing MS patient monocytes compared to HVs are 
shown in Table 5.1. Several of these genes are involved in lipid metabolism and 
are downstream of the RXR pathway. In addition, genes involved in 
promoting/inhibiting actin rearrangement in phagocytosis are shown as well as 
genes associated with IL-17 signalling and immunological diseases. 
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Figure 5.1 Monocytes from MS patients cluster independently of monocytes 
from HVs and show enhanced inflammatory pathways. Microarrays were used to 
compare MS patient monocytes to monocytes from HVs. A-B) Heat maps (A) and 
principal component analysis (B) of microarray data clearly distinguish clustering of 
MS patient monocytes and HVs. C) IPA identified highly expressed canonical 
pathways upregulated in MS patient monocytes. Several of the top pathways are 
important in pro-inflammatory functions of monocytes (IL-17 signalling, bacteria 
recognition, IL-8 signalling). n=4/group.  
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-log(p-value)
0.0    1.0   2.0   3.0    4.0
Fold ∆ in MS Patients vs HVs Fold ∆ in MS Patients vs HVs 
IL-17 Signalling in Immune Cells 
CCL20 3.37 CXCL3 2.39 
CXCL1 2.23 CCL5 2.00 
Pattern Recognition & IGF-1 Signalling 
NLRP3 2.27 SOCS3 2.55 
RIPK2 1.63 SRF 1.63 
TRAF1 1.88 
 Immunological Diseases 
TGFBR1 -1.51 GBP1 2.28 
STAT4 3.09 TNFSF15 2.44 
CXCR4 -2.95 GFTP1 -1.75 
ARL5B 1.53 MS4A4A 1.79 
CCRN4L 2.17 TBC1D2 -1.83 
CLEC4E 1.60 
Lipid Metabolism 
ACAT2 1.72 LIPA -1.53 
BTG2 1.54 LPL 1.97 
EDN1 2.23 NR4A1 2.12 
GBP2 2.15 PRLR -1.83 
Actin Rearrangement 
CD180 -3.81 GFPT1 -1.75 
DUSP16 1.67 NFKBIZ 1.63 
E2F7 3.85 NLRP3 2.27 
GBP3 2.99 ZC3H12A 1.87 
Table 5.1 Genes important in monocyte function and phagocytosis are 
dysregulated in MS patient monocytes. IPA revealed genes in several key 
monocyte and macrophage functions significantly changed by MS disease status. 
As monocytes from MS patients were clustered independently from HVs, we 
next aimed to determine if these transcriptional effects led to functional differences in 
myelin debris phagocytosis. Monocytes were isolated from young and old HVs and 
both young (≤35 years old) and old (≥55 years old) MS patients exposed to FITC+ 
pHrodo-labelled myelin. As in the initial experiment, the statistician first performed a 
sample size estimate on pilot data. After obtaining the pre-determined 
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n=18 volunteers per age group, we observed that monocytes from MS patients 
displayed significantly impaired myelin debris phagocytosis (Fig. 5.2A-B). However, 
there was no significant difference in myelin phagocytosis between young (RRMS) 
patients and old (progressive MS) patients (Fig. 5.2C). Due to this functional similarity, 
further studies analysed MS patients in one group, regardless of age. 
Figure 5.2 Myelin debris phagocytosis is reduced in MS patient monocytes 
regardless of age. A-B) Monocytes from young (A, ≤35 years old) and aged (B, ≥55 
years old) MS patients were treated with myelin debris, and phagocytosis was 
compared to HVs. C) Monocytes from MS patients show significantly impaired 
myelin debris uptake, in both young (Phagocytosis = 1.95±0.12) and aged 
(2.10±0.09) MS groups compared to young HVs (2.44±0.06). One-way ANOVA and 
post-hoc Tukey’s multiple comparisons test, **p<0.01, n≥24/group. 
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5.2 Bexarotene enhances RXR expression and myelin debris phagocytosis 
in MS patient monocytes 
Based on the significant effects of modulating this pathway in the murine 
system, we next aimed to determine the effects of this potent RXR agonist on 
myelin-phagocytosing human monocytes to elucidate its efficacy in human subjects. 
Since monocytes were significantly altered by MS disease status, both functionally 
and transcriptionally, the potential effects of bexarotene on myelin-phagocytosing 
monocytes were determined using microarrays. This study would ascertain the 
effects of bexarotene on MS patient monocytes. Bexarotene treatment significantly 
increased the expression of several genes in the RXR pathway (shown in green) and 
significantly decreased expression of negative regulators of RXR (shown in red) in 
monocytes from MS patients. The treatment significantly affected 4 groups of RXR-
related genes.  
RXR activators, highlighted by the green box, were primarily upregulated 
upon bexarotene treatment compared to untreated MS monocytes (Fig. 5.3A). 
Nuclear receptor binding partners of RXR and the genes they regulate are in the 
purple box, including receptors in the RAR and PPAR families, and were primarily 
upregulated as well. In addition, genes inhibited by PPAR-RXR signalling were 
largely downregulated, including the inflammatory cytokines CXCL1 and CXCL3 as 
well as the negative regulator of remyelination, endothelin-1 (EDN1) (Hammond et 
al., 2014). Inhibitors of RXR in the red box are mainly downregulated upon 
bexarotene treatment. In addition, a select few other binding partners of RXR (blue 
box), were differentially upregulated upon treatment. Of the many genes upregulated 
upon bexarotene treatment, 10 statistically significant genes made patient monocytes 
behave more like young, healthy controls (Fig. 5.3B). For example, genes such as 
EDN1 and CXCL3 are more highly expressed in MS patient monocytes compared to 
young HVs. However, when MS patient monocytes were treated with bexarotene, 
the expression of these genes decreased to levels similar to those seen in HVs. 
Thus, the gene profiles of patient monocytes became more similar to the profiles of 
healthy controls. This result further suggests that bexarotene treatment is able to 
create a healthier, more youthful state in human myelin-phagocytosing monocytes 
via activation of the RXR pathway.   
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Figure 5.3 Bexarotene activates the RXR pathway in MS patient monocytes. A) Heat 
map showing independent clustering of bexarotene-treated samples in HVs and MS 
patients. B) IPA was used to analyse microarrays comparing MS patient monocytes to 
treated MS monocytes. Several RXR-related genes are upregulated with bexarotene 
treatment, shown here. Green box=RXR Activators, Purple box=Nuclear Receptor 
Binding partners, Red box=RXR inhibitors, Blue box=Other binding partners. B) Upon 
bexarotene treatment, 10 genes had significant fold changes (p<0.05) and expression 
profiles more like HVs (HV=1) compared to patient monocytes. n=4/group. MS patients 
ages (years old): 32, 38, 60, 69
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Due to the significant upregulation of RXR pathways upon bexarotene 
treatment and significant difference between MS and HV monocytes, functional 
studies of myelin debris phagocytosis assessed the effects of bexarotene treatment 
on monocytes. Monocytes from young HVs were not significantly affected by 
bexarotene treatment (Fig. 5.4A, 2.39±0.07), while monocytes from MS patients 
showed significantly improved myelin debris phagocytosis compared to untreated 
cells (Fig. 5.4B-C, 2.20±0.06), further suggesting that altering this pathway in 
patients will enhance myelin debris phagocytosis.  
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Figure 5.4 Bexarotene increases myelin debris phagocytosis by MS patient 
monocytes. A-B) Monocytes from young HVs (A, ≤35 years old) and all MS patients 
(B) were treated with myelin debris and bexarotene, and phagocytosis was 
compared to untreated, young HVs. C) The impairment in myelin debris 
phagocytosis was significantly improved by adding 1 μM Bexarotene in MS patient 
monocytes (2.20±0.06), while it had no significant effect on young HVs (2.39±0.07). 
However, there was still a significant difference between treated MS monocytes and 
young HVs. Two-way repeated measures ANOVA and post-hoc Tukey-Kramer 
adjustment for multiple comparisons, ***p<0.001, n≥36/group.  
5.3 CD14 and CD163, monocyte markers of inflammatory activity, show 
small changes due to age, disease status, and activation 
Due to their proven roles in affecting inflammatory pathways in monocytes, 
CD14 and CD163 were studied in myelin-phagocytosing monocytes. In addition, the 
role of bexarotene in modulating these two receptors and soluble molecules was 
determined in activated, myelin-phagocytosing cells. In order to establish the 
optimum incubation time to measure CD163 and CD14 in the supernatants of 
monocytes, cells were plated for 1-24 hours and supernatants were collected at pre-
selected time intervals. Using an ECL assay, the release of both sCD14 and sCD163 
was determined over the time course (Fig. 5.5A-D). sCD14 reached a peak at 24 
hours in all three groups tested (control resting cells, myelin-phagocytosing cells, 
and phagocytosing bexarotene-treated cells) (Fig. 5.5A). The standard curve 
developed for sCD14 followed a precise curve, with a coefficient of variation (CV) 
≤15.5% (Fig. 5.5B). sCD163 also reached a peak at 24 hours, but showed less 
accumulation in supernatants compared to sCD14 (Fig. 5.5C). For further 
experiments, supernatants were collected after 24 hours to measure sCD14 and 
sCD163. 
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Figure 5.5 Optimisation of soluble CD14 and CD163 time course. MesoScale 
Discovery ECL Assays were used to detect soluble CD14 (sCD14) and soluble 
CD163 (sCD163) levels in monocyte supernatants. Levels (pg/ml) were calculated in 
supernatants from monocytes plated for 1-24 hours with myelin and bexarotene 
treatments. A) sCD14 increased over time, and peaked at 24 hours incubation 
(6701-12,276 pg/ml). B) The standard curve for sCD14, with low CVs (≤15.5%), is 
shown here. C-D) sCD163 also peaked at 24 hours incubation (673-726 pg/ml) and 
had an accurate standard curve.  
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Both sCD163 (measured by ECL) and surface CD163 expression (measured 
by FACS) were determined in 2 different groups with 3 separate treatments. The 
effects of MS disease status, phagocytosis, and bexarotene treatment were 
determined for each group. For sCD163, MS disease status resulted in significantly 
higher sCD163 shedding compared to HVs in all 3 groups (resting controls, 
phagocytosing monocytes, and bexarotene-treated phagocytosing cells) (Fig. 5.6). 
These results suggest an increase in pro-inflammatory regulation of CD163 via 
shedding of this receptor in monocytes from MS patients. In addition, surface CD163 
expression was determined across all groups. Upon phagocytosis, both monocytes 
from MS patients and HVs display a significant increase in surface CD163 
expression, confirming an increase in the immunoregulatory phenotype upon 
phagocytosis. However, bexarotene treatment had no additional effect on surface 
CD163 expression in either group. Conversely, HV monocytes have significantly less 
surface CD163 expression overall, suggesting a less immunoregulatory phenotype in 
HVs perhaps due to less activation of this receptor. Since CD163 was affected by MS 
patient status, the effects of treatment and disease status on CD14 expression were 
determined in those cells. Compared to young HVs, bexarotene increased shedding 
of sCD14 in MS patient monocytes (Fig. 5.7A), suggesting activation of a more anti-
inflammatory, M2 cell type upon treatment with bexarotene and myelin debris. 
Although this increase was seen in sCD14, there was no significant difference in 
CD14 surface expression among monocytes (Fig. 5.7B). These results suggest that 
there is a mechanism for balancing sCD14 and surface CD14 expression in 
monocytes, with bexarotene tending to increase shedding of CD14.  
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Figure 5.6 sCD163 and surface CD163 are increased in monocytes from MS 
patients. Soluble CD163 (sCD163) in supernatants and Surface CD163 expression 
on monocytes (MFI) were calculated for monocytes from HVs and MS patients. A) 
sCD163 was compared in HVs and MS patients. Phagocytosis and bexarotene 
treatment had no significant effect on sCD163 expression. sCD163 was increased in 
supernatants from MS patients (7.8±0.5 ng/ml) compared to HVs (4.8±0.4 ng/ml). 
This increase was significant across all 3 treatment groups. B) Surface CD163 
expression in monocytes was increased due to myelin phagocytosis in both HVs and 
MS patients. MS monocytes displayed increased surface CD163 expression across 
all 3 groups. Two-way ANOVA and post-hoc Sidak’s multiple comparisons test. 
***p<0.001, p<-0.05. A) n=30/group; C-D) n≥50/group. 
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Figure 5.7 Bexarotene enhances sCD14 release in monocytes from MS 
patients. sCD14 in supernatants (pg/ml) and Surface CD14 expression on 
monocytes (MFI) were calculated for monocytes from HVs and MS patients. A) MS 
patient status had no significant effect on sCD14 expression in monocyte 
supernatants; however, bexarotene treatment did significantly increase sCD14 
(18.5±2.3 ng/ml) compared to untreated cells from MS patients (11.2±1.2 ng/ml). B) 
Surface CD14 expression was not changed due to disease status, phagocytosis, or 
treatment. Two-way ANOVA and post-hoc Sidak’s multiple comparisons test. 
*p<0.05. A) n=12/group; B) n≥50/group.
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5.4 Conclusions 
The goal of this study was to examine functional and molecular differences 
between young and MS patient myelin-phagocytosing monocytes, in order to identify 
therapeutically-modifiable pathway(s) that may enhance defective myelin debris 
clearance and therefore potentially also enhance remyelination in aged subjects with 
demyelinating disorders such as MS. By using multiple complementary assays, 
systemic differences in the RXR pathway were discovered between efficiently-
phagocytosing young and poorly-phagocytosing MS monocytes from humans. 
Similar to the results seen in mice, treatment with bexarotene enhanced 
activation of the RXR pathway as well as enhanced impaired myelin debris 
phagocytosis seen in MS patients, suggesting that activating this pathway has 
functional significance in human monocytes. The specific genes upregulated in 
response to bexarotene and RXR activation in young cells are related to several 
monocyte functions. Determining how to harness the specific activation of positive 
regulators of phagocytosis due to RXR activation will further provide evidence of the 
beneficial role of RXR in myelin debris phagocytosis. 
The balance of pro- and anti-inflammatory effects of m o nocytes are key to 
harnessing the beneficial role of these cells in remyelination. In this chapter, two 
important surface and soluble markers of inflammatory capacity in monocytes are 
highlighted. CD14 and CD163 both have complex roles in monocyte regulation, and 
the results shown here indicate that both receptors have an important role in 
modulating myelin phagocytosis in disease. Increased shedding of sCD163 in MS 
patient monocytes suggests that these cells tend toward a more pro-inflammatory 
state. The increase in surface CD163 upon phagocytosis further suggests that myelin 
debris phagocytosis induced a more immunoregulatory phenotype in human 
monocytes, skewing them towards M2, wound-healing macrophages. In addition, 
increased shedding of CD14 upon bexarotene treatment implicates a role for RXR 
activation in reducing pro-inflammatory surface markers. 
Since the genetic regulation of the RXR pathway is an incredibly complex 
and ongoing topic, highlighting the role of RXR binding partners in further affecting 
myelin debris phagocytosis may provide a more complex but more effective therapy 
in progressive MS. Several downstream genes have been discovered and are 
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highlighted here, but much work remains to determine other genes that are pivotally 
regulated by this pathway. Specifically, elucidating the role of nuclear receptors in 
anti-inflammatory pathways may enhance further knowledge on the effects of 
activating RXR in monocytes and will be highlighted in the next results chapter.
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6. Results
PPARγ activation enhances immunomodulation and myelin debris 
phagocytosis in MS patient monocytes 
 RXR activity was shown to be important in myelin debris clearance and CNS 
remyelination in both murine models and human monocytes. However, RXR 
activation did not fully recover myelin debris phagocytosis in aged BMMs or MS 
patient monocytes nor did RXR inhibition completely impair phagocytosis or 
remyelination in young subjects. In addition, there was a trend towards a more 
immunomodulatory phenotype in macrophages upon bexarotene treatment, but RXR 
activation could not largely enhance anti-inflammatory functions in myelin-
phagocytosing monocytes that have previously been shown to be important in the 
beneficial role of monocytes and macrophages in promoting remyelination (Miron et 
al., 2013; Takahashi et al., 2007; Zhao et al., 2006). These results suggest that other 
binding partners of RXR may also be playing a pivotal role in myelin debris 
clearance and beneficial macrophage functions. One of RXR’s permissive binding 
partners, PPARγ, has been shown to enhance M2 activation in macrophages and 
may also play a role in improving remyelination or treating MS. In addition, activating 
both RXR and its permissive binding partners has been shown to have a synergistic 
effect in downstream gene transcription (Chawla et al., 2001; Ogawa et al., 2005; 
Roszer et al., 2013); therefore, the additional role of modulating RXR’s binding 
partner, PPARγ, was further studied here. 
As a permissive binding partner of RXR, PPARγ, has also been shown to play 
an important role in remyelination biology and macrophage function (Bernardo et al., 
2009; De Nuccio et al., 2011; Lloberas and Celada, 2002; Ricote et al., 1999). 
PPARs have large ligand binding sites that are only partially filled by ligands, so 
multiple fatty acids can activate these receptors, and this activation has been shown 
to regulate gene expression in macrophages (Nagy and Schwabe, 2004). 
Unsaturated fatty acids largely activate PPARγ (Committee, 1999), and as myelin 
debris is composed of lipids, mainly galactocerebrosides with an unsaturated fatty 
acid tail (Hu et al., 2004), phagocytosis of myelin debris may assist in NR activation.  
Due to its immunoregulatory capacity, PPARγ has been considered a 
therapeutic target in MS (Drew et al., 2008). An MS mouse model revealed that the 
addition of PPAR and RXR agonists activated transcriptional pathways that resulted 
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in anti-inflammatory effects on macrophages, ultimately resulting in greater recovery 
of treated animals (Diab et al., 2004; Feinstein et al., 2002). In addition, treatment 
with pioglitazone in a small set of RRMS patients resulted in a reduction in gray 
matter atrophy and a reduced number of lesions (Shukla et al., 2010); however, 
there was no significant decrease in disability in these patients (Kaiser et al., 2009). 
Elevated levels of soluble PPARγ have been detected in the CSF of MS patients 
(Szalardy et al., 2013), and PPARγ agonists have also been shown to enhance OL 
maturation and differentiation (Bernardo et al., 2009; De Nuccio et al., 2011). 
PPARγ also plays a significant role in macrophage function. RXR and 
PPARγ heterodimerise during hematopoietic stem cell differentiation and are 
associated with their development into monocytes and myeloid cells (Safi et al., 
2009; Schneider et al., 2014; Tabe et al., 2012). PPARγ activation affects lipid 
accumulation in macrophages and proper lipid metabolism (Chawla et al., 2001; 
Chinetti et al., 2001; Moore et al., 2001). Several studies suggest that PPARγ 
activates an anti-inflammatory phenotype in macrophages (Huang et al., 1999; 
Odegaard et al., 2007; Ricote et al., 1998).  
Pioglitazone was used as the primary activator of PPARγ in the following 
studies. Pioglitazone is a thiazolidinedione, a class of drug also known as glitazones 
and currently used in the treatment of type 2 diabetes. Thiazolidinediones are oral 
drugs known to decrease triglycerides, increase cholesterol, and block pro- 
inflammatory genes. Other thiazolidinediones have also been prescribed for type 2 
diabetes but have been associated with severe toxicities and removed from the 
market, including rosiglitazone (increased cardiovascular risks) and troglitazone 
(increased hepatitis). Even pioglitazone, brand labelled as Actos, has been 
associated with bladder cancer (Lewis et al., 2014), but this has not been confirmed 
and the drug is still FDA-approved. Common side effects include sore throat, muscle 
pain, eye problems (such as blurred vision), and weight gain (DeFronzo et al., 2011). 
Pioglitazone is currently prescribed at a dose of 30 mg/day and achieves a maximum 
plasma concentration of 800 ng/ml, which is approximately 2 μM in the serum 
(Eckland and Danhof, 2000). Therefore, the in vivo achievable dose used in the 
following in vitro studies was 1 μM. 
Due to slight immunomodulatory effects of bexarotene treatment and pan- 
RXR activation, this study further aimed to determine the effects of the RXR binding 
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partner PPARγ by studying the expression levels of this receptor in ageing and the 
effects of modulating this receptor in myelin debris phagocytosis. 
6.1 RXRα and PPARγ bind in BMMs, and PPARγ plays a role in efficient myelin 
debris phagocytosis 
As ageing played a significant role in RXR expression (Chapters 3-4) and as 
previous studies have indicated a role for ageing in PPARγ expression (Dyall et al., 
2010; Sung et al., 2006), the role for ageing on expression of PPARγ heterodimers 
in myelin-phagocytosing BMMs was studied here. In order to confirm PPARγ-
RXRα interaction in BMM cultures, protein was lysed from control and myelin- 
phagocytosing BMMs, and co-immunoprecipitation was performed by eluting 
PPARγ-expressing isolates. After collecting specific PPARγ expressing proteins, 
western blots were performed on the elutes with antibodies against RXRα to 
determine the amount of PPARγ-RXRα co-expression. Nitrocellulose blots were 
stripped overnight and re-incubated with PPARγ antibodies to determine 
consistency of PPARγ expression across samples (used as a control). RXRα-
PPARγ heterodimers experienced interaction in both control and myelin-
phagocytosing BMMs (Fig. 6.1A-B). 
Once it was determined that these receptors do bind in BMMs, the effects of 
age on PPARγ expression were determined by western blots. Protein was lysed from 
myelin-phagocytosing, ageing BMMs (2mo, 8mo, 12mo, 16mo, 24mo). Resulting 
bands reached significantly decreased expression when comparing 2mo and 8mo 
BMMs to 24mo BMMs (normalised to β-actin and 2mo controls) (Fig. 6.1C-D). There 
was a trend towards decreased PPARγ expression with age, suggesting that this 
receptor has a similar expression pattern as RXRα and may also play a role in 
decreased myelin debris phagocytosis with age. 
141
Figure 6.1 PPARγ binds to RXRα and declines with age in BMMs. A) Co- 
immunoprecipitation followed by Western Blot was used to determine PPARγ and 
RXRα association in young BMMs. These receptors bind in BMMs, and B) myelin 
phagocytosis (mac+mye) does not significantly affect PPARγ-RXRα binding 
compared to resting controls (mac). C) Levels of PPARγ expression in macrophages 
derived from 2-24mo mice were determined by western blot and normalised to 2mo 
by ImageJ (C). Dividing line indicates different gels. D) There was a significant 
reduction in PPARγ expression in macrophages between 2mo and 24mo mice as 
well as 8mo and 24mo. One-way ANOVA and posthoc Tukey’s multiple comparisons 
test, **p<0.01, n=3/age group. 
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Since there was a significant decline in PPARγ expression with age, loss of 
PPARγ activity in young BMMs and its effects on myelin debris phagocytosis were 
studied. The synthetic antagonist for PPARγ, N-(4′-aminopyridyl)-2-chloro-5- 
nitrobenzamide (T007), was used to determine if PPARγ activation was necessary in 
young BMMs for efficient myelin debris phagocytosis. After antagonist treatment for 
24h and incubation with myelin debris, cells were stained with CD11b to identify 
BMMs. Myelin+CD11b+ cells were counted by immunocytochemistry and flow 
cytometry. Young cells were able to efficiently phagocytose DiO-labelled myelin (Fig 
6.2A-B, 36.6-42%), while macrophages treated with 10μM T007 showed reduced 
myelin debris uptake and significantly fewer double positive cells (Fig 6.2C-E, 22.3- 
26.3%). These results suggested that PPARγ activity may also be important in 
efficient myelin debris phagocytosis. These studies led to the question of how 
activating PPARγ would affect transcriptional profiling and function in ageing and 
patient myelin-phagocytosing human cells. 
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Figure 6.2 PPARγ antagonist slows myelin debris uptake in young BMMs. A-D) 
DiO-labelled myelin was used to measure myelin debris clearance by 
immunocytochemistry  and flow cytometry in young macrophages (A-B) and young 
macrophages treated with a synthetic PPARγ antagonist, T007 (C,D). E) Blocking 
PPARγ with10μM T007 reduced myelin debris uptake in young BMMs from 42.8% 
(±2.5%) in young controls to 22.3% (±3.5%). Scale bar = 50μm. Student’s t-test, 
**p<0.01, n=4/treatment. 
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6.2 Pioglitazone treatment enhances immunoregulatory pathways and reduces 
inflammatory CD14 expression 
Pioglitazone and bexarotene-treated monocytes were compared to controls 
from both MS patients and HVs. Microarrays were again used to study gene 
expression in these groups, and IPA was performed to determine the pathways 
affected. A principal component analysis was performed on monocyte groups to 
compare clustering of gene expression between 8 groups: HV Controls, HV 
Phagocytosing, HV Bexarotene-treated, HV Pioglitazone-treated, MS Controls, MS 
Phagocytosing, MS Bexarotene-treated, and MS Pioglitazone-treated. As previously 
shown (Fig. 5.3), bexarotene significantly affected myelin-phagocytosing monocytes 
and, in a select few genes, made MS patients monocytes more like HVs. However, 
bexarotene treatment caused significantly different clustering of monocytes from 
both treated MS patients and treated HVs compared to controls (Fig. 6.3A), 
suggesting a significant difference from normal HV monocytes. Alternatively, 
pioglitazone treatment only significantly affected gene expression of 8 specific genes 
in myelin-phagocytosing monocytes from MS patients. The expression of all of these 
genes was made more similar to expression in HVs compared to untreated MS 
monocytes. The relation of these eight genes to the PPARγ pathway are mapped 
here (Fig. 6.3B). The functions of these genes in macrophages are also shown in 
Fig. 6.3C. Several of these genes have been shown to be involved in 
immunoregulatory, M2 differentiation, such as the cytokine IL-19, which is a member 
of the anti-inflammatory IL-10 family (Richards et al., 2015). In addition, LRG1 has 
been shown to enhance the release of the growth factor TGF-β in macrophages, 
increasing their role in regeneration (Song and Wang, 2015). In addition, NFAT5 
regulated the expression of VEGF (Wiig et al., 2013), another important growth 
factor. Finally, PTGES promotes production of prostaglandin and encourages M2 
differentiation (Sica and Mantovani, 2012; Sica et al., 2006).  
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Figure 6.3 MS patient monocytes treated with pioglitazone experience a 
significant change in select genes related to immunoregulation. Microarrays 
were used to compare MS patient monocytes and HV monocytes to those treated 
with either pioglitazone or bexarotene. A) Principal component analysis of 
microarray data (performed by Dr. Kory Johnson) clearly distinguished clustering of 
MS patient monocytes treated with pioglitazone or bexarotene compared to HVs. 
Bexarotene treatment significantly altered both normal, HV monocytes and MS 
patient monocytes, while pioglitazone treatment did not cluster away from HVs. 
However, pioglitazone does have a small effect on MS monocytes. B) IPA mapped 
eight genes that were significantly upregulated in pioglitazone-treated MS 
monocytes and had expression levels more similar to HVs. Most genes have also 
been shown to be regulated by PPARγ activity. C) Gene function related to 
immunoregulatory macrophages. p<0.05, n=4/group.
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Due to the increased expression of immunoregulatory genes upon 
pioglitazone treatment, the effects of pioglitazone on CD163 and CD14 expression 
were expected to be more pronounced than in monocytes treated with bexarotene. 
This study determined the balance of these M1/M2 markers on the surface and in 
the supernatants of myelin-phagocytosing monocytes. As previously shown (Fig. 5.6- 
5.7), phagocytosis and patient status affect sCD163 and surface CD163 expression 
compared to resting controls. Treatment with pioglitazone had no significant effect on 
either sCD163 or surface CD163 expression in monocytes (Fig. 6.4A-B). Although 
there was no change in CD163 expression, the more inflammatory monocyte marker 
CD14 was affected by pioglitazone treatment. More sCD14 was found in the 
supernatants of myelin-phagocytosing monocytes from MS patients treated with 
pioglitazone compared to untreated controls (Fig. 6.5A), suggesting increased 
shedding of this inflammatory surface marker upon treatment. Surface CD14 trended 
towards reduced expression upon pioglitazone treatment in HVs and MS patients 
(Fig. 6.7B). With the reduction in inflammatory CD14 surface expression and 
increased sCD14 upon pioglitazone treatment, these results further suggest a trend 
towards a less inflammatory, more immunoregulatory phenotype upon treatment with 
pioglitazone.   
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Figure 6.4 sCD163 and surface CD163 in monocytes are not significantly 
affected by pioglitazone treatment. Soluble CD163 in supernatants and Surface 
CD163 expression on myelin-phagocytosing monocytes (MFI) were calculated 
before and after pioglitazone treatment. A) Pioglitazone treatment had no significant 
effect on sCD163 expression in either HVs or MS patients. B) Surface CD163 
expression in monocytes was also not affected by pioglitazone. As before, both 
surface and sCD163 were significantly higher in MS patients compared to HVs. Two-
way ANOVA and post-hoc Sidak’s multiple comparisons test. ***p<0.001, A) 
n=30/group; B) n≥50/group.  
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 Figure 6.5 Pioglitazone enhances sCD14 release and reduces surface CD14 
expression in MS patient monocytes. Soluble CD14 in supernatants and Surface 
CD14 expression on myelin-phagocytosing monocytes (MFI) were calculated before 
and after pioglitazone treatment. A) Pioglitazone treatment significantly increased 
sCD14 in MS patients (16.2±1.6 ng/ml) compared to myelin-phagocytosing controls 
(11.2±1.2 ng/ml). B) Surface CD14 expression in monocytes was not significantly 
affected due to pioglitazone treatment; however, both HVs and MS patients showed a 
trend (ns) towards decreased surface CD14 upon pioglitazone treatment. Two-way 
ANOVA and post-hoc Sidak’s multiple comparisons test. *p<0.05, A) n=12/group; B) 
n≥50/group.  
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6.3 M1/M2 polarised cells show increased CD163 expression upon pioglitazone 
treatment in MS patient macrophages 
 Since PPARγ activation tended to cause a less inflammatory phenotype in 
myelin-phagocytosing monocytes, the direct effects of pioglitazone treatment on M1 
and M2 polarisation were studied by polarising monocytes towards an M1 or M2 
macrophage phenotype. As previously described, these extreme states are largely 
an in vitro paradigm that can provide insights into the potential for modulating 
inflammatory capacity in macrophages. It was hypothesised that since PPARγ 
reduced CD14 expression and promoted immunoregulatory genes in non-polarised 
monocytes, activation by pioglitazone may also assist in converting M1, pro-
inflammatory macrophages to a more M2-like, regenerative phenotype. Monocytes 
were cultured and differentiated with M1, pro-inflammatory cytokines (granulocyte 
macrophage-colony stimulating factor, IFNγ, LPS, TNFα) or M2, anti-inflammatory 
cytokines (macrophage colony-stimulating factor, IL-10, IL-4). After 7 days of 
differentiation, cells were deemed M1 or M2 type cells. M1 macrophages tended to 
have a more rounded appearance compared to more bipolar M2 macrophages in 
culture (Fig. 6.86-D), also previously seen in other studies characterising these cells 
(Edin et al., 2013). Pioglitazone treatment did not appear to have a large effect, but 
some M1 cells took on a more elongated phenotype upon treatment (Fig. 6.6B). This 
difference in phenotype led to further investigation of expression of M1 and M2 
surface markers in these two macrophage cultures.  
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 Figure 6.6 M1 human macrophages have an amoeboid phenotype, and M2 
polarisation results in a bipolar structure. Light micrograph images of M1 and M2 
human monocyte-derived macrophages. A-B) M1 polarised macrophages have a 
flattened, amoeboid appearance. When treated with 1 μM Pioglitazone, some cells 
show a more elongated phenotype. C-D) M2 polarised macrophages display a 
bipolar appearance and maintain that with pioglitazone treatment.  
 
 Myelin debris phagocytosis has previously been associated with a more M2-
like phenotype (Boven et al., 2006). This study aimed to determine the effects of 
polarising macrophages from young HVs and old MS patients. CD80 and CCR7 (M1 
markers) and CD163 and CD206 (M2 markers) expression was determined in 
different treatment conditions for both HV and MS macrophages. However, the only 
marker that showed any significant or appreciable differences between M1/M2 
macrophages upon phagocytosis or pioglitazone treatment was CD163, with data 
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shown here. CD163 expression was determined by comparing 1) polarised cells 
treated with pioglitazone and/or myelin debris to 2) non-phagocytosing, untreated 
controls. In young HVs, there was no significant change in CD163 expression upon 
phagocytosis or pioglitazone treatment in M1-polarised macrophages (Fig. 6.7A-B). 
However, CD163 expression was significantly increased in pioglitazone-treated M1 
macrophages from MS patients (Fig. 6.7C-E). These results suggest that 
pioglitazone treatment does enhance M2 marker expression in M1-polarised 
macrophages from MS patients, but it has no significant effect on those 
macrophages from HVs, consistent with the microarray results in myelin-
phagocytosing monocytes.  
The effect of pioglitazone on CD163 surface expression on M2-polarised 
macrophages was also determined. Again, pioglitazone and myelin debris 
phagocytosis did not significantly affect CD163 expression in HVs, although there 
was a trend towards increased expression in both cases (Fig. 6.8A-B). In M2 
macrophages from MS patients, pioglitazone treatment significantly enhanced 
CD163 surface expression on myelin-phagocytosing macrophages compared to all 
other groups (Fig. 6.8C-E), indicating that pioglitazone treatment can enhance 
CD163 on M2-phagocytosing macrophages as well, further promoting the 
immunoregulatory state in these cells.  
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 Figure 6.7 M1-polarised macrophages from old MS patients experience an 
increase in CD163 surface expression upon pioglitazone treatment. A-B) There 
is no change in CD163 expression in either resting or myelin-phagocytosing M1 
polarised macrophages from young HVs, both before and after treatment with 1 μM 
pioglitazone. C) M1 polarised cells from MS patients do not experience a significant 
change in CD163 upon phagocytosis. D-E) However, CD163 expression is increased 
upon pioglitazone treatment compared to controls. This increase in expression is not 
maintained in myelin-phagocytosing M1 macrophages. Two-way ANOVA, post-hoc 
Sidak’s multiple comparisons, **p<0.01. n=10/group.  
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 Figure 6.8 Myelin-phagocytosing M2 macrophages from MS patients 
experience an increase in CD163 surface expression upon pioglitazone 
treatment. A-B) There is no change in CD163 expression in either resting or myelin-
phagocytosing M2 polarised macrophages from young HVs, both before and after 
treatment with 1 μM pioglitazone. C-E) M2, pioglitazone-treated macrophages show 
increased CD163 expression upon myelin debris phagocytosis compared to control 
and pioglitazone-treated resting cells. Two-way ANOVA, post-hoc Sidak’s multiple 
comparisons, ****p<0.0001. n=10/group. 
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6.4 PPARγ activation promotes myelin-phagocytosis in monocytes from MS 
patients 
As CD163 and M2-like phenotypes were promoted and CD14 and M1-lke 
phenotypes were downregulated by pioglitazone-treatment, the functional effects of 
pioglitazone on myelin debris phagocytosis were also determined. To determine if 
PPARγ activation can also enhance myelin debris phagocytosis and further study the 
role of PPARγ in MS patient monocytes, pioglitazone was added to myelin-
phagocytosing human monocytes. After pioglitazone treatment, cells were exposed 
to myelin debris and phagocytosis was determined by FACS. Young monocytes 
were able to effectively phagocytose debris both before (2.44±0.07) and after 
(2.56±0.08) pioglitazone treatment (Fig. 6.9A-B). As previously seen, there was a 
significant decrease in myelin debris phagocytosis in MS patient monocytes (Fig. 
6.9C, 2.01±0.06). When MS patient monocytes were treated with 1 μM pioglitazone, 
phagocytosis significantly increased to 2.33 (±0.06) (Fig. 6.9D). In addition, myelin 
debris phagocytosis by pioglitazone-treated MS monocytes was not significantly 
different from young HVs (Fig. 6.9E), suggesting that pioglitazone treatment is able 
to induce efficient phagocytosis by MS patient monocytes.  
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Figure 6.9 Pioglitazone significantly improves myelin debris phagocytosis in 
MS patient monocytes. A-D) Monocytes from young HVs (A-B, ≤35 years old) and 
MS patients (C-D) were treated with myelin debris (A, C) and pioglitazone (B, D). 
Histograms and FACS plots are shown. E) Monocytes from MS patients (2.01±0.06) 
show significantly impaired myelin debris uptake by flow cytometry compared to 
young HVs (2.44±0.06). This impairment was significantly improved in MS patients 
by adding 1 μM Pioglitazone (2.33±0.06) and was not significantly different from HVs 
after treatment. Two-way repeated measures ANOVA, ***p<0.001, *p<0.05, 
n≥35/group.  
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6.5 Conclusions 
The results shown in this chapter provide further evidence that RXR activation 
and enhancement of RXR-related pathways, specifically through PPARγ activation, 
provide enhancement of myelin debris phagocytosis and control of 
immunoregulatory pathways in monocytes and macrophages. The confirmation of 
RXRα-PPARγ binding in myelin-phagocytosing macrophages and decrease in 
PPARγ expression with age highlighted the importance of this permissive 
heterodimer in ageing macrophage functions. In addition, loss of PPARγ in young 
BMMs impaired myelin debris phagocytosis in these cells. Activating PPARγ, via 
treatment with the FDA-approved drug pioglitazone, enhanced myelin debris 
phagocytosis and immunomodulatory pathways in aged monocytes and monocytes 
from MS patients. This enhancement is likely through downmodulation of M1, pro-
inflammatory markers such as CD14. In addition, pioglitazone was able to increase 
the M2 marker CD163 on M1-polarised macrophages, further suggesting that this 
receptor may provide the capacity to enhance both myelin debris phagocytosis and 
immunoregulatory pathways in macrophages. These results further suggest that 
targeting RXR and PPARγ together may synergistically increase the beneficial 
functions enhanced by these receptors and allow them to act together to promote 
remyelination therapies in MS patients via myelin debris phagocytosis.  
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7. Discussion and Conclusions
The aim of this study was to examine functional and molecular differences 
between young and old myelin-phagocytosing myeloid cells to identify 
therapeutically-modifiable pathway(s) that may enhance defective myelin debris 
clearance and therefore potentially enhance remyelination in aged subjects with 
demyelinating disorders. By using multiple complementary assays, we identified 
systemic differences in nuclear receptor pathways, specifically RXR and PPARγ, 
between efficiently-phagocytosing young and poorly-phagocytosing old cells from 
both animal and human models. We further demonstrated the link between 
measured efficiency of phagocytosis of myelin debris by cells of the myeloid lineage 
and the speed of remyelination in the experimental model of focal demyelination. 
The experimental focus of this study was to determine the role of RXRs and their 
binding partner PPARγ in myelin debris phagocytosis and ageing monocyte/ 
macrophage function with the objective of determining the role of these proteins and 
complexes in the clearance of myelin debris and efficient remyelination.  
Although myelin debris clearance is mediated by an innate immune response 
performed by both monocyte-derived macrophages and microglia, we observed 
greater efficiency in myelin phagocytosis in BM-derived monocytes/macrophages in 
comparison to CNS-derived microglia. Macrophages and microglia are both myeloid 
cells with different origins and unique markers within the CNS. Microglia are derived 
from the yolk sac during early development and reside in the CNS through 
adulthood, whereas blood-derived monocytes are differentiated from bone marrow 
cells and are usually recruited to the CNS in response to an insult (Ginhoux et al., 
2010; Neumann et al., 2009; Ousman and Kubes, 2012). These cells are difficult to 
distinguish once they are activated, but studies have suggested that monocyte-
derived macrophages play a pivotal role in myelin debris clearance and CNS 
remyelination (Kotter et al., 2005; Ruckh et al., 2012), although both cell types can 
become phagocytic macrophages (Lampron et al., 2015; Neumann et al., 2009; Olah 
et al., 2012; Yamasaki et al., 2014). 
 In two of these previous studies suggesting a greater involvement of 
microglia in myelin debris clearance, the cuprizone model of demyelination was used 
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(Lampron et al., 2015; Olah et al., 2012). In this model, a copper chelator causing 
dysfunction in mitochondrial complex IV, results in selective oligodendrocyte toxicity 
in various CNS regions. This model is used for studies of resident CNS inflammatory 
cell response because little infiltration of recruited monocytes occurs (Krauthausen et 
al., 2014; McMahon et al., 2002). A recent study using fluorescently-labelled resident 
microglia and infiltrating monocytes determined that monocyte-derived cells are 
involved with myelin stripping from the axon and demyelination while microglia play a 
greater role in debris clearance in early stages of EAE (Yamasaki et al., 2014). 
However, this study failed to determine the roles of microglia and monocyte-derived 
macrophages during later stages of remyelination and only focused on initial 
demyelination. In this thesis, we found evidence that blood-derived macrophages 
play a larger role in myelin debris clearance and remyelination. This has previously 
been shown in other studies of remyelination as well (Kotter et al., 2005; Ruckh et 
al., 2012; Zhao et al., 2006). In addition to showing a significantly greater ability to 
phagocytose myelin debris in vitro (Fig. 3.2), changes affecting monocyte-derived 
macrophage function also impaired remyelination in vivo (Chap. 4), as the LysM-Cre 
shows little recombination in microglia (Goldmann et al., 2013), indicating the 
delayed myelin debris clearance seen in KOs is mainly due to RXR impairment in 
recruited myeloid cells.  
As myelin debris phagocytosis was impaired in both ageing BMMs and human 
monocytes, further studies on pathways involved in remyelination were considered 
here. Microarrays of human monocytes suggested that RXR pathways are less 
activated upon myelin phagocytosis in aged monocytes compared to young (Fig. 
3.5). Although human monocytes were grouped from a heterogeneous population, 
the effects of ageing on monocytes were clear. Variations in gene expression profiles 
between individuals reduce sensitivity in this model, but microarrays are still a 
valuable tool to study large-scale gene expression profiles. Due to the homogeneity 
among genes expressed by all monocytes, fold changes were relatively small among 
the two age groups. The low fold changes likely reflect the similarity among all 
monocytes, but nevertheless, these arrays identified multiple genes involved in RXR 
activity as primarily upregulated in young cells and downregulated in old monocytes. 
The fact that several genes in the same pathway show similar up/downregulation 
based on age group alone enhances the broader implication of these differences 
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regardless of the small fold changes of each individual gene. In addition, these 
genes were confirmed using qPCR and PCR arrays of RXR signalling in a larger 
group of subjects, suggesting that this result was not simply an artefact of large-
scale gene expression comparisons. The implications of these genetic changes were 
further studied in functional characterisation of monocytes and macrophages in 
response to myelin debris and in a focal demyelination model. In ageing, RXR 
expression declines (shown here in Fig. 4.2, previously shown in (Dyall et al., 2010)), 
likely resulting in reduced transcription of downstream genes. By activating RXR in 
aged monocytes and macrophages, we showed that recovery of this diverse 
pathway can restore a youthful state.  
In macrophage biology, RXRs have proven to be important. RXR expression 
is involved in macrophage differentiation from monocytes (Kazawa et al., 2009) as 
well as in the control of chemokine expression in macrophages (Nunez et al., 2010). 
RXR can form homodimers but also acts as a binding partner for several other 
nuclear hormone receptors. In resulting permissive heterodimers, such as PPAR and 
LXR, both RXR and its binding partner can bind their cognate ligands and cause 
ligand-dependent trans-activation. Moreover, each heterodimer has different DNA-
binding specificity, resulting in the expression of genes downstream of both RXR and 
its permissive binding partner (Evans and Mangelsdorf, 2014). Due to this 
combinatorial heterodimerisation, RXR pathways have far-reaching effects in 
different cell types. For example, in a previous study, RXRγ was highly expressed 
during OPC differentiation. Treatment with an RXR ligand (9cRA) improved 
remyelination in aged rats in this study (Huang et al., 2011). Furthermore, 
macrophage-specific knockouts of RXRα in mice resulted in impaired clearance of 
apoptotic cells in a model of autoimmune kidney disease (Roszer et al., 2011), and a 
clinically approved RXR agonist increased clearance of amyloid deposits in an 
animal model of Alzheimer’s disease (Cramer et al., 2012). Both of these studies 
support the conclusion derived from the current results in this thesis, that RXR plays 
a role in phagocytosis in general and in myelin-debris clearance in particular. The 
role of thyroid hormone in differentiation and the epidemiological link between 
Vitamin D deficiency and risk for development of MS (Ascherio et al., 2014) further 
strengthen our conclusions and suggest that modulating RXR pathways may 
influence the MS disease process.  
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In addition to this receptor having a positive role in remyelination and 
enhanced activity in young monocytes and macrophages, vitamin A (the precursor to 
the in vivo RXR ligand 9cRA) has also shown to be beneficial in patients with MS. 
Vitamin A is an essential, fat-soluble vitamin capable of crossing the BBB. Treatment 
with vitamin A activated anti-inflammatory functions in EAE and helped balance the 
pro-/anti-inflammatory response in mice, resulting in protection from reduced clinical 
scores in this model of MS. However, excess amounts of vitamin A have also proven 
to be harmful in MS, so an active balance in vitamin A concentration is imperative to 
harnessing its beneficial role (Massacesi et al., 1987; Salzer et al., 2013). Part of this 
beneficial activity may be through the conversion of vitamin A to 9cRA, which 
activates RXR pathways. Young BMMs were able to phagocytose myelin debris 
efficiently regardless of the presence of 9cRA. However, aged BMMs did not show 
impaired phagocytosis in the presence of serum (when more vitamin A was present), 
but they did show reduced myelin debris clearance in the absence of serum. This 
reduction was partially and significantly recovered when 9cRA was added to serum-
free media (Fig. 4.4), suggesting that RXR activation is one of the key regulators of 
myelin debris clearance in BMMs.  
Bexarotene also partially reverses the observed functional defect in myelin 
phagocytosis of MS monocytes, while changing their expression profile to a more 
“youthful” state, possibly through the autoregulatory activation of RXR. As RXR is 
downregulated with ageing, activating the receptor may not only enhance activation 
of RXR but also increase RXR expression in aged cells because RXR has previously 
been shown to act as a transcription factor for its own expression as well as for other 
nuclear receptors (Baker, 2011; Dave, 2012; Evans and Mangelsdorf, 2014). In 
young monocytes and macrophages, activation of RXR does not have a functional 
effect on myelin phagocytosis. We hypothesise that this is because young cells can 
optimally phagocytose myelin debris; therefore, further activating RXR does not 
affect function in these efficiently phagocytosing cells. In addition, RXR and its 
binding partners have previously been shown to display constitutive, ligand-
independent activation (Laursen et al., 2012; Nagpal et al., 1993), which may be the 
case in young cells and not in old. The functional necessity of RXR in young 
macrophages was confirmed by inactivating the receptor with an RXR antagonist 
(Fig. 4.5), further proving that this receptor is necessary for efficient myelin debris 
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phagocytosis. By activating this receptor with 9cRA or bexarotene, it is possible that 
we increased expression of this receptor, thus enhancing its activity and creating a 
more youthful state in aged monocytes and macrophages. Activation of this pathway 
may have then resulted in enhanced myelin debris clearance in ageing cells. 
Together, these data suggest that RXR may be a key regulator of myelin debris 
phagocytosis in ageing monocytes and macrophages. 
In order to determine the role of RXRs in myelin debris phagocytosis and 
remyelination, a LysM Cre-RXRα floxed knockout was created to remove RXRα 
function specifically in myeloid cells. Although the effect was not large, there was a 
time-dependent reduction in remyelination in the macrophage-specific RXR KOs. 
This recovery in delayed remyelination at later timepoints may be due to the KO of 
only the most significant form of RXR in monocytes, RXRα. We hypothesise that the 
other isoforms, β and γ, helped compensate for the loss of RXRα by 21dpl. In 
addition, nuclear receptor binding partners of RXR can still experience downstream 
transcription without RXR activation, so these other receptor pathways may also be 
playing a role in the recovery of remyelination at later timepoints. This finding 
suggests that RXRα is necessary for efficient myelin debris clearance at early stages 
of OPC differentiation and results in faster remyelination in vivo, and without this 
receptor, young mice experience delayed recovery after demyelination.  
While these observations are highly encouraging, they nevertheless cannot 
assure that RXR activation will promote remyelination in ageing subjects with MS. 
The major drawback of all models of experimental demyelination is the fact that 
remyelination is generally complete even without therapeutic interventions. 
Consequently, all remyelination-promoting therapies identified thus far are only 
speeding up remyelination, rather than inducing it in a system where spontaneous 
remyelination failed. We predict that this slowed remyelination is relevant to human 
disease despite the lack of functional deficit. Although this is different from the 
situation in progressive MS, where OPCs are recruited to demyelinated lesions but 
fail to differentiate into myelinating OLs (Chang et al., 2002), we also see the 
presence of OPCs at 14dpl and no defect in recruitment at earlier timepoints, 
suggesting that the defect in differentiation is common across models. While the 
persistent or delayed presence of inhibitors in myelin debris may indeed be one of 
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the factors underlying observed remyelination failure in MS, this hypothesis requires 
experimental confirmation. Interventional clinical trials can provide definitive answers 
on whether therapeutic agents that promote OPC differentiation, either directly or 
indirectly, via enhanced clearance of myelin debris, will promote remyelination in 
humans. Availability of bexarotene and pioglitazone makes such a proof-of principle 
clinical trial in human subjects with MS feasible. Determining the therapeutic window 
available for treatments that promote remyelination can help us understand how to 
boost regeneration in progressive MS. In this study, we also were able to further 
study the effects of bexarotene and pioglitazone in samples from MS patients that 
assist in translation of these results by studying measurable CSF biomarkers 
(Komori et al., 2015) and functional effects.  
As MS patients monocytes showed such a clear distinction in gene 
expression profiles compared to HVs (Fig. 5.1), we expected that this change in 
genetic make-up may also be reflected in functional activity, both in myelin debris 
phagocytosis and in the balance between pro/anti-inflammatory (M1/M2) markers 
and cytokines. Monocytes from MS patients displayed significantly reduced myelin 
phagocytosis compared to young HVs (Fig. 5.2). Interestingly, there was no 
significant difference in myelin debris phagocytosis between monocytes from RRMS 
patients and those from progressive MS patients, contrary to the expectation that 
young patients are likely able to clear myelin debris more efficiently than old patients. 
The similarity between RRMS and PPMS/SPMS patient monocyte phagocytosis has 
been suggested by previous studies as well (Brettschneider et al., 2002), where 
CD14-expressing cells (activated monocytes) were increased in both PPMS and 
RRMS. This similarity along with the similarity in phagocytosis among all MS 
monocytes further suggests that the MS disease state affects monocyte and 
macrophage function. However, since RRMS patients are likely able to overcome 
barriers to OPC differentiation, these findings may suggest that other factors in the in 
vivo situation for RRMS monocytes allows for remyelination in earlier stages that are 
prevented in later stages of progression. For instance, our study suggests that 
activation of the RXR pathway is an inhibitor of myelin debris phagocytosis, so 
activation of this pathway in vivo in RRMS patients compared to progressive MS 
patients may lead to more myelin debris phagocytosis in young MS patients 
compared to aged. Other effects in vivo, such as activation towards a more M2 
165
phenotype in vivo in RRMS which allows for more phagocytosis by these monocytes 
in subjects may not be recapitulated in the in vitro situation. Additionally, disease 
duration and rate of newly developing lesions were not considered in this study, so 
the similarity in RRMS and progressive patients may also reflect the similarity of 
disease duration among patients in these groups. Overall, MS patient monocytes 
showed consistent differences in functional, genetic, and biomarker studies, 
highlighting that modulating monocyte function and myelin debris phagocytosis may 
be relevant to all stages of the MS disease course.  
The functional changes in RXR-related pathways and expression of these 
genes were highly increased in response to bexarotene treatment. In addition, 
bexarotene treatment also changed the expression of 10 specific genes to be more 
similar to HVs (Fig. 5.3). This finding suggests that these specific proteins may be 
highly valuable downstream effectors in the RXR pathway. Determining the specific 
targets in the RXR pathway that create a “healthier” state in MS monocytes may be 
necessary to target this pathway more effectively because bexarotene also 
significantly altered gene expression in HVs (Fig. 6.3). Due to the role of RXR in 
several nuclear receptor pathways, activating this pathway may lead to unexpected 
off-target effects, and since it had a significant effect on healthy monocytes as well, a 
more targeted approach may be necessary.  
Recently, a study of remyelination highlighted that M2 cell densities increased 
in the lesions of old mice that were exposed to a young environment (Miron et al., 
2013). The findings from this study led us to not only determine the effect of MS 
disease status and bexarotene treatment on myelin debris phagocytosis in 
monocytes but also on M1 and M2 markers. Overall, bexarotene treatment did not 
have a large effect on the modulation of these representative surface markers and 
cytokines. MS patients released more sCD163, suggesting a reduction in M2 
markers in MS patients, which has also been previously suggested (Fabriek et al., 
2007; Stilund et al., 2014). Bexarotene increased sCD14 shedding, suggesting a 
more anti-inflammatory phenotype in these monocytes upon treatment; however, 
there was no effect on CD163 or M2-related genes in the microarray, leading us to 
study more anti-inflammatory effects of one of RXR’s permissive binding partners, 
PPARγ. Previous studies have shown a role for RXR and its nuclear receptor binding 
partner PPARγ in changes in macrophage gene expression and cytokine profiles 
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(Lloberas and Celada, 2002). The activation of the RXR/PPARγ pathway has 
previously been shown to lead to the transcription of molecules associated with anti-
inflammatory pathways (Diab et al., 2004). These pathways have immunoregulatory 
functions, orchestrate encapsulation and containment of particles, and promote 
tissue repair (Boven et al., 2006; Vereyken et al., 2011). 
In the present study, PPARγ showed similar functional characteristics to RXR, 
with decreased expression with age and modulation of myelin debris clearance upon 
activation/inhibition of this receptor. However, in comparison to bexarotene’s effects, 
the PPARγ activator pioglitazone led to a larger and more significant increase in 
myelin debris phagocytosis in MS patients (Fig. 6.9), and reached an efficiency in 
myelin debris phagocytosis that was not significantly different from HV monocytes. In 
addition to this important functional effect, this FDA-approved drug also caused no 
difference in gene clustering in young HVs and a slight but significant difference in 
clustering of MS monocytes upon pioglitazone treatment. This result suggests that 
this drug may allow for a more targeted change in monocytes. In this case, the 
genes upregulated upon pioglitazone treatment were largely related to anti-
inflammatory, M2 pathways. Pioglitazone treatment did not appear to affect CD163 
in early monocyte phagocytosis; however, it did show a significant reduction in 
surface CD14 expression and increased sCD14 in MS patient monocytes (Fig. 6.5), 
suggesting a more M2-like phenotype upon pioglitazone treatment. Then, at later 
stages of monocyte differentiation and macrophage polarisation, in our M1/M2 
culture conditions, pioglitazone did significantly increase surface CD163 expression 
in both M1 and M2 macrophages from MS patients. Again, this drug caused no 
significant difference in receptor expression in young HVs. This study using the 
functional results on myelin debris phagocytosis and the modulation of measurable 
CSF biomarkers (Komori et al., 2015) can be utilised to compare functional effects 
that can be observed with clinical tests in MS, and the effects of pioglitazone can 
also be correlated to the change in sCD14/sCD163 in the CSF of MS patients. This 
will allow us to determine whether these in vitro studies display similar 
pharmacodynamic effects that can be observed in vivo as the clinical tools to study 
these changes are readily available.  
Further combined and targeted modulation of both the RXR and PPARγ 
pathway may lead to both a more controlled system (as seen with pioglitazone 
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treatment) and a larger activation of RXR/PPARγ pathways and enhanced myelin 
debris phagocytosis (as seen with animal models of RXR and bexarotene treatment). 
Currently, some modulators exist that function to activate both of these receptors, 
such as the synthetic agonist LG 100754 (Tocris). However, in order to effect 
enhanced synergistic activation of these receptors, both ligand binding domains 
must be activated and engaged. In the case of current modulators, they only function 
to enhance PPARγ binding to the ligand when RXR is present. Development of a 
drug that can activate both pathways and reduce the off-target effects of activating 
all forms of RXR may further enhance our understanding of these pathways and 
allow for a more targeted and more effective approach to enhancing myelin debris 
clearance and anti-inflammatory pathways to promote CNS remyelination. In addition 
to identifying a more applicable activator of this pathway, further correlation between 
the role of monocyte function and disease status in MS may lead to a greater 
understanding of how these cells directly affect disease status and disability. The 
current study is able to correlate activation of these pathways in in vitro monocyte 
cultures from MS patients and animal models of demyelination. However, further 
studies on the disability state of the MS patients that monocytes were isolated from 
may increase our understanding of how deficiencies in myelin debris phagocytosis 
and enhanced inflammatory markers may affect disability in these patients. Through 
studying MRI scans, biomarkers of MS, and clinical disability scales, we can further 
correlate the role of monocytes to remyelination in patients.  
In CNS biology, signals from the systemic environment, such as those from 
young macrophages, can improve CNS recovery. When these cells are targeted in 
aged subjects, enhancing the RXR and PPARγ pathways results in efficient 
phagocytosis of myelin debris and may override age-related deficits in CNS 
remyelination. In the pathogenesis of progressive MS, OPC differentiation is inhibited 
and removing barriers to remyelination is critical to the therapeutic efficacy of future 
treatments. In addition, we know that factors affecting macrophage plasticity in the 
ageing environment affect phagocytic ability. Since these cells have a great deal of 
heterogeneity and can adapt to different biological cues, modulating their 
environment and expression profiles can help recover age-related deficits, making 
them an ideal target for endogenous repair. Through the activation of the RXR-
PPARγ pathway in monocyte-derived macrophages, we have shown that it is 
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possible to reverse the age-related decline in nuclear receptor expression and 
enhance myelin debris phagocytosis, thus making this an intriguing therapeutic 
target for progressive stages of demyelinating diseases.  
In conclusion, we identified activation of therapeutically-modifiable pathways 
during efficient clearance of myelin debris by phagocytes in humans and mice. We 
observed that efficiency of myelin phagocytosis declines in ageing and that this age-
related defect can be partially reversed, in both animal and human systems, by 
activating nuclear receptor pathways. Efficient clearance of myelin debris enhances 
remyelination in experimental models, while ageing in humans is associated with 
defective/insufficient remyelination. These combined observations raise a possibility 
that pharmacological enhancement of myelin phagocytosis in humans through the 
RXR-PPARγ pathway may promote OPC differentiation and enhance remyelination 
in ageing patients with demyelinating diseases. 
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